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Dyslipidaemia is a commonly encountered clinical condition and is a major risk factor for 
cardiovascular diseases. Although there are many factors associated with dyslipidaemia, a 
strong genetic component is evident. Apolipoprotein E (APOE), proprotein convertase 
subtilisin/kexin type 9 (PCSK9), and cholesteryl ester transfer protein (CETP) are key 
regulators of plasma cholesterol levels. Thus, genetic variation in the genes coding for these 
proteins contributes to dyslipidaemia. In this study, a cohort of black South African Type 2 
Diabetes Mellitus (T2DM) patients was characterized for mutations in genes coding for 
APOE, PCSK9, and CETP, and the possible effects of these variants on their lipid profiles 
was evaluated. 
Participants (n=417) were recruited from the Chris Hani Baragwaneth Hospital Diabetes 
Clinic, Johannesburg from whom blood samples were obtained for DNA extraction. The 
cohort was further stratified into two groups; individuals on statin treatment (Sim+, n=291), 
and the second that was not on treatment (Sim-, n=87). Lipid profiles were determined by 
enzymatic methods. DNA was genotyped for APOE, PCSK9, and CETP variants using PCR-
RFLP and Sanger sequencing. Analysis of the effects of the genetic variants was carried out 
in two ways. Firstly, for all the participants combined, and then by separating those on statin 
treatment from those without (Sim+ vs. Sim-). Genotype and allele frequencies were 
calculated followed by genotype-phenotype correlations with lipid profiles. 
Univariate analysis showed a significant association between the APOE4 isoform and lower 
HDL-c levels in the combined cohort (p=0.034). The effects were more pronounced in the 
Sim- group (p=0.004) but were absent in the Sim+ group. Contrary to above, APOE2 was 
significantly associated with lower total cholesterol (TC) (p<0.001) and lower LDL-c 
(p<0.001) when compared to APOE3 in the combined cohort. Upon analysing treatment 
groups, the correlations were observed in the Sim+ group (p=0.027 and p=0.003, 
respectively), while there were no observed correlations in the Sim- group. The CETP 
rs34065661C/G and G/G genotypes were significantly associated with increased HDL-c 
levels (p=0.017; when applying a dominant genetic model) in the combined cohort, as well as 
in the Sim+ group (p=0.026). Multivariate analysis, using a generalized linear model, 
confirmed associations between APOE rs429358C and lower HDL-c (OR=0.881, p=1.64e-
04), and APOE rs7412T and decreased LDL-c (OR=0.759, p=0.012). No significant 
associations were observed for PCSK9 polymorphisms. 
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We report significant associations between APOE and CETP genetic variations and altered 
lipid levels in this black South African T2DM population. These genetic variants could be 
biomarkers for dyslipidaemia among Africans. However, it is imperative that the APOE, 
PCSK9, and CETP genes are fully characterized for additional polymorphisms in order to 
come up with a better genetic profile that explains the variance in lipid levels observed in the 
black South African population. The impact of these genetic variants could be relevant to 
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Summary of thesis outline 
 
• In Chapter 1, we deal with the motivation and justification of this study. We review 
the recent literature on the genetics of dyslipidaemia in order to gain perspective on 
the topic and how this can used to guide our own study. A clear understanding of 
potential aspects of dyslipidaemia in type 2 diabetes mellitus patients and how this 
problem can be tackled in our own study is further explored. We outline the research 
topic, namely the genetics of dyslipidaemia in black South Africans, in the context of 
its increasing burden to the global and local health systems. In doing so, we will put 
the research problem into perspective, outlining its broad impact on society, and why 
it is necessary to study the genetics of complex non-communicable diseases such as 
dyslipidaemia in South Africans at all.  
• Chapter 2 outlines a comprehensive explanation of the methods and materials used to 
achieve the aims and objectives set out in Chapter 1. We outline the exact approach 
used to investigate the impact of genetic variants on dyslipidaemia in a T2DM cohort. 
• Chapter 3 presents the results of the experiments performed to complete the 
objectives outlined in Chapter 2. A comprehensive overview of the data analysis 
employed to achieve the aim of the study is presented. 
• In Chapter 4 we further discuss the results obtained from the experiments we 
employed to investigate the contribution of genetic variations in APOE, PCSK9, and 
CETP on the aberrant lipid profiles of black South Africans with T2DM. We evaluate 
these results and discuss any inferences or conclusions which can be taken from them, 
whilst comparing this to the literature. We also discuss the technical and analytical 







Chapter 1: Literature Review  
1.1) Non-communicable disease (NCD) 
Non-communicable diseases (NCD) are slowly progressing disorders, which are typically of 
long duration, and are not transferred by a pathogen host. They fall into four main groups: 
cardiovascular diseases (CVD), cancers, chronic respiratory diseases and diabetes. NCDs are 
rapidly becoming a global health epidemic. The World Health Organization (WHO) 
estimated that in 2015, out of a total of 56.4 million reported global deaths, 39.5 million (70.1 
%) were a direct result of NCDs1,2. This is up from the 31.4 million (60.2 %) global deaths 
which were reported in 20002.  
The reports show that the number of NCD related deaths has increased in every global region 
since 2000, and is expected to rise to a staggering 52 million by 20301,3. A commonly held 
view of NCDs is that it is a “Western” phenomenon. The burden of NCD deaths is highest in 
high-income countries, with 88 % of recorded deaths a result of NCDs compared to 37 % in 
low-income countries3. However, 78 % of total global deaths due to NCDs occurred in 
low‐ and middle‐income countries in 20153. Figure 1.1, shows the probability of dying from 












Figure 1.1: Probability of dying from the four main NCD between the ages of 30 and 70 years in 
2012. Adapted from: WHO. Global status report on noncommunicable diseases. (2014).  
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The burden of NCDs in Africa have increased substantially as well. In 2000, the number of 
NCD related deaths in the African region was 2.17 million (22.2 %). By 2015, the number 
had risen to 3.08 million deaths (33.5 %)2. The scale of the rising crisis hits home with six out 
of the top ten causes of natural deaths in South Africa in 2015 being a direct result of NCD, 
accounting for 27.7 % of deaths in females and 32.5 % of deaths in males4. The leading cause 
of NCD deaths in South Africa and, indeed, the rest of the world are CVDs. 
 
1.2) Cardiovascular disease (CVD) 
CVDs are a group of disorders affecting the circulatory system, namely the blood vessels and 
the heart. Of the reported 17.6 million global CVD deaths in 2015, 8.75 million were due to 
ischaemic heart disease (e.g. heart attacks), and 6.24 million deaths were caused by 
cerebrovascular disease (e.g. stroke)2. CVDs caused by atherosclerosis are responsible for the 
largest proportion of CVD related deaths. 
Atherosclerosis is a complex inflammatory disease process in which the walls of medium-
sized and large- sized arteries are mainly affected5,6. Atherosclerosis occurs over time, can be 
present throughout a person’s lifetime, and may present as early as infancy5,7. The process of 
atherosclerosis can be initiated by the exposure of the endothelium of the blood vessels to 
elevated levels of low-density lipoprotein cholesterol (LDL-c) or free radicals (e.g. caused by 
cigarette smoking), resulting in a dysfunctional endothelium which becomes permeable to 
monocytes and lymphocytes. These cells then emigrate from the blood to the deeper layers of 
the artery cell walls, multiplying in a forming cell lesion. Activation of these cells results in 
the release of cytokines, chemokines, growth factors, and hydrolytic enzymes which continue 
to cause further damage5. LDL-c can be attracted to and trapped in the lesion site where it is 
modified by oxidation in the artery cell walls through a number of reactions8. The LDL-c 
particles are engulfed by monocytes, which are in turn transformed into macrophages. 
Smooth muscle cells migrate to the lesion site, and fibrous tissue is formed, further enlarging 
the lesion. It eventually becomes covered by a fibrous cap, consisting of smooth muscle cells 
and collagen that covers a core of lipid and necrotic tissue5,6. The lesions are capable of 
accumulating even more lipids and cells and enlarge to the point where they protrude into the 
artery lumen. If the lesions burst, cellular debris and lipid fragments are released which can 
form a thrombus if exposed to thrombogenic agents on the endothelial surface. A large 
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enough thrombus can block a coronary artery or cerebral blood vessel, resulting in a heart 
attack or stroke, respectively5,6. 
 
1.3) Individual behavioural CVD risk factors:  
There are number of factors which have been reported to modify the risk of atherosclerosis 
induced CVD. These include preventable environmental and behavioural lifestyle factors, as 
well as CVD disease comorbidities9. The exact role and effect size of these risk factors has 
been thoroughly investigated in a number of large-scale studies, due to the overwhelming 
global burden of CVD. Figure 1.2 shows the intricate relationship between associated CVD 

















Figure 1.2: The major causal chain of ischaemic heart disease which shows the intricate 
relationship between CVD risk factors and comorbidities. Adapted from: WHO. Global 
Health Risks: Mortality and burden of disease attributable to selected major risks. Bull. 




It is currently estimated that 31 % of men and 6 % of women smoke some form of tobacco 
product every day and although the use of tobacco based products has been steadily declining 
in most countries since 1980, smoking remains one of the highest reported CVD risk 
factors9,11. Patterns of smoking can vary between different global regions, sex, and 
socioeconomic status. The WHO estimates that the smoking of tobacco products causes 
approximately 10 % of reported CVD cases10. The INTERHEART case-control study 
examined modifiable risk factors of acute myocardial infarction (ACM) events in 15 152 
cases and 14 820 sex- and age- matched controls across 52 countries12. What they found is 
that regular smoking was significantly associated with non-fatal ACM (odds ratio (OR) 2.95, 
95 % confidence interval (CI) 2.77–3.14, p<0.0001) when compared to non-smoking 
controls, and that smoking even one cigarette a day increased your risk of ACM 
substantially12. They also reported on a linear relationship between the number of cigarettes 
smoked per day and increasing ACM risk, with the risk increased by 5.6 % per additional 
cigarette smoked12. A meta-analysis and literature review by Barnoya and Glantz found that 
the effects of second hand smoking on the cardiovascular system were, on average, between 
80 % and 90 % as large as chronic active smoking13. The evidence is clear that any form of 
tobacco smoking greatly increases your risk of CVD and as such, it should always be 
accounted for when studying CVD related co-morbidities. 
 
1.3.2) Alcohol consumption 
The excessive use, or abuse of alcohol is associated with a multitude of negative health 
outcomes including severe liver cirrhosis, pancreatitis, and neuropathy6. However, the 
relationship between general alcohol use, and CVD risk is more complex. There have been 
reports in which different ranges of CVD risks are found depending on the amount of alcohol 
consumed14. It has also been thought that low levels of alcohol consumption are associated 
with lower risk of CVD, however, an extensive review of alcohol and health by the United 
Kingdom’s Chief Medical Officers found that any protective effect was limited to the elderly, 
who are already at high risk for ischaemic CVD15. Additionally, they report that there may be 
confounding factors which were unaccounted that may contribute to the associated 
protection15. Conversely, heavy consumption of alcohol has been consistently associated with 
an increased risk for CVD9,14.  
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1.3.3) Obesity  
There has been a steady increase in the global prevalence of obesity (Body Mass Index ≥30 
kg/m2), with the incidence of obesity rising from 3 % to 11 % in men and 6 % to 15 % in 
women between 1975 and 201416. The incidence of obesity is highest in high-income 
countries, but it is not isolated to these regions. In South Africa, approximately 25 % of 
adults are obese with women being the worst affected and the rate of obesity in children 
rising1,17. Obesity is strongly associated with other reported CVD risk factors, and can cause 
adverse metabolic effects on blood pressure and lipid profiles6. The INTERHEART study 
found a linear association between Body Mass Index (BMI), waist circumference, and waist–
hip ratio and an increased the risk of myocardial infarction18. However, the association with 
BMI was not a predictor of myocardial infarction in those with a history of hypertension or 
raised APOB/APOA ratio18. Conversely, waist-to-hip ratio remained consistently associated 
with myocardial infarction risk when adjusting for hypertension and raised APOB/APOA, 
and was found to be a better predictor of risk than waist circumference alone18. This suggests 
that waist-to-hip ratio is a better index of obesity which is as a predictor of CVD in most 
populations. However, a study done by Gelber et al. found that the magnitude of associations 
of BMI, waist circumference, waist–to-hip ratio and waist– to- height ratio with CVD risk 
were similar, but that using BMI as an obesity index might miss individuals with increased 
CVD due to central fat distribution19.  
It must be noted that there are ethnic differences in waist-to-hip ratios. It has been shown that 
South African black women have significant interindividual variability in BMI at a given 
body fat percentage20. Additionally, they were shown to have less visceral abdominal adipose 
tissue at a similar waist-to-hip ratio when compared to European women20,21. However, the 
cut-off points for waist-to-hip ratios is largely based on European derived data and may not 
be valid for all ethnicities. As such, population specific cut-offs must be used as a measure of 
obesity for CVD risk20. 
 
1.4) Dyslipidaemia 
Dyslipidaemias, are disorders of lipoprotein metabolism and cover a wide spectrum of lipid 
abnormalities defined by aberrant lipid profiles. Dyslipidaemias are commonly encountered 
in clinical settings and been consistently identified as a major risk factors for the occurrence 
of CVD22–25. Dyslipidaemias may be primary or secondary. Primary dyslipidaemias are 
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caused by the interactions of environmental factors with genetic predispositions. Secondary 
dyslipidaemias are related to other diseases. In order to better understand the pathology of 
dyslipidaemias, we have to investigate the various lipids components and the molecular 
mechanisms of the lipid metabolism pathway. 
 
1.4.1) Overview of the lipid metabolism pathway 
Cholesterol is an essential constituent of the cell needed for normal cell growth and 
development, whilst providing the building blocks for several cell processes. A constant 
supply of cholesterol is needed for these cell processes, which include cell growth, steroid 
hormone synthesis and the structural maintenance of cellular membranes26. Lipids can be 
made available to the cell through three processes: i) the dietary exogenous pathway, ii) the 
endogenous pathway, and iii) through the process of reverse cholesterol transport pathway 
(Figure 1.3)26. Cholesterol uptake and cholesterol biosynthesis are interdependent, so any 
changes to dietary uptake or changes to cellular requirements influence the rate of cholesterol 
biosynthesis through complex feedback mechanisms26. The human body synthesises 
approximately 700-900 mg of cholesterol every day while dietary sources of cholesterol 
account for 300-600 mg of cholesterol/day26,27. The primary sites of cholesterol metabolism 




























1.4.1.1) The exogenous lipid metabolism pathway 
In the exogenous pathway, dietary fats consisting of mostly triglycerides (TG), 
phospholipids, and fat soluble vitamins cholesterols are emulsified by bile salts making them 
susceptible to hydrolysis by pancreatic lipase28. The TGs are hydrolysed into 2-
monoacylglycerols and free fatty acids which are then absorbed into intestinal enterocytes. In 
the intestinal wall, TGs are resynthesized by the 2-monoacylglycerol pathway29. Cholesterols 
are esterified by the endoplasmic reticulum (ER) localised enzymes cholesterol esterase, and 
acyl-CoA: cholesterol acyltransferase (ACAT) and are packaged along with newly 
synthesised TG, phospholipids, apolipoprotein B’s (APOB), and apolipoprotein A’s (APOA) 
into particles called chylomicrons (CM)28,29.  
CMs circulate throughout the intestinal lymphatic system and in the blood. It is here where 
they acquire APOCI, APOCII, APOCIII and apolipoprotein E (APOE). As the free CMs 
circulate they interact with endothelial bound APOCII activated lipoprotein lipase (LPL), 
which mediates the hydrolysis of CM bound TGs. This results in a reduction of the CM core 
Figure 1.3: A representative image of the lipoprotein transport pathways in humans where the exogenous and 
endogenous uptake pathways are briefly outlined. Adapted from: Russell, D. W. Cholesterol biosynthesis and 
metabolism. Cardiovasc. Drugs Ther. 6, 103–10 (1992).  
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volume, and the release of free fatty acids which enter muscle cells for energy production and 
adipocytes for storage28. Some CM components such as phospholipids, free cholesterol, 
APOCII and APOCIII are repackaged into high-density lipoproteins (HDL). The remaining 
CM remnants are TG- depleted, and cholesterol ester and APOE enriched. They are then able 
to interact with the receptors on hepatocytes and are subsequently removed from 
circulation28,30. 
 
1.4.1.2) The endogenous lipid metabolism pathway 
Endogenous lipoproteins are synthesised and released into circulation where they move to the 
peripheral tissues in the form of very low-density lipoproteins (VLDL). The VLDL synthesis 
process is very similar to that of CM synthesis, and VLDL production is synchronised with 
CM secretion28. This is essential to avoid hepatic steatosis and unfavourable lipid 
concentrations in the blood31. TGs are synthesised in the liver in response to free fatty acid 
influxes from adipocytes, CM remnants, and the intestine31. These TGs, along with 
phospholipids, cholesterol esters, and certain apolipoproteins, are the core components of 
VLDL particles (Figure 1.4)31,32. VLDL is synthesised in the lumen of the ER in a two-step 
process. Newly translated APOB is translocated across the ER into the lumen, where it is 
partially lipidated to pre-VLDL particles by microsomal triglyceride transfer protein (MTP). 
It then moves into the Golgi apparatus where it fuses with TG rich particles into mature 
VLDL28,31. Mature VLDL is secreted into the plasma where it undergoes hydrolysis by LPL, 
generating the smaller denser particles called intermediate density lipoproteins (IDL) and 
VLDL remnants. Free fatty acids are once again released and used for energy production in 
muscle cells and storage in adipocytes.  During this process, the remnants become enriched 
with APOE, which is a high affinity ligand for LDL receptors (LDLR)28. VLDL remnants 
and some IDL particles are taken up by the liver via LDLRs, however, IDL particles can 
undergo further hydrolysis to become LDL particles28. 
Circulating LDL is the principal transporter of endogenous cholesterols and active 
phospholipids synthesized in the liver (such as lysophosphatidic acid (LPA)) to the rest of the 
body32. LDLs contain fewer lipids in their core than VLDLs but have more lipids than 
HDLs32. The structural composition of LDL can be observed in Figure 1.4. LDL particles are 
catabolised by two pathways: i) A receptor-dependant pathway in the liver, and ii) a receptor 
independent pathway in non-hepatic tissues32. The receptor dependant pathway is mediated 
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by the LDLR. LDL particles bind with high affinity to the LDLR, which is mediated by 
APOB100 and APOE. This results in the hydrolysis of LDL leading to the release of 
cholesterol esters, and degradation of apolipoproteins in the lysosome33. LDL derived 
cholesterol in the lysosome suppresses 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMG-CoA) activity, which is responsible for the rate of cholesterol synthesis by inhibiting 
the sterol-regulated transcription proteins (SREBPs) pathway33. LDL blocks SREBP 
transcription factor transport and the SREBP’s targets’(HMG-CoA and LDLR) transcription 
is inhibited which results in reduction of cellular cholesterol production33,34. In this manner, 
the amount of cholesterol being produced at any given time is regulated by the total amount 
of cholesterol present in the liver33,34. 
LDL-c processing by the receptor-independent pathway, in non-hepatic cells, is regulated by 
LDL-c plasma concentration, however, even at low LDL-c concentrations LDLRs are 
saturated32,35.  When LDL-c plasma concentrations are high, receptor-independent uptake of 
LDL is greater than the amount of LDL catabolised by the receptor-dependant pathway in the 
liver and LDLs accumulate in non-hepatic cells.32,35 This is clinically important as the 














Figure 1.4: A representative image of the lipid content and surface protein makeup of very 
low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density 
lipoprotein (HDL). Adapted from: Helkin, A. et al. Dyslipidaemia Part 1—Review of 





1.4.1.3) Reverse cholesterol transport and HDL-c synthesis 
HDL particles are lipoproteins which regulate plasma cholesterol and TG levels by mediating 
the transport of cholesterols from peripheral tissues back to the liver in a process called 
reverse cholesterol transport28,36. HDL particles are the smallest forms of lipoproteins and 
have a similar structural composition to VLDL and LDL particles (Figure1.4). The 
accumulation of cholesterol in non-hepatic peripheral tissues is toxic as it cannot be 
metabolised, thus, removal of cholesterol via HDL particles in the reverse cholesterol 
transport pathway contributes to the homeostasis of cholesterol28. HDL particles activate a 
number of anti-oxidant and anti-inflammatory pathways in endothelial cells and 
macrophages32. Thus, in the context of CVD, HDL is often referred to as “good” cholesterol.  
APOAI is the major protein constituent of HDL, and is produced by enterocytes and 
hepatocytes37. It is in these cells that free cholesterol is added to APOAI particles to make 
nascent HDL-c via adenosine triphosphate binding cassette A1 (ABCA1)32,38.  The 
mechanism of the interaction between APOAI and ABCA1 is not yet fully understood, and 
an accepted model for the mechanism for the creation of nascent HDL-c through this 
interaction does not exist, though several models have been proposed28,39. Nascent HDL-c 
particles exist in different particle sizes. HDL2 and HDL3 form the two major spherical 
subpopulations of circulating HDL. HDL3 is smaller and denser, with fewer cholesterol esters 
and more proteins, while HDL2 is larger with more cholesterol esters
28,40. Nascent HDL-c 
particles in the plasma is modified by lecithin cholesteryl acyl transferase (LCAT)41. LCAT 
esterifies cholesterol present in HDL to form the more spherical and mature HDL particles41.  
In the indirect reverse cholesterol transport pathway, HDL cholesterol esters are exchanged 
for TG with VLDL and LDL particles, which is then followed by the uptake of LDL by 
LDLR in hepatocytes28. The phospholipid transfer protein (PLTP) mediates the transferal of 
phospholipids between VLDL and HDL, while also remodelling HDL particles to smaller 
and larger sizes28,42. Lipids can also be transferred between the cell membranes of 
hepatocytes, as well as other cholesterol utilizing tissues, and HDL via the HDL scavenger 
receptor protein BI (SRB1) in a bidirectional manner28,32,43. 
 
1.4.2) Dyslipidaemia and CVD risk 
Dyslipidaemia has consistently been shown to be a major risk factor for the development of 
CVDs. Elevated TC and LDL-c, a combination which can lead to atherosclerosis, were 
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shown to increase the risk of ischaemic heart disease regardless of patient age or blood 
pressure levels in The Prospective Study Collaboration23. Additionally, the WHO estimates 
that raised cholesterol levels results in approximately 2.6 million deaths globally and is 
responsible for a third of reported ischaemic heart disease cases10.  Further evidence of the 
critical role of elevated LDL-c levels in the development of CVD can be found in the analysis 
of LDL-c lowering therapies. Statins, or 3-hydroxy-3-methylglutarylcoenzyme A (HMG-
CoA) reductase inhibitors, have a well-documented effect on lipid profiles, especially with 
prolonged use. LDL-c is the primary target of statin therapy. Statins target hepatocytes and 
inhibit HMG-CoA reductase by competitively binding to the active site, altering protein 
conformation44. Mevalonate, the product of HMG-CoA reductase activity, has a variety of 
cellular functions. Thus, statin therapy leads to inhibition of cholesterol biosynthesis, less 
secretion of lipoproteins, and increased rates of LDL uptake and degradation44,45. Meta-
analysis of randomized trials analysing statin therapy suggest that the frequency of annual 
major vascular events can be reduced by approximately a fifth for each 1 mmol/L reduction 
in LDL-c24. In another review of the efficacy of statin therapy, it is reported that lowering 
LDL-c by 2 mmol/L in 10 000 patients with statin therapy over a 5 year period would prevent 
the onset of major CVD events in about 1000 patients with pre-existing CVD, as well as in 
500 patients who are at high risk but who have not yet had a CVD event46. 
The meta-analysis also found that a similar risk reduction could be achieved in patients with 
significantly elevated HDL-c levels24. HDL-c plays a protective role in the development of 
CVD through its action in the reverse cholesterol transport pathway, but also through its 
reported anti-inflammatory, anti-oxidative and anti-apoptotic effects47. Strong evidence from 
epidemiological studies, as we as the known physiological role of HDL, has contributed to 
the long held notion that raising HDL-c through pharmacological therapies should lead to 
decreased risk of CVD48. However, large scale clinical trials of three cholesteryl ester transfer 
protein (CETP) inhibitors, which raise HDL-c levels, failed to produce reduced risk of CVD 
and were terminated prematurey49–51. It has also been reported, however that under certain 
circumstances, which are related to inflammation and oxidation, HDL-c can lose its 
protective effects, which may be a possible explanation for the trial’s negative outcomes47,48. 
The role of elevated TG as a risk factor for atherosclerosis and ischemic heart disease is not 
as clear and is still under debate. Individuals with high TGs are often found with low HDL-c 
levels, and high LDL-c levels52. As such, it is difficult to distinguish between the effect of 
high TG concentrations on CVD from those of low HDL-c/high LDL-c. In one study, 
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seemingly positive associations found between fasting plasma TG and increased CVD risk 
were not repeated after adjusting for other risk factors, such as HDL-c levels25. Data from the 
Copenhagen City Heart Study showed a stepwise association between elevated non-fasting 
TG levels and increased myocardial infarction risk, most notably in women53. Large scale 
Mendelian randomization genetic studies provide further evidence that supports the 
hypothesis that increased TG levels is independently associated with increased CVD risk54,55. 
Additionally, meta-analysis of a large number of studies found a positive association between 
elevated TG and risk of stroke56. Thus, there is conflicting evidence on the role of 
triglycerides, but the consensus appears to be that significantly elevated triglyceride levels are 
detrimental to CVD outcomes. 
 
1.4.3) The influence of environmental risk factors on dyslipidaemia 
A number of environmental factors have been shown to influence lipid profiles. These risk 
factors are almost always also CVD risk factors/ co-morbidities. A risk factor such as an 
unhealthy diet (defined as a high intake of dietary fats and sugars) may affect dyslipidaemia 
by causing increased endogenous LDL-c levels57. Dyslipidaemia is then, itself, a risk of 
CVD. But an unhealthy diet also affects other CVD risk factors, such as increased body fat 
and blood pressure. There is an intricate relationship between these risk factors and CVD co-
morbidities (Figure 1.2). Some additional key environmental and lifestyle factors which have 
been shown to have significant effects on lipid profiles include body weight and physical 
activity, alcohol usage, and smoking58–60. 
 
1.4.4) The genetics of dyslipidaemia 
Dyslipidaemia has been shown to have a strong genetic component. A paired twin study 
conducted by Heller et. al. showed that approximately 50 % of the interindividual variation in 
plasma lipid levels could be explained by genetic variations61. There has been a concerted 
effort over the past few decades, with varying success, to identify genes and genetic variants 
associated with altered lipid profiles62. Rare genetic variants, usually encoding protein loss-
of-function, are often the sole cause of dyslipidaemias such as familial 
hypercholesterolemia63.  
Common genetic variants, which usually have a smaller effect on gene function but are 
involved in the polygenic modulation of plasma lipid levels, have been identified in 
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population-based association studies64. The most common method used in this approach has 
been large-scale genome wide association studies (GWAS). In this approach large number of 
unrelated individuals belonging to a specific, defined population group, are genotyped for 
millions of candidate SNPs across the entire human genome62. Meta-analysis of 46 lipid 
GWAS studies carried out by Teslovich et.al. reported on 95 GWAS significantly loci which 
were associated with altered lipid profiles in more than 100 000 individuals of European 
descent64. The number of identified loci was then increased to 157 in a subsequent GWAS 
meta-analysis of 188 578 individuals of European descent and 7898 Non-Europeans (African 
= 3263)65. Genes with loci that have been associated with abnormal lipid profiles include 
LDLR, PCSK9, CETP, APOE, LPA, LCAT, LPL, APOB65. 
The advent of cheaper next generation sequencing technology has allowed for rare variant 
association studies in dyslipidaemia. These studies have identified rare coding variants, with 
large effect sizes, in large numbers of unrelated individuals62. Peloso et al. carried out exome 
wide analysis to genotype more than 200 000 low frequency, rare coding variants in 42 208 
European ancestry and 14 330 African ancestry individuals66. Through this method they were 
able to replicate associations in a large number of variants in both populations, as well as 
identify 4 novel loci which had significantly large effects on HDL-c or TG66. A study by 
Lange et al. carried out whole exome sequencing of 1153 European American and 854 
African American individuals and identified low frequency variants in patatin like 
phospholipase domain containing 5 (PNPLA5), a gene which was not previously associated 
with altered LDL-c levels67.  
Genetic studies have been used to bolster evidence from observational epidemiological 
studies that link abnormal lipid profiles to CVD risk. A large-scale Mendelian randomization 
study used a genetic score consisting of 14 SNPs commonly associated with HDL-c, and 
tested this score in 12482 cases of myocardial infarction (MI) and 41331 controls68. They 
used a generated score made from 13 SNPs commonly associated with LDL-c which was 
then tested in the cohorts as a positive control. They expected, from observational 
epidemiological studies, that a 1-standard deviation (1-SD) increase in LDL-c due to genetic 
scores (≈1.94 mmol/l increase) would be associated with a 54 % increase in MI risk. What 
they found was that a 1-SD increase due to the genetic score of the 13 SNPs resulted in a 113 
% increase in MI risk (P=2×10–10) (Figure 1.5)62,68. Thus, there is clear evidence that there is 
















The same study did not find any evidence of a similar causal role of HDL-c in CVD. A 1-SD 
(0.832 mmol/L) increase of HDL-c caused by the 14 SNPs was expected to confer a 38 % 
decreased risk of MI using data from observational epidemiological studies. They found that 
the genetic score conferred no significant change in MI risk (7 % decrease, P=0.63) (Figure 
1.5)62,68. While the data does not rule out the possibility that there are biological mechanisms 
leading to increased plasma HDL-c that also protect against CVD, it does lend evidence to 
the clinical trials that found that pharmacologically raising HDL does not reduce CVD risk62. 
SNPs that have been associated with the modulation of plasma TG are pleiotropic, also being 
associated with other lipids. Of the 157 loci associated with lipid traits, 37 were associated 
with TG in some way, but only 16 were associated with TG only (Figure 1.6)65. While this 
pleiotropy makes interpreting data from Mendelian randomization studies difficult to do, it is 
not unexpected as TG are carried by multiple classes of lipoprotein particles and plasma TG 
concentrations are a reflection of the contribution of various physiological processes62. 
Multivariable Mendelian randomization was recently developed to try to separate the TG 
associated genetic effects from those of LDL-c and HDL-c on CVD risk55. The study 
Figure 1.5: The cumulative effect of genetic variants that raise plasma lipid 
concentrations by 1-SD on MI risk. Adapted from: Musunuru, K. & Kathiresan, S. 
Surprises from Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circ. Res. 




confirms the observations made by Peloso et al. that also show an increase in TG due to 
genetic effects, when adjusted for HDL-c and LDL-c, and an increase the risk of CVD in a 



















Complex lipid metabolism phenotypes are often seen in the clinical setting; thus, it is 
important to take contribution of multiple loci into consideration in patients with less clearly 
defined dyslipidaemia disorders. There are a multitude of previously identified loci with 
varying degrees of reported association with altered plasma lipid profiles. In this study we 
look at genetic variation in three of these genes, APOE, PCSK9, and CETP, which have all 
Figure 1.6: Venn diagram showing number of identified loci associated with multiple lipid traits.  
Adapted from: Willer, et al. Discovery and refinement of loci associated with lipid levels. Nat 
Genet 45, 1274–1283 (2013).  
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consistently been shown to be of great importance when looking at the genetics of 
dyslipidaemia in various population groups. 
 
1.4.5) Apolipoprotein E (APOE) 
The well-studied gene APOE is a key regulator of plasma lipid levels. APOE is located on 
chromosome 19q13.2, within an apolipoprotein gene cluster, and contains 4 exons. APOE is 
mainly expressed in the liver and encodes a 299 amino acid protein, with two independently 
folding protein domains28,69. APOE consists of an N-terminal domain of 22kDa (residues 1-
191) and the 10kDa C-terminal domain (residues 222-299), with a short flexible hinge region 
connecting the two domains70. APOE functions by mediating the clearance of VLDL and CM 
remnants by acting as a ligand for cell surface receptors28,69. The N-terminal contains the 
LDLR binding site, whilst the C-terminal is responsible for the binding of lipids, and to 
LDLR, LRP1 heparan sulphate proteoglycans (HSPG).71  APOE is a key component of 
various lipoproteins (Figure 1.4), thus, genetic variation in this gene is likely to be of concern 
in the context of aberrant lipid profiles. 
 The APOE protein primarily exists in three major isoforms named Ɛ2, Ɛ3 and Ɛ4. Ɛ3 is the 
most common isoform, being referred to as the ‘wild type’ in humans, and is characterised by 
the presence of cysteine and arginine at residues 112 and 158, respectively69.  Ɛ2 has cysteine 
at both sites, while Ɛ4 has arginine at both sites69. The determination of APOE isoform can be 
achieved by genotyping for the rs429358T>C (Ɛ4) and rs7412C>T (Ɛ2) polymorphisms. Both 
Ɛ3 and Ɛ4 isoforms bind to LDLR with high affinity, but Ɛ2 has severely defective LDLR 
binding and is associated with type III hyperlipoproteinemia72. Additionally, Ɛ4 binds with 
better affinity to VLDL than Ɛ3, while Ɛ2 and Ɛ3 are found to have a higher affinity for 
HDL73. Ɛ4 expression was found to increase VLDL levels and decrease HDL-c levels relative 
to Ɛ3 in APOE-null mice74. In contrast, Ɛ2 was to be associated with lower LDL-c and higher 
HDL-c in children, and Ɛ2 homozygotes were found to be associated with increased plasma 
TG and lower LDL in mice75,76.  Further evidence has been shown in a comprehensive meta-
analysis of 82 lipid studies and 121 studies of coronary outcomes where an approximately 
linear relationship between APOE genotypes (Ɛ2/ Ɛ2, Ɛ2/ Ɛ3, Ɛ2/ Ɛ4, Ɛ3/ Ɛ3, Ɛ3/ Ɛ4, Ɛ4/ Ɛ4), 
LDL-c and CVD risk has been seen77. They also reported a weak inverse relationship with 
APOE genotypes and HDL-c, as well as an increase in TG levels when comparing Ɛ2/ Ɛ2 
individuals to Ɛ3/ Ɛ3 individuals77.  APOE has been studied in a South African cohort before, 
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but as it is seen as a major predictor of altered lipid levels, it will be important to evaluate its 
effect on our specific cohort. 
 
1.4.6) Pro-protein convertase subtilisin/kexin type 9 (PCSK9) 
The PCSK9 gene, located at 1p32.3, consists of 12 exons and encodes a 692 amino acid 
protein belonging to the mammalian serine proprotein convertase family78. This family of 
proteins is involved in the proteolytic maturation of secreted proteins such as cytokines, 
receptors and cell surface proteins79. PSCK9 consists of a signal sequence (residues 1–30), a 
prodomain (residues 31–152), a catalytic domain (residues 153-449), and a 243–amino acid 
cysteine rich and histidine-rich C-terminal region (Figure 1.7)78,80. PCSK9 is primarily 
expressed in the liver, but is also found at lower levels of expression in the kidneys, intestine 
and brain81. PSCK9 has been shown to play a vital role in lipoprotein metabolism through its 
functional relationship with LDLR. LDL bound to LDLR is internalized in clatherin coated 
pits where it eventually undergoes lysosomal degradation. LDLR dissociates from the LDL 
and is then recycled back to the plasma membrane where it is available to bind more LDL, 
shuttling back and forth in a continuous process69. Circulating PCSK9, in sera, binds to the 
extracellular domain of LDLR resulting in the redistribution of LDLR from the cell surface to 
lysosomes where the LDLR undergoes degradation. This action also prevents the receptor 
from recycling to the surface82–84. Thus, high PCSK9 activity promotes increased levels of 




























To date a number of common gain-of-function mutations in PCSK9 have been reported in 
several population groups, which were associated with increased LDL-c levels (Figure 1.7)78.  
These are good candidates to study in a South African cohort of patients with high LDL-c 
levels. The E670G (PCSK9 rs505151A>G) polymorphism in PCSK9 has been associated 
with altered LDL-c levels in a number of studies. Chen, et al. reported that a haplotype group 
defined by the E670G polymorphism was significantly associated with elevated LDL-c, 
accounting for 3.5 % of plasma LDL-c variability85. This association was repeated by Evans 
and Beil, who reported an increase in LDL-c levels in men with the 670G variant, however, 
the association was not repeated in women86. These results have not been consistent. A study 
done in a Chinese cohort found that carriers of the 670G allele had significantly lower LDL-c 
levels than non-carriers but it was not found to be associated with CVD risk87. In order to 
Figure 1.7: A representative image of the PSCK9 gene structure, with corresponding protein 
domain, and relative positions of commonly identified genetic variants which are associated 
with increased or decreased LDL-c. Variants in red are found only in patients with high LDL-c. 
Variants in blue are found only in patients with low LDL-c. Variants found in only African 
populations are underlined. Variants found with high frequency in both African and Caucasian 
populations are in italic. Adapted from: Abifadel, M. et al. Mutations and polymorphisms in 
the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and 
disease. Hum. Mutat. 30, 520–529 (2009).  
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resolve this inconsistency, a meta-analysis was carried out by Cai, et al. on all the studies 
with published results to date88. Their analysis confirmed that the 670G allele was indeed 
associated with higher LDL-c levels in all reported population groups analysed both 
separately and combined88. 
Nonsense mutations in PCSK9 were found to be common in African American individuals in 
the Atherosclerosis Risk in Communities study, with approximately 2.6 % of the African 
American cohort having at least one allele with a Nonsense mutation PCSK9 (Y142X or 
C679X)89. These variants were found to reduce LDL-c levels by 28 % and also reduced the 
incidence of CVD by 88 %89. Additionally, C679X (PCSK9 rs28362286C>A) carriers were 
found to significantly reduce LDL-c levels by 36.9 % in African Americans in the Dallas 
Heart Study90. In Africans, the C679X variant was found at an incidence of 3.7 % in 
Zimbabwean women, and was associated with a decrease in LDL-c levels by 27 %91.  The 
C679X truncation disrupts the folding of the C-terminal domain, which is thought to be 
important for the successful secretion of the protein80. PCSK9 protein with the C679X 
truncation is efficiently expressed and processed in human liver cells and retains its catalytic 
activity, but is localised in the ER and is not secreted into the cell medium92.  As such, the 
prevalence and role of both gain-of- and loss-of-function mutations in PCSK9 should be 
explored in our cohort in order to understand the nature of PCSK9 genetic variation in the 
South African population. 
 
1.4.7) Cholesteryl ester transfer protein (CETP) 
CETP is located at chromosome 16q12-21 and spans 25 kb, encoding a 476 amino acid 
protein, and is expressed predominantly in the liver, spleen and adipose tissue40,93. The CETP 
protein plays an essential role in the reverse cholesterol transport pathway by mediating the 
exchange of cholesteryl esters for TGs, from HDL to APOB-rich LDL and VLDL 
particles40,93.  Increased CETP activity contributes to adverse plasma lipoprotein profiles by 
lowering HDL-c levels and increasing LDL-c levels40,93,94. CETP activity was shown to 
increase the total cholesterol content in the liver, while lowering the levels of LDLR mRNA 
and protein, in CETP transgenic mice studies95. 
 A number of common and rare CETP variants have been associated with altered lipid levels, 
and CETP activity through sequencing efforts, GWAS and Mendelian randomization 
studies94,96,97. However, the association of many of these SNPs with lipids and CVD, has not 
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been consistent. The vast majority of research on CETP genetic variation and its effects on 
lipids has been done in European and Asian populations. Studies conducted in Japanese 
cohorts failed to detect CETP mass and activity in individuals who were homozygous for the 
5′ splice donor site of intron 14 (Int14+1G→A) or Q309X nonsense mutations and these 
variants were also significantly associated with increased plasma HDL-c levels98–100. 
One of the most common CETP polymorphisms that has been widely studied is the TaqIB 
(CETP rs708272G>A) variant. CETP rs708272G>A is a silent SNP affecting the 277th 
nucleotide of the intron 169. The TaqIB B2 allele (rs708272A allele) has repeatedly been 
associated with increased HDL-c101,102. Meta-analysis carried out by Boekholdt and 
Thompson, in over 10 000 individuals, reported that B2/B2 homozygotes had lower CETP 
activity and an average increase in HDL-c of 12mmol/L when compared to B1/B1 
homozygotes96. These results are supported by an even larger meta-analysis of 47 studies, 
which investigated 23,928 cases and 27,068 controls, where it was reported that the B2 allele 
was weakly associated with reduced CVD risk103. Further analysis of the B2 allele’s role in 
HDL-c modulation, in 3,600 cases and 5,929 controls, found an increase of roughly 0.25 
mmol/L in HDL-c in a Caucasian cohort103. However, as CETP rs708272G>A is a 
synonymous mutation with no predicted effect on CETP function and no predicted effects on 
regulation or splicing site alteration, it is hypothesised that this association is caused by 
another SNP in strong linkage disequilibrium (LD) with CETP rs708272G>A.  
One of the proposed candidate SNPs is CETP rs1800775C>A which lies in the CETP 
promoter region and has been found in strong LD with CETP rs708272G>A in Caucasians. 
The CETP rs1800775A allele was associated with increased HDL-c levels and was also 
found to reduce CETP protein mass and CETP promoter activity by 28 % and 26 %, 
respectively104. However, this variation may not be the causative allele in the CETP 
rs708272G>A haplogroup as demonstrated in a recent study by Pirim et al. which re-
sequenced the CETP gene and flanking regions in Caucasians and Africans with extreme 
plasma HDL-c levels97. They reported on 12 SNPs which were associated with altered HDL-c 
in both the Caucasian and African cohorts, including CETP rs708272G>A and CETP 
rs1800775C>A97.  However, the CETP rs708272G>A and CETP rs1800775C>A variants 
were not in strong LD in the African cohort (r2 = 0.19)97. This suggests that there could be 
other additional functional genetic variants, other than CETP rs1800775C>A, that are in LD 
with CETP rs708272G>A, and which are responsible for its reported association to increased 
HDL-c. They also report on large proportion of HDL-c altering CETP haplotypes that are 
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located in the 5’region, the promoter, and the first 12kb of CETP, making it a prime region to 
investigate in our cohort97. The relationship between CETP, dyslipidaemia, and CVD requires 
further elucidation in more population groups in order determine the true role of CETP 
genetic variation on aberrant lipid profiles. 
 
1.5) Diabetic dyslipidaemia (DD) 
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder which is characterized by 
chronic hyperglycaemia and unfavourable alterations to carbohydrate, fat and protein 
metabolism105.  These metabolic irregularities are caused by defects in insulin secretion, 
and/or insulin activity105. T2DM is especially important in the context of CVD as T2DM 
patients are at significantly increased risk of developing atherosclerotic CVD106. A 
population-based retrospective cohort study investigating CVD events in 379,003 adults with 
T2DM and in 9,018,082 adults without  T2DM, found that the T2DM patients typically 
developed more severe CVD approximately 14.6 years sooner than people without T2DM107. 
CVD is the leading cause of mortality in T2DM patients with about two thirds of T2DM 
deaths being attributed to CVD, of which approximately 40 % is due to ischemic heart 
disease106,108. Thus, the incidence of T2DM compounds the effect of other CVD risk factors 
such as race, hypertension, smoking, diet and obesity. 
Dyslipidaemia is very common in T2DM patients, with an estimated 60-70% presenting with 
abnormal lipid profiles109. Both glucose and lipids play important interrelated roles in energy 
metabolism, with both groups being regulated in the liver. DD is characterized by elevated 
TG and LDL-c levels, and lowered HDL levels110. It has been found that LDL particles are 
more atherogenic in T2DM patients, regardless of LDL-c concentrations111. The molecular 
mechanisms of this phenomenon are not completely understood.  
Insulin is a key regulator of the metabolism of VLDL, which is the main carrier of TG 
particles110. Insulin mediates the transferal of TG to APOB and is a regulator of lipoprotein 
lipase (LPL) activity, which is responsible for the delipidation of VLDL110. LPL activity can 
be suppressed by circulating free fatty acids. In individuals with insulin resistance, free fatty 
acids are elevated, APOB degradation is decreased leading to overproduction of VLDL, LPL 
activity is impaired and VLDL hepatic uptake is decreased. This results in increased TG 
(Hypertriglyceridemia)106,110. Hypertriglyceridemia stimulates CETP activity and leads to 
lipoproteins with high TG content. HDL with enriched TG content is more susceptible to 
41 
 
catabolism, lowering HDL levels in T2DM patients, while LDL particles are hydrolysed and 
are subsequently smaller and denser106,110. Thus, it is important to investigate factors which 
could compound the already increased risk of CVD in T2DM patients, such as genetic 
variations which cause dyslipidaemia. 
 
1.6) The importance of studying the genetics of dyslipidaemia in black 
South African T2DM patients 
 
Historically, there have been low rates of CVD and T2DM reported in individuals of African 
descent, which has been attributed to low levels of TC, LDL-c, and TGs and high levels of 
HDL-c found in these populations112,113.  However, as lifestyle factors have changed, so too 
have the CVD risk profiles of black South Africans. Results published by the Heart of 
Soweto Study showed that of the 1832 black South Africans observed, 39 % had raised 
cholesterol profiles, 63 % had low HDL-c, 44 % had high LDL-c and 23 % had high TG 
levels114. Approximately 25% of South African adults are obese (BMI ≥30 kg/m2), with 
women being the worst affected, and the rate of childhood obesity rapidly rising1,17,115. The 
International Diabetes Federation (IDF) estimates that the global incidence of DM will 
increase by 55 % by 2040116. The greatest increase is expected in Africa where impaired 
glucose tolerance is estimated to rise by 126.4 % in Sub-Saharan Africa116. An estimated 
2.286 million South African adults are living with DM, a prevalence rate of 7 %105. The 
incidence of T2DM in the urban Xhosa population has increased from 7 % in 1990, to 11.7 % 
in 2009117. CVD co-morbidities and associated risk factors are also on the rise. 
Therefore, it is becoming increasingly important to determine the prevalence and impact of 
population specific genetic variations in black South Africans, which may predispose them to 
developing dyslipidaemia as their lifestyles and diets change. These variations can be used as 
biomarkers to predict future dyslipidaemia.  This is even more pertinent in T2DM patients 
who are already at a higher risk of dyslipidaemia and CVD, and in whom the changes to lipid 
profiles caused by genetic predisposition could have an even bigger impact on disease 
outcomes. Complex lipid metabolism phenotypes are often seen in the clinical setting; thus, it 
is important to take the contribution of multiple loci into consideration in patients with less 
clearly defined dyslipidaemia disorders. The impact of the above-mentioned genetic 
variations has been well characterized in individuals of European and Asian descent, but little 
work has been done on the indigenous black South African population for the majority of 
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these genes. There is insufficient data on its role in African populations, where the burden of 
dyslipidaemia and its related co-morbidities is rapidly increasing. Thus, we carried out 
genetic research to identify population-specific genetic markers that are associated with 
altered lipid metabolism in indigenous black South African patients with T2DM. It is crucial 
to understand the aetiology of dyslipidaemia, in a setting where the burden of CVD, obesity 
and diabetes is rapidly increasing, to apply appropriate management and preventative 
strategies. 
 
1.7) Aims and Objectives 
This study aims to characterize the impact of genetic variations in APOE, PCSK9 and CETP 
on altered lipid metabolism in an indigenous black South African population with T2DM. 
Ultimately, we aim to identify a panel of relevant genetic variations that predispose black 
South Africans to dyslipidaemia and may be used as biomarkers to inform and apply 
appropriate management and preventative strategies. 
Primary end-points: 
Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol 
and triglyceride concentrations (mmol/L) taken from the blood of T2DM patients 
Secondary end-points: 
HbA1c levels, correlation of genetic markers and phenotypes 
 
The study aim was achieved through completion of a number of objectives: 
• Recruitment of participants presenting for diabetes screening or treatment at the Chris 
Hani Baragwanath Academic Hospital  
• Determination of patient lipid profiles  
• Evaluation of patient’s medical records for demographic and clinical information 
related to diabetes  
• Evaluating the contribution of additional clinical variables on altered lipid profiles 
• Determination of the prevalence of known APOE, PCSK9 and CETP variations in 
black South Africans with T2DM by genotyping methods 
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• Investigating the contribution of these variations to altered TC, HDL-c, LDL-c, TG 
and HbA1c levels by genotype-phenotype associations using univariate and 
multivariate analysis  




Chapter 2: Methodology  
 
2.1) Study design 
A quantitative cross-sectional study design was used for our approach to the research 
question.  This allowed us to clearly define the pathogenicity of our selected genetic variants 
in our study population, as well as allowing us to better explain some of the reported 
heterogeneity of these genes.  
 
2.2) Research site and resources 
Recruitment and determination of clinical parameters for this study was completed by Dr. 
Donald Tanyanyiwa at the Diabetes Clinic at Chris Hani Baragwanath Academic Hospital as 
part of a larger project on dyslipidaemia in diabetic South Africans. Medical information 
obtained at the Chris Hani Baragwanath Academic Hospital is kept confidential and curated 
according to their own protocols. Collected whole blood and DNA samples were stored in 
freezers at the University of Cape Town according to ethics clearance (HREC REF 
231/2010), which allows for the storage biological samples for research. Biological samples 
were given a lab code number and anonymised. All further downstream analysis, including 
genotyping, was carried out at the premises of the University of Cape Town’s division of 
Human Genetics, or relevant authorised service providers.  
Clinical platforms for measuring lipid profiles and monitoring blood glucose levels, as well 
as medical staff who carried out blood sample collection, were made available by the Chris 
Hani Baragwaneth Academic Hospital Diabetes clinic in Johannesburg. These resources were 
coordinated by Dr. Donald Tanyanyiwa. Genotyping platforms and relevant research supplies 
and equipment were available through Professor Collet Dandara at the University of Cape 
Town. Data analysis and statistical analysis was performed by researchers involved in the 
study at the University of Cape Town. Funding for the study was provided by the National 
Research Foundation (NRF) and the University of Cape Town through grants awarded to 
Professor Dandara. Funding of students was also awarded by the NRF and the University of 




2.3) Ethics clearance 
This project forms part of a broader study on dyslipidaemia which has approved ethical 
clearance (HREC REF 089/2013) from the University of Cape Town Health Sciences Ethics 
Committee. Ethical clearance for our linked sub-study was approved for ethical clearance 
(HREC REF 750/2016) from the University of Cape Town Health Sciences Ethics 
Committee (Appendix VII). 
 
2.4) Recruitment and Enrolment of Study Cohort 
Recruitment was carried out in the following manner; Patients were invited to participate in 
the study through an information package that explained the aims of the study (Appendix 
VI). The information package was explained by the recruitment team in a language that the 
patient could easily understand. The patients were asked to sign consent forms allowing for 
the extraction of 5 ml whole blood samples for DNA extraction for use in genomic analysis. 
Patients were asked to consent to the researchers accessing their medical records for 
information relating to dyslipidaemia and medication use. The patients were asked a series of 
additional questions relevant to the project at the time of recruitment, such as their 
demographic information, family history and lifestyle choices. To date approximately 1000 
participants have been recruited from which the study case cohort was drawn. 
 
2.5) Study Population 
Our study population consisted solely of individuals from the indigenous Bantu black South 
African ethnicities. We focused on this population group in particular as there is little data on 
the exact role of genetics in dyslipidaemia for black South Africans. The few genetic studies 
available, which include black South African populations, have relatively small sample sizes 
and focus on a few commonly reported variants in clinically significant genes. We aimed to 
greatly improve on the sample size and number of variants investigated, as the need for 
comprehensive data on the effects of genetics on non-communicable disease becomes 
increasingly relevant in the African context. 
A number of the pathogenic genetic variants, published in Caucasian populations, are present 
at low frequencies (>1 %) in individuals of African descent. Comprehensive screening of our 
genes of interest in Caucasian and African American cohorts has revealed that a multitude of 
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variants are specific to each group. There is large genetic variability in Africans, thus, it is 
probable that there are unidentified novel variants in our population that may be pertinent in 
understanding the rise in dyslipidaemia and its comorbidities in South Africa. 
 
2.6) Inclusion and exclusion criteria 
The study included a cohort of dyslipidaemic patients who were attending the diabetes clinic 
at Chris Hani Baragwanath Academic Hospital. All of the patients included in this study have 
been diagnosed as having T2DM by a physician according to the Society for Endocrinology, 
Metabolism and Diabetes of South Africa 2017 guidelines for the management of T2DM105. 
Patients from the larger sample group of approximately 1000 individuals were stratified by 
lipid levels into 4 distinct groups which were included in this study’s cohort. Group 1 (high 
TC), group 2 (high TG), group 3 (mixed dyslipidaemia) and group 4 (normal lipid levels). 
Lipid levels were defined to be dyslipidaemic based on the European Atherosclerosis Society 
(EAS) guidelines for non-diabetic individuals52. Abnormal levels were, thus, defined as 
follows: 
• TC > 5.2 mmol/L, 
•  LDL-c > 4.1 mmol/L,  
• Triglycerides > 2.3 mmol/L, 
• HDL-c < 1 mmol/L.  
 
Selection of samples to include by stratification by lipid profile into the 4 groups was done to 
ensure that a there was a wide range of lipid traits present in the cohort. The samples were 
combined into one case cohort during analysis. Thus, potential alterations to lipid levels 
caused by genetic variations were likely to be teased out. 
The exclusion criteria were a) all patients with known primary causes of dyslipidaemia, and 
b) those with non-diabetic related secondary cause of dyslipidaemia. These included thyroid 
disorders, treatment with antiretroviral drugs protease inhibitors associated with 




2.7) Study cohort sample size 
The lowest frequency of 2% for a SNP was be used for sample size determination with the 
method outlined by Naing, et al.118. We wish to estimate the population proportions of black 
South Africans with the abnormal lipid levels (high TC, high TG, mixed dyslipidaemia and 
normal levels). To obtain a 95 % confidence interval for each of these parameters with a 




If we assume that 5% of the sampled patients will have abnormal lipid levels in each group 
and we want a 95% confidence interval of width 0.05 (i.e. Δ = 0.05), then the required sample 
size is n = (1.96/0.05)2 0.05 (1 – 0.05) = 73 (rounding up). Thus, the study needed 73 
participants in each of the four groups: group 1 (high TC), and group 2 (high TG), group 3 
(mixed dyslipidaemia) and group 4 (normal levels) which is 73×4 =292.  
After selection of relevant samples based on inclusion criteria, adding at least 100 samples 
from each group for added power, we ended up with a final sample size of 417 participants. 
 
2.8) Lipid Profile Determination 
The lipid profiles of each participant were measured using the Roche/Hitachi cobas c systems 
(Roche, Mannheim, Germany) according to the manufacturer’s instructions, at the Chris Hani 
Baragwanath Academic Hospital laboratories. A brief overview of the enzymatic methods 
employed by the system is summarised here. 
 
2.8.1) Total Cholesterol determination 
The CHOL2 kit uses an in vitro enzymatic/colorimetric test to quantitively determine TC 
levels in human serum and plasma. Cholesterol esters are cleaved by cholesterol esterase 
(CE) activity yielding fatty acids and free cholesterol. Cholesterols are, in turn, oxidised to 
form cholest‑4‑en‑3‑one and hydrogen peroxide by the action of cholesterol oxidase 
(CHOD). The hydrogen peroxide formed effects the oxidative coupling of phenol and 
4‑aminophenazone to form a red quinone‑imine dye, in the presence of peroxidase (POD). 
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The colour intensity of the red quinone‑imine dye is determined by measuring an increase in 
absorbance and is directly proportional to TC concentration. 
 
2.8.2) HDL-c determination 
The Roche direct-HDLC3 assay is an in vitro homogeneous enzymatic colorimetric 
diagnostic test for determining human serum and plasma HDL-c concentrations. LDL, 
VLDL, and chylomicrons form water-soluble complexes with dextran sulphate in the 
presence of magnesium ions. These complexes are resistant to polyethylene glycol (PEG)-
modified enzymes, which are have selectively catalytic activities to lipoproteins in the 
following order LDL < VLDL ≈ chylomicrons < HDL119. 
HDL-c esters are cleaved by PEG modified-CE activity yielding fatty acids and free HDL-c. 
HDL-c’s are, in turn, oxidised to form Δ4‑cholestenone and hydrogen peroxide by the action 
of PEG-modified CHOD. The generated hydrogen peroxide reacts with 4‑amino‑antipyrine 
and Sodium N‑(2‑hydroxy‑3‑sulfopropyl) -3,5‑dimethoxyaniline (HSDA) to form a 
purple‑blue dye. The colour intensity of this dye is measured photometrically and is also 
directly proportional to HDL-c concentration.  
 
 
2.8.3) Triglyceride determination 
The Roche direct-TRGL assay is an in vitro homogeneous enzymatic colorimetric diagnostic 
test that was used to determine human serum and plasma TG concentrations. TG are 
hydrolysed to glycerol through the action of LPL. This is followed by oxidation of glycerol to 
dihydroxyacetone phosphate and, subsequently, hydrogen peroxide through the catalytic 
actions of glycerokinase (GK) and glycerol phosphate oxidase (GPO) respectively. POD 
catalyses the reaction of 4‑aminophenazone and 4‑chlorophenol to form 
4‑(p‑benzoquinone‑monoimino) -phenazone, which is a red dyestuff that can be measured 
photometrically, the intensity of which is directly proportional to TG concentration.  
 
2.8.4) LDL-c determination 
LDL-c levels were estimated using the Friedewald equation. This method for the indirect 
estimation of LDL-c concentrations requires the direct measurement of TC, TG and HDL-c. 
In this method the assumption that the TC is made up of LDL-c, HDL-c and VLDL-c. Thus, 
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in order to estimate LDL-c concentrations: LDL = TC - HDL - TG/5.0 (mg/dL), where 
TG/5 is an estimation of VLDL-c120. 
The assumption of VLDL:TG = 1:5 is convenient as most of circulating TG is carried in the 
VLDL fraction, however, the method does not take into account the contribution of CMs. In 
most plasma samples CMs are not detectable, thus, it is has been proven to be a reliable 
method to use121. The Friedewald equation is not without limitations. In cases of 
dysbetalipoproteinemia (Type Ill hyperlipoproteinemia), VLDL-c concentrations are 
underestimated, and LDL-c concentrations are overestimated. Additionally, in cases where 
TG ≥ 4.5 mmol/l the equation overestimates VLDL-c concentrations and underestimates 
LDL-c concentrations121. Downstream analyses of LDL-c associations were excluded for 
patients with TG ≥ 4.5 mmol/l in our study. 
 
2.9) Haemoglobin A1C (HbA1c)  
Haemoglobin (Hb) is a protein located in the erythrocytes and consists of four subunits 
containing a haem moiety. Hb functions by mediating the transport of oxygen and carbon 
dioxide in the blood. Hb is heterogeneous, with 90% of Hb in human erythrocytes being 
HbA122. There are a number of other Hb derivatives, including HbA1c which is a post 
translational modification of HbA. HbA1c is formed by a non-enzymatic reaction  of glucose 
to the N-terminal amino group of the β-chain of normal adult HbA122. HbA1c% as a fraction 
of Hb levels has been shown to be correlated with response to glucose tolerance tests and 
fasting blood sugar levels123,124.  Stable HbA1c formation is limited to approximately 100-
120 days, the lifespan of erythrocytes, thus, HbA1c% is a reflection of the average blood 
glucose level of the previous 2 to 3 months and is a useful parameter for monitoring long-
term blood glucose control in T2DM patients122. HbA1c% has also been shown to be a 
predictor of diabetic complications in T2DM patients, with T2DM patients having a 2-3 fold 
increase in HbA1c123,125,126. 
 
2.9.1) HbA1c% determination 
HbA1c levels were measured using the Tina-quant Haemoglobin A1c Gen.2 whole blood 
application on the Roche/Hitachi cobas c systems (Roche, Mannheim, Germany) according 
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the manufactures instructions, at the Chris Hani Baragwanath Academic Hospital 
laboratories.  
The turbidimetric inhibition immunoassay (TINIA) for haemolysed whole blood is the bases 
for HbA1c determination. HbA1c reacts with anti-HbA1c antibodies and forms soluble 
complexes. Polyhaptens are added to the solutions, which react with the anti-HbA1c 
antibodies. This results in the formation of insoluble antibody-polyhapten complexes which 
can be measured turbidimetrically. Hb in the samples is converted to a derivative with a 
characteristic absorption spectrum which is then measured bichromatically. The HbA1c% 
calculated from the HbA1c/Hb ratio:  
HbA1c (%) = (HbA1c/Hb) × 91.5 + 2.15 
 
2.10) DNA isolation 
DNA was extracted from whole blood samples using a modified version of the salting out 
protocol adapted from Gustafson et al.127.  Whole blood samples (5 mL), frozen in storage, 
were thawed at room temperature and diluted with 2 X volume of phosphate buffered saline 
(PBS) (Appendix I). The PBS solution ensures a constant pH which preserves the white 
blood cells during maceration. The samples were then centrifuged at 2200 g for 10 minutes, 
after which the supernatant was carefully discarded, and the pellet re-suspended in Sucrose 
Triton X-100 lysis buffer (10 mL) (Appendix I) and vortexed. The Tris-HCl in solution 
maintains a favourable pH of 8, the magnesium chloride (MgCl2) provides Mg²⁺ ions which 
are co-factors for the enzymes in the solution, the sucrose increases osmolarity of the cells 
which results in the intake of water aiding in cell lysis, and Triton X-100 is a non-ionic 
surfactant which weakens cell membranes while not denaturing proteins. The tubes were then 
placed on ice for 5 minutes, allowing the completion of cell lysis and hindering the action of 
DNA cleaving enzymes in solution. The tubes were again centrifuged at 2200 g for 10 
minutes, and the supernatant was discarded. The pellet was re-suspended in 0.6 X volume of 
blood sample T20E5 (3 mL) containing ethylenediaminetetraacetic acid (EDTA) (Appendix 
I), which captures the divalent cations needed by DNase enzymes, inhibiting DNA 
degradation. 200 uL of 10 % sodium dodecyl sulphate (SDS) (Appendix I), which breaks 
down membranes, and 200 ug/mL Proteinase K was added to degrade any remaining proteins 
in solution. The samples were then incubated at 45°C overnight in a water bath.  
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Saturated sodium chloride (NaCl) (1 mL) was added to each sample the following day, 
followed by vigorous mixing. Increased NaCl concentration results in some of the H2O 
molecules being attracted by Na+ ions, which do not interact with hydrophilic residues of 
proteins. The result is that protein: protein interactions are stronger than protein: water 
interactions, causing the proteins to coagulate. The tubes were then centrifuged at 2400 g for 
30 minutes, pelleting out the protein fragments and leaving DNA in solution. The DNA 
containing supernatant was transferred to a new tube, and 2X volumes of room temperature 
100 % ethanol was added. DNA is not soluble in ethanol; thus, the addition of 100 % ethanol 
allows for the precipitation of DNA out of the solution. The tubes were gently agitated, and 
the precipitated DNA was spooled and transferred to an Eppendorf tube, and washed in ice 
cold 70 % ethanol (1 mL) to remove any remaining salts. The DNA was then air dried and re-
suspended in 1 X Tris-HCl, EDTA (TE) buffer for storage.   
 
2.11) Determination of DNA yield, purity, and integrity 
Quality control of the extracted DNA samples was carried out to ensure the success of 
subsequent downstream experiments. The methods used are outlined below. An example of 
DNA yield and purity, as well as DNA integrity can be found in Appendix II. 
 
2.11.1) DNA yield and purity quantification 
The yield and purity of extracted DNA was quantified by spectrophotometry using a 
NanoDrop™ 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA).  
Sample concentrations were calculated for each sample from optical density (OD) according 
to the following equation:  
A = -log (Intensity sample/Intensity blank) 
A is absorbance is measured at 260nm. A modified version of the Beer-Lambert equation is 
then employed to correlate absorbance to concentration: 
c = (A * e)/b 
Where c is the nucleic acid concentration in ng/μL, A is the absorbance in AU, e is the 
wavelength-dependent extinction coefficient in ng-cm/μL (50 ng-cm/μL for double stranded 
DNA) and b is the pathlength in cm.  
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DNA purity was determined by measuring the A260 nm/A280 nm ratio. A DNA sample with a 
A260 nm/A280 nm ratio of greater than 1.8 is generally accepted as high purity. Contaminants 
that absorb at 280nm, such as proteins, will lower the ratio. The A260 nm/A230 nm ratio is 
another parameter used to determine purity and is used to check for contaminants such as 
phenol, carbohydrates and EDTA which absorb at 230 nm. A DNA sample with A260 nm/A230 
nm ratio of between 1.8 and 2.2 is considered pure.  
 
2.11.2) Determination of DNA integrity using agarose gel electrophoresis 
DNA samples were evaluated for potential degradation using agarose gel electrophoresis. In 
this method, DNA fragments are visualised and separated based on size in an agarose gel. 
Powdered agarose (Seakem® LE Agarose, Lonza, Rockland, USA) is added to 1 X Tris-
Borate EDTA (TBE) buffer at a concentration of 1 % (w/v). The solution is mixed, 
superheated in a microwave until the solution is clear and all the agarose is fully melted in the 
1XTBE. The solution was allowed to cool and stained with 40 uL EZ-VISION™ DNA Dye 
(VWR Life Science, AMRESCO, Philadelphia, USA) /100 mL gel, a non-mutagenic agent 
that inter-chelates with DNA and fluoresces under ultraviolet (UV) light. The cooling 
solution was set in a plastic cast to form a solid gel. Agarose polymers form a gel-matrix with 
pore sizes proportional to the concentration of agarose in the gel solution. DNA samples were 
mixed with loading dye (2 uL) and added to wells formed in the fully set gel, along with a 
lane containing GeneRuler® 100 bp Plus DNA Ladder (Fermentas, Ontario, Canada) 
(Appendix I) consisting of fragments of known size. The DNA ladder was used to visually 
estimate the size of DNA fragments of interest. 
The gel is placed into a tank containing 1 X TBE attached to an Enduro™ power pack 
(Labnet, Woodbridge, USA). An electric current (100 V) was then passed through the gel 
which for 60 minutes, which caused DNA with a negatively charged phosphate backbone and 
uniform mass/charge ratio to move towards the positively charged anode. DNA fragments of 
a smaller size were able to pass through larger pores in the agarose matrix more easily than 
larger fragments and move faster than larger fragments. The distance that a fragment moves 
in a defined period of time is inversely proportional to the log of its molecular weight. DNA 
was visualized by exposure to UV light in the a UVItec FireReader V4 UV gel 
documentation machine (UVItec, Cambridge, UK) using the UVItec FireReader imaging and 
editing software (UVItec, Cambridge, UK). The integrity of the DNA is determined by the 
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banding pattern seen in the captured gel image. Intact genomic DNA will appear as a large, 
bright band. Degraded DNA will appear as a smear, or series of smaller fragmented bands. 
The greater the intensity of the smearing, the greater extent of the degradation.  
 
2.12) Working samples 
Working samples of 100 ng/uL were made from stock DNA samples to reduce free-thawing 
of the DNA and ensure the availability of DNA for downstream applications, as well as to 
minimize the risk of contamination of the stock DNA samples. DNA samples with a 
concentration that was greater than 100 ng/uL were diluted in Sabax sterile distilled water 
(sdH20) (Adcock Ingram, Johannesburg, South Africa) to a final concentration of 100 ng/uL. 
Samples with concentrations less than 100 ng/uL were not diluted, rather a volume of 30 uL 
of the stock was aliquoted into new tubes for downstream experiments. Working solutions 
were stored at 4 °C to prevent degradation due to repeated thawing. 
 
2.13) Characterization of APOE, PCSK9, and CETP genetic variations 
DNA samples from the selected patients in the study cohort were genetically characterised 
for selected SNPs in the APOE, PCSK9, and CETP genes which are known to play crucial 
roles in the lipid metabolism pathway. Gene annotation was performed using PerlV5 based 
Annottv programme written by Dr. George Rebello (April 2006, Division of Human 
Genetics, UCT, SA).  The CETP gene was analysed for known SNPs positions and 
intron/exon lengths were determined. The 5'region was included in this analysis. Gene 
sequences for primer designing were annotated from information in the reference sequences 
provided by the National Centre for Biotechnology Information (NCBI) Gene Entrez website 
(URL: http://www.ncbi.nih.gov) and the Ensembl website (URL: http://www.ensembl.org).  
 
2.13.1) Selection of genetic variations for analysis 
Genetic variations in the APOE, PCSK9, and CETP genes were selected for characterization 
based on previous reports in the literature on their functional significance in the lipid 
metabolism pathway, or association with altered lipid profiles. Many loci have previously 
been shown to be associated with altered lipid metabolism (Figure 1.6), thus a number of 
selection criteria were employed in order to select SNPs likely to be relevant to our cohort for 
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cost-effective genotyping. In addition to being linked to dyslipidaemia in other studies, the 
SNPs had to have been reported in other African populations so as to be frequent enough to 
have observable effects in our cohort. SNPs with previously reported and validated 
genotyping assays that allowed for timely and cost-effective analysis of two or more SNPs in 
one assay were given preference and are summarised in Table 2.1. 
Based on these criteria 2 SNPs (APOE rs429358T>C and APOE rs7412C>T) were selected 
for genotyping in APOE. The genotyping of these SNPs, in combination, allows for the 
characterization of the APOE protein isoform. These SNPs have been widely studied in other 
population groups, as well as South Africans, in diabetic and non- diabetic cohorts, with 
variable results77,128. However, as the APOE Ɛ4 and Ɛ2 isoforms have been consistently 
linked to dyslipidaemia, they were included in this study as they were likely to play a major 
role in our cohort.  Thus, they were essential to investigate in the context of our study. 
The PCSK9 gene was included as it is hot topic in the genetics of lipid metabolism, with 
several African specific variations being strongly associated with altered LDL-c 
metabolism88,89,90. Of these potential targets, two SNPs in the PCSK9 gene (rs505151A>G 
and rs28362286C>A) were selected for genotyping for the following reasons. Firstly, 
rs505151A>G encodes the E670G gain-of-function amino acid change, while 
rs28362286C>A encodes the African specific loss-of-function C679X variation. Secondly, 
these SNPs are in close proximity, so they can be genotyped together with a single 
sequencing assay. 
CETP is another gene that is currently being widely investigated for its role in HDL-c 
metabolism, with little work being done in African cohorts94,96,97. The CETP rs708272G>A 
(Taq1B) polymorphism was selected as a potential target for genotyping despite it encoding a 
silent SNP with no predicted effects on regulation or splicing site alteration69. It has also been 
consistently associated with altered lipid metabolism which may be due to it being in LD 
with another unknown functionally important SNP103. Pirim et al. reported a strong 
association between the CETP rs708272A allele and slightly increased HDL-c levels in an 
African cohort97. Upon annotation of the region encompassing CETP rs708272G>A, it was 
found that a total of 12 CETP SNPs (Table 2.1) were in close enough proximity (761bp) to 
be genotyped in a single sequencing assay. Of these SNPs, 5 (CETP rs17231520G>A, CETP 
rs34065661C>G, CETP rs711752G>A, CETP rs708272G>A and CETP rs3816117C>T) 
were reportedly associated with altered HDL-c metabolism in the same study97. Thus, a 
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sequencing assay of the encompassing DNA region would provide data on 12 SNPs, and also 
possibly reveal novel SNPs in a greatly variable region of CETP. 
 
Table 2.1: APOE, PCSK9 and CETP genetic variants selected for genotyping in the study 
cohort. 








APOE rs429358T>C Increased LDL-c 0.268 PCR-RFLP 128 
  rs7412C>T Decreased LDL-c 0.103 PCR-RFLP 128 
      
PCSK9 rs505151A>G Increased LDL-c 0.288 Sanger seq. 86 
 rs28362286C>A Decreased LDL-c 0.008 Sanger seq. 86 
      
CETP rs17231520G>A Increased HDL-c 0.082 Sanger seq. 97 
 rs34065661C>G Increased HDL-c 0.083 Sanger seq. 97 
 rs711752G>A Increased HDL-c 0.247 Sanger seq. 97 
 rs708272G>A Increased HDL-c 0.247 Sanger seq. 97 
 rs5884C>A None 0.056 Sanger seq. 97 
 rs34680782C>A None 0.012 Sanger seq. 97 
 rs17231534C>A None 0.133 Sanger seq. 97 
 rs3816117C>T Decreased HDL-c 0.404 Sanger seq. 97 
 rs561260717C>T None 0.001 Sanger seq. 97 
 rs34119551A>T None 0.005 Sanger seq. 97 
 rs5030708C>T None 0.000 Sanger seq. 97 
 rs183782798G>T None 0.003 Sanger seq. 97 
Minor allele frequencies (MAF); * average of African population frequencies; frequencies obtained from the 
1000 genomes project 
 
 
2.14) Molecular methods for the characterization of APOE, PCSK9, and 
CETP genetic variations 
Following the identification of genetic variants for analysis in this study, the appropriate 
genotyping methods were selected and optimized for use with the reagents and equipment 
that were available. The APOE and PCSK9 SNPs were characterized using modified versions 
of the methods and primers available from the literature, while the CETP SNPs were 
characterized with a new assay designed for this study (Table 2.1). The principal of the 






2.14.1) Principal of polymerase chain reaction (PCR) amplification 
Polymerase chain reaction (PCR) amplification is a widely used technique that allows for the 
exponential amplification of a specific genomic DNA region of interest. The technique relies 
on the design of oligonucleotide primers which hybridise to the region of interest with high 
specificity, allowing the replicating action of Taq DNA polymerase to take place inside a 
thermocycler. The reaction consists of repeated thermal cycling steps, starting with an initial 
denaturation cycle at 94°C during which the double-stranded DNA strands are separated into 
two complimentary strands. This is followed by repeated cycling of: a 94°C denaturation 
step, an annealing step at a temperature which is primer dependant and allows the specific 
binding of forward and reverse primers to the complementary template sequence, and an 
extension at 72°C which is the optimum temperature for the action of Taq DNA polymerase. 
Taq DNA polymerase is a thermo-stable DNA polymerase, which catalysis the addition of 
deoxynucleotides (dNTPs) 3' downstream of the bound primers in the presence of the co-
factor MgCl2. Two new daughter strands complementary to the parent template DNA strands 
are formed in each cycle and thus, the theoretical number of amplicons per cycle is 
represented by 2n where n = number of PCR cycles. Several PCR amplification-based 
techniques have been developed for the genotyping of selected genetic variants including: 
restriction fragment length polymorphism (RFLP) analysis, and Direct cycle dye-terminator 
(Sanger) sequencing. 
 
2.14.2) Principal of PCR-RFLP analysis 
PCR-RFLP analysis is one of the more widely used methods for the detection of variation at 
the DNA sequence level. The PCR-RFLP technique makes use of restriction enzymes (RE), 
isolated from bacteria and archaea, which bind to and cleave DNA substrates at specific sites 
based on the recognition of specific DNA sequences. These cleaving sites are called 
restriction sites and are often palindromic. A SNP in the DNA sequence can create or abolish 
a restriction site. This is useful as it allows for the determination of wild-type or variant 
alleles based on the digestion of a PCR amplification product with appropriate RE’s.   
PCR-RFLP analysis makes use of RE that only cleave at a specific site, creating DNA 
fragments of a defined length. This is determined by the size of the PCR amplification 
product, and the position of the restriction sites on the DNA sequence. Digestion with an 
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appropriate RE will result in DNA fragments of defined and deferent lengths, that dependent 
on wild-type or variant allele being present. These fragments can then be separated and 
visualised by agarose gel electrophoresis. Thus, the genotype of the SNP of interest can be 
elucidated. RFLP digest reactions were designed using the online program NEBcutter v2.0 
(New England BioLabs, Inc., Ipswich, USA) (http://tools.neb.com/NEBcutter2/index.php).  
 
2.14.3) Direct Cycle Dye-terminator Sequencing 
Direct Cycle Dye-terminator Sequencing is a powerful tool used for the direct determination 
of the nucleotide sequence PCR amplified product. This method is based on the incorporation 
of fluorescently-labelled dideoxynucleotides (ddNTP’s) and dNTP’s by Taq DNA 
polymerase to newly synthesized complementary DNA strands.  The post-PCR reaction takes 
place in a BioRad T100 ThermocyclerTM (BioRad Laboratories Inc, USA) and follows much 
of the same steps as a regular PCR amplification. Denaturing of the double-stranded DNA 
fragments is followed by hybridisation of oligonucleotide primers to their specific binding 
sites. dNTPs are incorporated 3' downstream of the bound primers into the growing chain of 
the complimentary strand by the action of Taq DNA polymerase. Taq DNA polymerase 
simultaneously randomly incorporates fluorescently-labelled ddNTP’s into the nascent strand 
as. ddNTPs are similar to dNTPs except they contain a hydrogen group on the 3' carbon 
instead of a hydroxyl moiety. This modification prevents the incorporation of further 
nucleotides, as phosphodiester bond cannot form between the ddNTP and the incoming 
dNTPs, resulting in chain termination.  
The reaction is repeatedly cycled allowing for synthesis of complimentary fragments of every 
possible length. The DNA fragments are then heat denatured and separated according to size 
by capillary electrophoresis, with resolution at a single nucleotide. The ddNTPs are labelled 
with fluorescent dyes which emit light at different wavelengths under laser excitation. Light 
emissions are detected and recorded as they pass through a genetic analyser detector. This 






2.15) Genotyping study cohort for selected SNPs 
 
2.15.1) PCR Primer design 
PCR primer sequences were available for the 218 bp APOE fragment and the 168 bp PSCK9 
fragment from two previous studies by Marrzoq et al. (2011) and Evans and Beil (2006), 
respectively86,128. Primers for the characterization of the 12 CETP SNPs were designed for 
this study. A primer pair was designed to amplify a 761 bp region flanking part of the 5' 
UTR-Exon1-Intron1 region of CETP, which contains all 12 relevant CETP SNPs in 
Table2.1. Details of the primers used for the three assays are described in Table 2.2 below.  
CETP primers were designed using the annotated sequence as a guide. Primer pairs were 
designed using the PrimerQuest online tool (Integrated DNA Technologies Inc, 2016) (URL: 
https://eu.idtdna.com/PrimerQuest/). Optimal primers were chosen to have lengths between 
17-28 bp, a GC content of approximately 50 %, and were checked so that no SNPs were 
present in the sequence. Primers were assessed for these parameters, as well as for primer 
melting temperatures, and significant secondary structures and dimer formations using the 
OligoAnalyzer v3.1 software (Integrated DNA Technologies Inc, 2017) (URL: 
https://www.idtdna.com/analyzer/Applications/OligoAnalyzer/).  
The primer pair that met the aforementioned criteria were then analysed using the National 
Centre for Biotechnology (NCBI) Primer-BLAST search tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) to determine the specificity of the primers 
binding. Primers that were shown to bind with low specificity to many sites in the human 
genome were excluded. Primers were designed to be highly specific to only the region of 
interest to ensure that no non-specific PCR products were amplified in the reaction. 
Primers were ordered from and synthesised by Integrated DNA Technologies, Inc. 
(Coralville, IA, USA) and resuspended in 1 X TE buffer with a final concentration of 100 








Table 2.2: Oligonucleotide primer pair summary of three PCR amplification assays. 
A) APOE PCR Fragment 
 
B) PCSK9 PCR Fragment  
 
C) CETP PCR Fragment 
 
 
Primer pairs that were obtained from the literature, namely those for the APOE and PSCK9 
fragments, were then re-optimised for PCR amplification in this study. Successful 
amplification of a target sequence required optimisation of the reaction conditions. These 
conditions are dependent on the nature of the primers, the condition of the template DNA, 
and the thermocycler being used for the reaction. Common PCR optimisation steps include: 
optimisation of the annealing temperature (Ta), the amount of initial template DNA added 
MgCl2 concentration, extension cycle length, and the amount of Taq DNA polymerase added 
per reaction. Agarose gel electrophoresis, as discussed in Chapter 2.11.2, was used to 




Primer Forward Reverse 
Sequence (5'-3') TCCAAGGAGCTGCAGGCGGCGCA GCCCCGGCCTGGTACACTGCCA 
Length (bp) 23 22 
Melting temperature °C 70.1 68.7 
GC content (%) 69.6 72.7 
Product size (bp) 218 
Primer Forward Reverse 
Sequence (5'-3') TACGCCGTAGACAACACG TCCCCAGACACCCATCCTGG 
Length (bp) 18 20 
Melting temperature °C 54.6 61.4 
GC content (%) 55.6 65 
Product size (bp) 168 
Primer Forward Reverse 
Sequence (5'-3') GGGAGACAAGTAGAAGTTGGG TCCCCAGACACCCATCCTGG 
Length (bp) 21 19 
Melting temperature °C 54.8 55.7 
GC content (%) 52.4 52.6 
Product size (bp) 761 
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2.15.2) Genotyping for the APOE rs429358T>C and APOE rs7412C>T single nucleotide 
polymorphisms 
 
2.15.2.1) Annealing temperature optimisation and PCR amplification of the APOE 
fragment flanking APOE rs429358T>C and APOE rs7412C>T 
A temperature gradient PCR amplification was performed to determine the optimal Ta for the 
successful amplification of the 218 bp APOE fragment. The temperature gradient PCR 
amplification was performed on a BioRad T100 ThermocyclerTM (BioRad Laboratories Inc, 
USA).  
Following Ta optimization, PCR amplification of the 218 bp fragment of APOE fragment 
flanking APOE rs429358T>C and rs7412C>T was performed on the same BioRad T100 
ThermocyclerTM with the following cycling conditions: an initial denaturation step at 95 °C 
for 3 minutes, followed by 35 cycles of 95 °C for 30 seconds, annealing at 65.6 °C for 30 
seconds and elongation at 72 °C for 30 seconds. This was followed by a final extension at 72 
°C for 10 minutes. Each reaction contained 1 X Green GoTaq® Reaction Buffer (Promega, 
Madison, USA) with added loading dye, 0.4 mM dNTPs (BioLine, London, UK), 1.5 mM 
MgCl2, 0.1 uM of each primer and 0.5 Units (U) GoTaq® DNA polymerase (Promega, 
Madison, USA). Each reaction was made up to its final volume of 25 uL with sdH2O.  
PCR products from both the optimisation and amplification reactions were electrophoresed 
on 1.5 % (w/v) agarose gels run at 100 V for 60 minutes. Agarose gels were visualized by 
EZ-VISION™ DNA Dye (VWR Life Science, AMRESCO, Philadelphia, USA) gel staining 
followed by exposure to UV light in a UVItec FireReader V4 UV gel documentation machine 
(UVItec, Cambridge, UK) using the UVItec FireReader imaging and editing software 
(UVItec, Cambridge, UK). GeneRuler® 100 bp Plus DNA Ladder (Fermentas, Ontario, 
Canada) was used as a size standard (Appendix I).  
 
2.15.2.2) PCR-RFLP genotyping for the characterisation of APOE rs429358T>C using 
AflIII restriction enzyme digest 
The 218 bp APOE fragment was digested using the AflIII RE to genotype the APOE 
rs429358T>C SNP. Briefly, 10 ul of APOE PCR product was digested with 3 U AflIII RE 
(New England BioLabs, Inc., Ipswich, USA) in 1 X NEB3.1 buffer (New England BioLabs, 
Inc., Ipswich, USA), made up to a final volume of 30 uL with sdH2O. AflIII digestions were 
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incubated in a water bath at 37 °C overnight. The products of the digest were visualised by 
electrophoresis at 60 V for 6 hours on a 3.5 % (w/v) Nusieve™ 3:1 agarose gel (Lonza, 
Rockland, USA) stained with GelRed® nucleic acid dye (Biotium, Inc., Fremont, CA, USA). 
The GeneRuler® 100 bp Plus DNA Ladder (Fermentas, Ontario, Canada), and GeneRuler® 
50bp DNA Ladder (Fermentas, Ontario, Canada) were used as a size standard (Appendix I). 
The AflIII RE recognises the 5'... A↓C R Y G T ...3' restriction site. APOE rs429358TT 
homozygotes have one AflIII restriction site, resulting in two fragments sized 168 bp and 50 
bp after complete digestion. Introduction of the APOE rs429358C allele abolishes the 
restriction site. Thus, APOE rs429358CC homozygotes present with one 218 bp fragment, 
while APOE rs429358TC heterozygotes present with three fragments sized 50 bp, 168 bp, 
and 218 bp, following digestion with AflIII. 
 
2.15.2.3) PCR-RFLP genotyping for the characterisation of APOE rs7412C>T using 
HaeII restriction enzyme digest 
The 218 bp APOE fragment was digested using the HaeII RE to genotype the APOE 
rs7412C>T SNP. Briefly, 10 uL of APOE PCR product was digested with 3 U HaeII RE 
(New England BioLabs, Inc., Ipswich, USA) in 1 X CutSmart® buffer (New England 
BioLabs, Inc., Ipswich, USA), made up to a final volume of 30 uL with sdH2O. HaeII 
digestions were incubated in a water bath at 37 °C overnight. The products of the digest were 
visualised by electrophoresis at 60 V for 6 hours on a 3.5 % (w/v) Nusieve™ 3:1 agarose gel 
(Lonza, Rockland, USA) stained with GelRed® nucleic acid dye (Biotium, Inc., Fremont, 
CA, USA). The GeneRuler® 100 bp Plus DNA Ladder (Fermentas, Ontario, Canada), and 
GeneRuler® 50 bp DNA Ladder (Fermentas, Ontario, Canada) were used as a size standard 
(Appendix I). 
The HaeII RE recognises the 5'... G G↓C C ...3' restriction site. APOE rs7412CC 
homozygotes have one HaeII restriction site, resulting in two fragments sized 195 bp and 23 
bp after complete digestion. Introduction of the APOE rs7412T allele abolishes the restriction 
site. Thus, APOE rs7412TT homozygotes present with one 218 bp fragment, while APOE 
rs7412CT heterozygotes present with three fragments sized 23 bp, 195 bp, and 218 bp, 




2.15.2.4) Validation of PCR-RFLP genotyping of APOE fragment flanking APOE 
rs429358T>C and APOE rs7412C>T by Direct Cycle Dye-terminator Sequencing 
The PCR-RFLP genotyping of APOE rs429358T>C and APOE rs7412C>T variants was 
validated using direct cycle Sanger sequencing. This is done to ensure the identification of 
banding patterns is correct, so that genotyping of the study cohort can be carried out en 
masse. The digest of APOE rs7412C>T by HaeII resulted in banding patterns of 23 bp, 195 
bp, and 218 bp for APOE rs7412CT heterozygotes, and a single 218 bp fragment for APOE 
rs7412CC homozygotes. The 23 bp difference in band size is difficult to see in high 
percentage gel pictures which are not perfectly clear, making the calling of APOE rs7412CC 
homozygotes more difficult. For this reason, all samples which were thought to be APOE 
rs7412CC by means of RE digest were sequenced to confirm their genotype. 
The post-PCR sequencing process starts with a clean-up protocol which includes adding 1 U 
Fast alkaline phosphatase (FastAP) (Thermo Fisher Scientific, Wyham, USA) and 2 U 
Exonuclease I (ExoI) (Fermentas, Ontario, Canada) to 10 uL PCR product which is made up 
to a final reaction volume of 20 uL with sdH2O. FastAP dephosphorylates unincorporated 
dNTPs and ddNTPs rendering them inert. The ExoI degrades single stranded DNA, including 
remaining primers. The reaction was incubated at 37 °C for 60 minutes, followed by 72 °C 
for 15 minutes to denature both enzymes. 
Direct cycle sequencing reaction was carried out using the ABI Prism® BigDye® Terminator 
Cycle Sequencing v3.1 Kit (Applied Biosystems, Carlsbad, CA, USA). 3 ul of cleaned-up 
PCR product was added to: 2 uL BigDye® Terminator v 3.1 mix containing fluorescently-
labelled ddNTPs and Taq DNA polymerase, 1 X sequencing buffer to ensure optimal 
conditions for Taq DNA polymerase activity, and 1 uM forward or reverse primer. This was 
made up to a total volume of 10 uL with sdH2O.Thermal cycling amplification was 
performed on a BioRad T100 ThermocyclerTM (BioRad Laboratories Inc, USA), starting with 
an initial denaturation at 96 °C for 5 minutes. This was followed by 35 cycles of 96 °C for 30 
seconds, primer annealing at 50°C for 15 seconds, and lastly elongation at 60 °C for 4 
minutes. 
Sequencing products were purified for capillary electrophoresis by ethanol precipitation. In 
this process 1 uL 3 M NaOAc and 22 uL of ice-cold absolute ethanol are added to each tube 
of 10 uL sequenced PCR product, which is then vortexed and left overnight at -20 °C. The 
following day, the samples were centrifuged at 10000 g for 10 minutes and the supernatant 
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was discarded. 70 % (v/v) ice-cold ethanol (35 uL) was added to each tube, followed by 
centrifugation at 10000 g for 10 minutes. The supernatant was discarded, and the pellets left 
to air dry. The pellets were then re-suspended in 10uL sdH2O. Sequencing sample (5 uL) was 
added to 5 ul Hi-Di (highly de-ionised) formamide in a MicroAmp® 96-well reaction plate 
(Applied Biosystems®, Life Technologies, California, USA), and denatured at 94°C for 
5minutes. The plate was loaded onto an ABI Prism 3130xl Genetic Analyser (Applied 
Biosystems®, Life Technologies, California, USA) for capillary electrophoresis. Analysis 
and alignment of the sequenced PCR products was carried out on the DNASTAR® 
Lasergene Software (DNASTAR, Inc., Madison, USA) at the University of Cape Town. 
 
2.15.3) Genotyping for the PCSK9 rs505151A>G and PCSK9 rs28362286C>A single 
nucleotide polymorphisms 
 
2.15.3.1) Annealing temperature optimisation and PCR amplification of the PCSK9 
fragment flanking PCSK9 rs505151A>G and PCSK9 rs28362286C>A 
A temperature gradient PCR amplification was performed to determine the optimal Ta for the 
successful amplification of the 168 bp PCSK9 fragment. The temperature gradient PCR 
amplification was performed on a BioRad T100 ThermocyclerTM (BioRad Laboratories Inc, 
USA). 
 Following Ta optimization, PCR amplification of the 168 bp PCSK9 fragment flanking 
PCSK9 rs505151A>G and PCSK9 rs28362286C>A was performed on the same BioRad 
T100 ThermocyclerTM (BioRad Laboratories Inc, USA) with the following cycling 
conditions: an initial denaturation step at 95 °C for 3 minutes, followed by 34 cycles of 95 °C 
for 30 seconds, annealing at 56.6 °C for 30 seconds and elongation at 72 °C for 30 seconds. 
This was followed by a final extension at 72 °C for 5 minutes. Each reaction contained 50 ng 
of sample DNA, 1 X Green GoTaq® Reaction Buffer (Promega, Madison, USA) with added 
loading dye, 0.4 mM dNTPs (BioLine, London, UK), 1.5 mM MgCl2, 0.4 uM of each primer 
and 0.5 Units (U) GoTaq® DNA polymerase (Promega, Madison, WI, USA). Each reaction 
was made up to its final volume of 25 uL with sdH2O.  
PCR products from both the optimisation and amplification reactions were electrophoresed 
on 1.5 % (w/v) agarose gels run at 100 V for 60 minutes. Agarose gels were visualized by 
EZ-VISION™ DNA Dye (VWR Life Science, AMRESCO, Philadelphia, USA) gel staining 
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followed by exposure to UV light in a UVItec FireReader V4 UV gel documentation machine 
(UVItec, Cambridge, UK) using the UVItec FireReader imaging and editing software 
(UVItec, Cambridge, UK). GeneRuler® 100 bp Plus DNA Ladder (Fermentas, Ontario, 
Canada) was used as a size standard (Appendix I).  
 
2.15.3.2) Direct Cycle Dye-terminator Sequencing for the characterisation of PCSK9 
rs505151A>G and PCSK9 rs28362286C>A 
The 168 bp PCSK9 PCR amplified product was genotyped for PCSK9 rs505151A>G and 
PCSK9 rs28362286C>A by direct cycle dye-terminator sequencing. The post-PCR 
sequencing process of all the samples was done at the University of Cape Town with the 
same clean-up protocol mentioned in Chapter 2.15.2.4. Samples were sequenced at the 
University of Cape Town using this protocol, and at the Central Analytical Facilities service 
at Stellenbosch University using their own optimised protocols.  
The direct cycle sequencing reaction was carried out using the ABI Prism® BigDye® 
Terminator Cycle Sequencing v3.1 Kit (Applied Biosystems, Carlsbad, CA, USA), using the 
same protocol as described in Chapter 2.15.2.4 above. Analysis and alignment of the 
sequenced PCR products was carried out on the DNASTAR® Lasergene Software 
(DNASTAR, Inc., Madison, USA) at the University of Cape Town. 
 
 
2.15.4) Genotyping for the CETP single nucleotide polymorphisms 
 
2.15.4.1) Annealing temperature optimisation and PCR amplification of the 761 bp 
CETP fragment flanking 12 CETP polymorphisms 
A temperature gradient PCR amplification was performed to determine the optimal Ta for the 
successful amplification of the 761 bp CETP fragment. The temperature gradient PCR 
amplification was performed on a BioRad T100 ThermocyclerTM (BioRad Laboratories Inc, 
USA)  
Following Ta optimization, PCR amplification of the 761 bp CETP fragment was performed 
on the same BioRad T100 ThermocyclerTM (BioRad Laboratories Inc, USA) with the 
following cycling conditions: an initial denaturation step at 94 °C for 3 minutes, followed by 
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40 cycles of 94 °C for 30 seconds, annealing at 66.4 °C for 30 seconds and elongation at 72 
°C for 30 seconds. This was followed by a final extension at 72 °C for 10 minutes. PCR 
amplification reactions of 100 ng of sample DNA contained 1 X Green GoTaq® Reaction 
Buffer (Promega, Madison, USA), 0.4 mM dNTPs (BioLine, London, UK), 1.5 mM MgCl2, 
0.4 uM of each primer and 0.5 U GoTaq® DNA polymerase (Promega, Madison, USA). 
Each PCR was made up to its final volume of 25 uL with sdH2O.  
PCR products from both the optimisation and amplification reactions were electrophoresed 
on 1.5 % (w/v) agarose gels run at 100 V for 60 minutes. Agarose gels were visualized by 
EZ-VISION™ DNA Dye (VWR Life Science, AMRESCO, Philadelphia, USA) gel staining 
followed by exposure to UV light in a UVItec FireReader V4 UV gel documentation machine 
(UVItec, Cambridge, UK) using the UVItec FireReader (UVItec, Cambridge, UK) imaging 
and editing software. GeneRuler® 100 bp Plus DNA Ladder (Fermentas, Ontario, Canada) 
was used as a size standard (Appendix I). 
 
2.15.4.2) Direct Cycle Dye-terminator Sequencing for the characterisation of the CETP 
fragment flanking 12 CETP polymorphisms 
The 761 bp CETP PCR amplified product was genotyped for 12 CETP SNPs by direct cycle 
sequencing. The post-PCR sequencing process of all the samples was done at the University 
of Cape Town with the same clean-up protocol mentioned in Chapter 2.15.2.4. Samples 
were sequenced at the University of Cape Town using this protocol, and at the Central 
Analytical Facilities service at Stellenbosch University using their own optimised protocols.  
The direct cycle sequencing reaction was carried out using the ABI Prism® BigDye® 
Terminator Cycle Sequencing v3.1 Kit (Applied Biosystems, Carlsbad, CA, USA), using the 
same protocol as described in Chapter 2.15.2.4 above, with 45 cycles of the sequencing 
reaction as the CETP PCR product was larger than the APOE, and PCSK9 products. Analysis 
and alignment of the sequenced PCR products was carried out on the DNASTAR® 






2.16) Statistical analysis 
 
2.16.1) Descriptive statistics 
The GraphPad Prism® v5.04 (GraphPad Software, California, USA) software package was 
used to determine the descriptive statistics of the study cohort. Demographic characteristics 
such as age and gender, as well as the clinical data of the study cohort such as BMI, smoking 
status, statin therapy regimen, HbA1c% levels and lipid profile levels were summarized for 
further analysis. 
 
2.16.2) Stratification of the study cohort by Statin usage status 
Nearly 77 % of the study cohort were on statin (mostly Simvastatin) treatment regimens. This 
was not unusual as CVD accounts for 70% of deaths in T2DM patients105,  so one would 
expect a large proportion of dyslipidaemic T2DM patients to be on lipid lowering therapy 
regimens from the outset. Statin usage did have a profound impact on the analysis of this 
study.  LDL-c is the primary target of statin treatment regimens and was, thus, likely to have 
a significant effect on lipid profiles of the cohort based on published literature (see Chapter 
1.4.2). Statin usage was also likely to confound any association tests between genetic profiles 
and lipid profiles. 
Therefore, the study cohort was further stratified into individuals that were on statin treatment 
regimens at the time of enrolment (Sim+) and those who were not on statin treatment 
regimens (Sim-) for further analysis. This was done in order to assess the impact of statin 
usage on lipid profiles, as well as to try to account for the effect it would have on further 
analysis of altered lipid profiles and genetic variation. The GraphPad Prism® v5.04 
(GraphPad Software, California, USA) software package was used for this analysis. 
 
2.16.3) Hardy-Weinberg Equilibrium (HWE) 
Hardy-Weinberg Equilibrium (HWE) was calculated by comparing the observed and 
expected frequencies of the study cohort APOE, PCSK9, and CETP genotype frequencies. 
The HWE principal states that genetic variations in a randomly selected, randomly mating, 
and indefinitely large population containing discrete generations will remain constant from 
one generation to the next in the absence of factors such as mutations, natural and artificial 
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selection, inbreeding, genetic drift, or random sampling from a population of finite size129. 
For example, in individuals with alleles A and a, p = expected frequency of A, and q = 
expected frequency of allele a. The equilibrium frequencies for the genotypes AA, Aa, and aa 
are calculated using the equation: 
 
 p2 + 2pq +q2 = 1, where: 
 
p2 = expected frequency of AA homozygotes  
q2 = expected frequency of aa homozygotes 
2pq = expected frequency of Aa heterozygotes. 
 
Deviation from this equilibrium gives us a standard from which to detect and estimate the 
effects of these ever-present factors. Technical error during genotyping is most likely the 
explanation for deviation from HWE, however, nonconforming loci may need to be followed 
up on with further analysis129. In this study, HWE was calculated using the required equations 
inputted in a Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) spread sheet. 
Observed and expected allele/genotype frequencies were compared using the Chi2 (χ2) test 
with one degree of freedom (dF) and a two-sided Fischer Exact (FE) test was used to 
calculate p values. Genotype frequencies with p values <0.05 were considered a statistically 
significant deviation from HWE.  
 
2.16.4) APOE, PSCK9 and CETP genetic variation distribution 
The genotype frequencies of genotyped APOE, PSCK9 and CETP genetic variants were 
compared between patients in the Sim+ and Sim- cohorts using the χ2 test, and the FE test 
where categorical numbers were <5. Genetic variants with frequencies with p value <0.05 
were determined to have statistically significant differences in genotype frequencies. The 
STATA® v11.2 (StataCorp®, Texas, USA) programme was used to perform genotype 




2.16.5) Linkage disequilibrium (LD) analysis 
Linkage disequilibrium (LD) is the non-random association of two or more alleles at different 
loci. LD analysis is a powerful tool as it gives us genome level insight into a population’s 
history, pattern of geographical subdivision, history of natural selection, genetic drift and 
mutations which change allele frequencies and are directly influenced by recombination.130 It 
also has a more practical use in environments with time and money constraints. If two alleles 
are in complete LD, then one of the alleles can be used as a genetic marker of the other. Two 
common measures of LD are the D' and r2 statistics. The D' statistic is constrained by allele 
frequencies, thus the r2 statistic is a better measure of LD. r2 can be between 0-1. With r2 = 1 
indicating complete LD and vice versa. Separate LD analysis for each gene was performed 
using the SHEsis online software (http://analysis2.bio-x.cn/myAnalysis.php), as the APOE, 
PSCK9, and CETP genes are all on different chromosomes (see Chapter 1.4). 
 
2.16.6) Univariate association analysis of clinical and genetic variables 
Continuous variables were evaluated for normal distribution by the Shapiro-Wilk test. 
Attempts were made to normalise the variables by various transformations with no success. 
No samples were excluded for being outliers, as the sample size of the study cohort was 
already small. Thus, nonparametric tests of association, which do not assume Gaussian 
distributions, were used to evaluate the associations between clinical parameters and genetic 
profiles. 
 Spearman’s rank test of correlation was used to determine the possible associations between 
the continuous clinical variables and lipid profiles. The χ2 test was used to test for association 
between multiple categorical variables. The Mann-Whitney U-test (for comparing two 
groups) and Kruskal-Wallis test with Dunn’s multiple comparison test (for comparing 3 or 
more groups) were used to determine the association between APOE, PCSK9 and CETP 
genetic variants and median lipid profile values, as well as the associations between stratified 
groups and lipid profiles. Genetic variants with minor allele frequency (MAF) <0.01 were 
excluded from analysis as there were too few variant-carrying patients to investigate any 
meaningful associations. The GraphPad Prism® v5.04 (GraphPad Software, California, 
USA) and STATA® v11.2 (StataCorp®, Texas, USA) software packages were used to 




2.16.7) Multivariate analysis of clinical and genetic variables with lipid profiles 
Following univariate association of genetic variants and lipid profiles, after stratifying for 
statin usage status, multivariate analysis was performed to investigate the effects of multiple 
clinical traits and genetic variations on lipid profiles in combination as a means to confirm 
and/or compare the previous univariate results. In the univariate analysis single genetic 
variants or clinical variables were investigated for their potential association with altered lipid 
profiles. The impact of multiple independent variables, in combination, on a single dependant 
variable was investigated by multivariable linear regression. 
The method employed was a multivariable linear regression using a generalised linear model 
(GLM) with the default Identity link function (Gaussian family). In GLM the dependant 
variable does not need to be normally distributed. The R Studio V 1.0.153 (RStudio,Inc, 
Boston,MA, USA) statistical computing software package was used to perform multivariable 
linear regression using a GLM to investigate the relationship between the lipid profiles (TC, 
TG, LDL-c, and HDL-c) and possible confounding clinical variables (Gender, Age, Statin 
usage status, BMI, Smoking status, and HbA1c% as an indicator of T2DM control).  
Lipid profiles were then regressed against APOE, PCSK9, and CETP genetic variants, using 
an additive model for variant alleles and adjusting for the clinical variables that were 
significantly associated for each lipid as determined in the previous GLM analysis. Genetic 
variants included in the model had MAF >0.01 as there were too few variant-carrying 
patients to investigate any meaningful associations. Where SNPs were in strong LD, only one 
of the pair was included in analysis.  
Where a statistically significant association was observed, and a non-normally distributed 
independent variable was being accounted for, the p value was adjusted by performing a 
permutation test by random resampling 10000X. This test involves randomly re-pairing X 
and Y variables to create a distribution expected by the null hypothesis131. This method is 
recommended in analyses where sample sizes are small, and variables are nonnormally 
distributed. Assumptions from tests which assume normal distributions do not need to be met 
in order to draw valid inferences from permutation tests, and they do well at limiting Type 1 




Chapter 3: Results 
 
Dyslipidaemia in South Africans is on the rise and the data on the genetics of dyslipidaemia 
in our indigenous black population is insufficient. It is for this reason that we aimed to 
characterize the impact of genetic variations in the three important genes APOE, PCSK9 and 
CETP on altered lipid metabolism in a population of T2DM patients who are high risk for 
developing CVD. We aimed to identify genetic biomarkers of dyslipidaemia in our 
population which can be used in the future to predict predisposition to high risk lipid profiles. 
This information could be used to better inform clinicians, who would be able apply 
appropriate management and preventative strategies. 
We set out to achieve this aim by completing of a number of objectives. We recruited 
participants presenting for diabetes screening or treatment at the Chris Hani Baragwanath 
Academic Hospital and determined their lipid profiles. We combined this information with 
clinical and demographic data, to gain insight into the potential contribution of these 
variables to altered lipid profiles. We identified and characterised several genetic variants in 
APOE, PCSK9 and CETP which had been shown to affect lipid metabolism in other study 
populations. We then investigated the contribution of these variations to altered TC, HDL-c, 
LDL-c, TG and HbA1c levels by genotype-phenotype associations using both univariate and 
multivariate analysis techniques. In doing so we identify here several biomarkers of 
dyslipidaemia in a black South African T2DM cohort. 
 
 
3.1) Demographic and clinical features of the research cohort 
A total of 417 participants were included in our research cohort and were genotyped for 
selected genetic variants in APOE, PCSK9, and CETP. These patients had data on TC, TG, 
LDL-c, HDL-c and HbA1c% levels, as well as data on other important clinical and 
demographic features. (Table 3.1). All of the study participants were black South Africans of 
Bantu origin. The median age of the cohort was 59 years old, with patients ranging from 19 
to 91 years. The majority of the cohort was female (65.04 %). Only 23.02 % of patients self-
reported as smokers. A number of (n=20) patients had TG levels >4.5 mmol/L and, as a result 
of the limitations of the Friedewald equation method, did not have estimated LDL-c levels. 
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Additionally, a small number of patients had various clinical/demographic data missing from 
the database, thus the number of observations listed in Table 3.1 was used for subsequent 
analysis.  
 
Table 3.1: Demographic and clinical features of the combined type 2 diabetes mellitus cohort. 
Clinical/Demographic feature n=417 
Median Age (years) (n=378) 59 (19 – 91) 
Median BMI (kg/m2) (n=378) 29.5 (17.0 – 63.3) 
Gender M/F (%) (n=409) 143 (34.96) / 266 (65.04) 
Smoker Y/N (%) (n=376) 82 (21.11) / 294 (78.89) 
Statin Treatment Y/N (%) (n=378) 291 (76.98) / 87 (23.02) 
Median HbA1c (%) (n=411) 6.60 (2.20 – 28.90) 
Median Total Cholesterol (mmol/L) (n=417) 4.92 (1.64 – 13.28) 
Median Triglycerides (mmol/L) (n=416) 1.64 (0.33 – 14.53) 
Median HDL-C (mmol/L) (n=417) 1.23 (0.11 – 3.42) 
Median LDL-C (mmol/L) (n=397) 2.70 (0.48 – 6.08) 
Continuous results reported as median (range); Categorical results reported as n (%); Total cholesterol = TC; 
Triglycerides = TG; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-
c; BMI = Body mass index; HbA1c = Haemoglobin A1C. 
 
Of the combined study cohort, 180 patients (43.17 %) had TC levels >5.2 mmol/L, 140 
patients (33.57 %) had TG >2.3 mmol/L, 60 patients had LDL-c >4.1 mmol/L, and 125 
(29.98 %) had HDL-c levels <1.0. TC, TG, and LDL-c levels above, and HDL-c levels below 
these conservative cut-off are indicators of a high risk of CVD events according to the 
ESC/EAS guidelines for non-diabetic individuals52. As these patients are T2DM, they would 
be considered as high CVD risk patients and were taken as highly dyslipidaemic individuals 
in this study. Table 3.2 shows a comparison of the number of patients considered 
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dyslipidaemic from our study and and the Heart of Soweto study according to the cut-offs in 
their published study114. There is a significantly higher proportion of TC, TG, and LDL-c 
dyslipidaemic patients and lower proportion of HDL-c dyslipidaemic patients from our 
cohort, than from the Heart of Soweto Study (p<0.0001, in all cases). 
 
Table 3.2: Comparison of number of black South African patients with dyslipidaemic traits 
in this study and those reported in the Heart of Soweto study. 
Dyslipidaemic Trait This Study Heart of 
Soweto 
Study114 
Chi2 P value 
TC >4.5 mmol/l 253 (61 %) 715 (39 %) <0.0001 
TG >1.7 mmol/l 200 (48 %) 386 (23 %) <0.0001 
LDL-c >2.5 mmol/l 229 (55 %) 718 (44 %) <0.0001 
HDL-c <1.0 mmol/l 125 (30 %) 1044 (63 %) <0.0001 
Results reported as n (%). Total cholesterol = TC. Triglycerides = TG. High-density lipoprotein cholesterol = 
HDL-c. Low-density lipoprotein cholesterol = LDL-c. p<0.05 is significant. 
 
 
The incidence of dyslipidaemia is significantly higher in our cohort. We wanted to determine 
what clinical and demographic factors, if any, were associated with the aberrant lipid profiles 
seen in our study cohort. 
 
3.2) Test of normality by Shapiro-Wilk test 
The distribution of the lipid profiles and co-variates of our case cohort were tested for 
normality using the Shapiro Wilk test. BMI, HbA1c%, TC, TG, LDL-c, HDL-c are all non-
normally distributed with p<0.05. Age is approaching a normal distribution (p=0.033) and 
Gender, a binary variable, is normally distributed. Thus, non-parametric tests of association 




3.3) Stratification by Statin use 
A large percentage of the research cohort (77 %) were on statin (mostly simvastatin) 
treatment. Thus, the cohort was stratified by statin treatment status in further analysis. We 
report significant differences in demographic data and lipid levels between Sim+ and Sim- 
cohorts (Table 3.3). Patients on statins had significantly higher median age (59 years vs.50.5 
years; p=0.0002), higher median HbA1c% levels (6.9 % vs. 5.5 %; p=0.0001), and generally, 
significantly increased lipid levels than those not on statins (p=0.0001 in all cases). A trend 
towards significantly higher median BMI (30.1 kg/m2 vs 29.4 kg/m2; p=0.058) was seen in 
the Sim+ cohort. There no differences observed for gender and tobacco smoking status. Statin 
treatment status has a significant effect on observed lipid profiles and needed to be accounted 
for in the further analysis of the potential genetic contribution to dyslipidaemia. 
 
Table 3.3: Demographic characteristics of study cohort stratified by statin therapy usage. 
 Sim+ (n=291) Sim- (n=87) P Value 
Median Age (years) 59 (32 – 91) 50.5 (19 – 85) 0.0002 
Median BMI (kg/m2) 30.1 (17.0 – 63.3) 29.4 (18.6 – 49.9) 0.058 
Gender M/F (%) 92 (35.12) / 198 (64.88) 36 (41.38) / 51 (58.62) 0.095 
Smoker Y/N (%) 63 (21.65) / 229 (78.69) 19 (22.35) / 66 (77.65) 0.89 
Median HbA1c (%) 6.9 (2.2 – 28.9) 5.5 (2.6 – 17.3) 0.0001 
Median Total Cholesterol (mmol/L) 5.42 (1.64 – 13.28) 3.66 (1.78 – 7.64) 0.0001 
Median Triglycerides (mmol/L) 1.86 (0.40 – 14.53) 1.23 (0.33 – 4.48) 0.0001 
Median HDL-C (mmol/L) 1.28 (0.15 – 3.42) 1.01 (0.11 – 2.90) 0.0001 
Median LDL-C (mmol/L) 3.08 (0.48 – 6.08) 1.9 (0.71 – 5.17) 0.0001 
Sim+ = patients on statins; Sim- = patients not on any statins; Continuous results reported as median (range); 
Categorical results reported as n (%); Total cholesterol = TC; Triglycerides = TG; High-density lipoprotein 
cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; BMI = Body mass index; HbA1c = 




3.4) Investigating associations between clinical characteristics, 
demographic features, and altered lipid profiles 
The most apparent confounding factor that was identified as significantly associated with 
aberrant lipid profiles was patients being treated with lipid lowering therapies in the form of 
statins. We wanted to determine if there were any other clinical or demographic factors that 
had a significant impact on lipid profiles, which might need to be accounted for when trying 
to identify potential genetic biomarkers of dyslipidaemia. We employed two methods of 
analysis to investigate these variables. The potential associations between single clinical 
variables and lipid profiles was evaluated by the non-parametric Spearman’s rank test of 
correlation. This method allows for the non-parametric testing of correlations between 
continuous and categorical variables.  
Spearman’s rank test of correlation testing (Table 3.4) showed that there were significantly 
more women among the older participants than males (Rho=0.102, p=0.048). Statin therapy 
regimens were seen more frequently in the elderly (Rho=0.206, p=0.001), in individuals with 
higher BMI (Rho=0.110, p=0.034), and in patients with higher blood glucose concentrations 
(HbA1c%) (Rho=0.352, p<0.001). Patients with increased HbA1c% levels were also slightly 
older (Rho=0.117, p=0.025). No significant correlations were found between smoking and 














Table 3.4: Correlation of clinical and demographic variables by the Spearman’s rank test. 
Clinical Variable Gender 
(Female) 
Age On Statins Smoking BMI HbA1c% 
Gender (Female) - - - - - - 
Age 0.102 
p=0.048 
- - - - - 
































Table shows Rho coefficient and corresponding p value. A positive Rho indicates a positive correlation. p<0.05 
is significant. Total cholesterol = TC; Triglycerides = TG; High-density lipoprotein cholesterol = HDL-c; Low-
density lipoprotein cholesterol = LDL-c; BMI = Body mass index; HbA1c = Haemoglobin A1C. 
 
The Spearman’s rank correlation test was used to investigate potential univariate associations 
between clinical variables and TC, TG, LDL-c and HDL-c lipid profiles in the combined 
study cohort, the results of which are seen in Table 3.5. We also employed multivariable 
linear regression, using a GLM framework, to investigate the effects of multiple clinical 
characteristics and demographic features on lipid profiles to better inform the subsequent 
analysis of selected genetic variants. The following variables were investigated for their 
combined effects on TC, TG, LDL-c, and HDL-c: Gender, Age, Statin therapy status, 
smoking status, BMI, and HbA1c% - as an indicator of how well controlled a patient’s 
glucose metabolism is. The results of which are shown in Table 3.6. In instances where 
p<0.001 or where an independent variable was not normally distributed, permutation tests 
using random shuffling 10000x were performed to correct for non-normal distribution of the 
test statistic.  
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The first result that stands out is the confirmation of the association of statin therapy with 
increased levels of TC (OR=5.69, p=3.53e-05), TG (OR=1.56, p=0.016), LDL-c (OR=3.40, 
p=1.76e-05), and HDL-c (OR=1.40, p= 1.03e-05).  Thus, statin therapy status is an indicator of 
TC, TG and LDL-c dyslipidaemia.  
From the combination of analysis, we see that females had significantly increased in HDL-c 
levels than males (Rho=0.110, p=0.034). This was confirmed by the multivariate analysis 
(OR=1.12, p=0.044). The correlation seen between older patients and increased HDL-c levels 
(Rho=0.136, p=0.009) was not repeated when adjusting for multiple variables (p=0.328), 
however older patients were significantly associated with slightly decreased TG levels 
(OR=0.98, p=0.003). Patients with greater BMIs were significantly correlated with increased 
TG levels in both univariate and multivariate analysis (Rho=0.159, p=0.002; OR=1.03, 
p=0.011). Poor blood glucose control was significantly correlated with increased TG 
(Rho=0.378, p<0.001; OR=1.11, p=3.26e-05) and very slightly decreased HDL-c (OR=0.99, 
p=3.28e-05). Associations between HbA1c%, TC and LDL-c were not repeated when 
adjusting for other confounding factors. Smoking was not associated with altered lipid 
profiles in our cohort. 
 
Table 3.5: Spearman’s rank test of correlation between clinical variables and lipid profiles. 
Variable Gender 
(Female) 



















































Table shows Rho coefficient and corresponding p value. A positive Rho indicates a positive correlation. p<0.05 
is significant. Total cholesterol = TC; Triglycerides = TG; High-density lipoprotein cholesterol = HDL-c; Low-
density lipoprotein cholesterol = LDL-c; BMI = Body mass index; HbA1c = Haemoglobin A1C. 
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Table 3.6: Multivariate analysis of associations between confounding clinical variables and lipid profiles in the combined South T2DM cohort by 
multivariable linear regression using a generalised linear model 
 Total Cholesterol Triglycerides LDL-c HDL-c 
Variable OR 95%CI P value OR 95%CI P value OR 95%CI P value OR 95%CI P value 
Gender 1.10 0.87 - 1.39 0.50 1.21 0.94- 1.55 0.216 0.95 0.79- 1.14 0.62 1.12 1.02- 1.22 0.044 
Age 0.99 0.98 - 1.00 0.18   0.98 0.97- 0.99 0.003 0.99 0.99- 1.01 0.63 1.00 0.99- 1.01 0.328 
On Statins 5.69 4.28 - 7.58 3.53e-05* 1.56 1.15- 2.11 0.016 3.40 2.72- 4.25 1.76e-05* 1.40 1.26- 1.56 1.03e-05* 
Smoking 1.00 0.76 - 1.31 1.00 1.31 0.98- 1.75 0.124 0.93 0.75- 1.16 0.59 0.95 0.86- 1.06 0.438 
BMI 1.00 0.98 - 1.02 0.80 1.03 1.01- 1.05 0.011 0.98 0.97- 1.00 0.12 1.00 0.99- 1.01 0.694 
HbA1c% 1.03 0.99 - 1.06 0.20 1.11 1.07- 1.15 3.26e-05* 0.99 0.97- 1.02 0.77 0.99 0.97- 0.99 3.28e-05* 
N=369 due to missing data; *= random shuffling of p value 10000x; Bold indicated statistically significant p values (<0.05). Total cholesterol = TC; Triglycerides = TG; 
High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; BMI = Body mass index; HbA1c = Haemoglobin A1C. CI = Confidence 




3.5) Genotyping results for characterisation of variants in APOE, PCSK9, 
and CETP 
We now had a clear picture of the clinical and demographic variables which were playing 
significant roles in the variation of aberrant lipid profiles. We decided to adjust for statin use 
by stratification when investigating the univariate effects of APOE, PCSK9, and CETP 
genetic variants on lipid profiles. In the multivariate analysis, we adjusted for a unique 
combination of associated clinical variable for each lipid. We then characterised our cohort 
for the selected genetic variants. 
 
3.5.1) Characterisation of APOE rs429358T>C and APOE rs7412C>T 
The APOE 218 bp DNA fragment which flanks the APOE rs429358T>C and APOE 














Genotyping of the APOE rs429358T>C variant was performed by PCR-RFLP using the 
AflIII restriction enzyme.  Digestion of the 218 bp PCR product resulted in 2 fragments sized 
1000 bp 
500 bp 
M       1       2        3        4        5        6        7        8        9       10      11     12      BL 
218 bp 
Figure 3.1: PCR amplification of the 218 bp APOE fragment electrophoresed at 100 V for 60 
minutes on a 1.5 % (w/v) agarose gel. Lane M represents the GeneRuler® 100 bp Plus DNA 
Ladder Molecular Weight Marker (Fermentas, Ontario, Canada). Lanes 1-12 represent 12 case 
cohort DNA samples. Lane BL is a no template control. 
79 
 
168 bp and 50 bp in the APOE rs429358TT homozygotes. If the C allele is present, the 
restriction site is abolished. APOE rs429358CC homozygotes present with one 218 bp 
fragment, while APOE rs429358TC heterozygotes present with three fragments sized 50 bp, 
168 bp, and 218 bp.  Figure 3.2 shows successful RFLP digestion of the 218 bp APOE 












Genotyping of the APOE rs7412C>T variant was performed by PCR-RFLP using the HaeII 
restriction enzyme.  Digestion of the 218 bp PCR product resulted in fragments sized 195 bp 
and 23 bp in APOE rs7412CC homozygotes. If the T allele is present, the restriction site is 
abolished. APOE rs7412TT homozygotes present with one 218 bp fragment, while APOE 
rs7412CT heterozygotes present with three fragments sized 23 bp, 195 bp, and 218 bp.  
Figure 3.3 shows successful RFLP digestion of the 218 bp APOE fragment with HaeII for 
the characterisation of APOE rs7412C>T. The 23 bp band has run off the gel by the time the 
gel has run long enough to resolve the 195 bp and 218 bp bands. The molecular weight 
marker in lane M has run slightly faster than the digested PCR products in lanes 1, 2, and 3. 




250 bp 218 bp 
168 bp 
50 bp 
M       1      2       3       4      5       6       7       8       9     10     11    12     13    14     15    16    17     18 
Figure 3.2: AflIII Digest of the 218 bp APOE fragment electrophoresed at 60 V for 6 hours on a 
3.5 % (w/v) agarose gel. Lane M represents the GeneRuler® 50 bp Plus DNA Ladder Molecular 
Weight Marker (Fermentas, Ontario, Canada). Lanes 1, 2, 3, 8, 9, 14, 16, and 18 represent the T/T 
genotype. Lanes 4, 5, 6, 7, 10, 12, 13, and 15 represent the T/C genotype. Lane 17 represents the 
C/C genotype.  

















The PCR-RFLP protocols for genotyping the APOE rs429358T>C and APOE rs7412C>T 
variants were quite challenging due to the very similar sizes of the digested bands, with 
APOE rs7412C>T being difficult to call in particular. As such, it was essential to validate 
genotyping calls by direct cycle dye-termination sequencing. Figure 3.4 shows the 
electropherograms of three successfully aligned APOE PCR amplified fragments, which have 
been sequenced to verify the rs7412C/C, rs7412C/T and rs7412T/T genotypes, and the APOE 
rs429358T/T, APOE rs429358T/C, and APOE rs429358C/C genotypes. Following the 
successful genotyping and validation, thereof, of the APOE rs429358T>C and APOE 
rs7412C>T variants, the APOE isoform of each patient could be determined using a 






M          1         2          3         4 
218 bp 
195 bp 
Figure 3.3: HaeII Digest of the 218 bp APOE fragment electrophoresed at 60 V for 6 hours on a 3.5 
% (w/v) agarose gel. Lane M represents the GeneRuler® 100 bp Plus DNA Ladder Molecular 
Weight Marker (Fermentas, Ontario, Canada). Lane 1, represent the C/C genotype. Lanes 2 
represent the C/T genotype. Lane 3 represents the T/T genotype. Lane 4 is empty. The 23 bp band 
has run off the gel. 

















3.5.2) Characterisation of PCSK9 rs505151A>G and PCSK9 rs28362286C>A 
The 168 bp PCSK9 DNA fragment which flanks the PCSK9 rs505151A>G and PCSK9 
rs28362286C>A SNPS was successfully amplified (Figure 3.5) following PCR optimisation. 
 
Figure 3.4: Electropherogram of sequenced APOE PCR amplified fragments. The APOE 
rs7412C>T variant is highlighted by the red box. The APOE rs429358T>C variant is highlighted 
by the orange box. A represents a sample with the rs7412C/C genotype. B represents a sample 
with the rs7412C/T genotype. C represents a sample with the rs7412T/T genotype. D represents a 
sample with the rs429358T/T genotype. E represents a sample with the rs429358T/C genotype. F 







APOE rs429358T>C APOE rs7412C>T 
1000 bp 
500 bp 
M              1                2                3                4               BL     
Figure 3.5: PCR amplification of the 168 bp PCSK9 fragment electrophoresed at 100 V for 60 
minutes on a 1.5 % (w/v) agarose gel. Lane M represents the GeneRuler® 100 bp Plus DNA 
Ladder Molecular Weight Marker (Fermentas, Ontario, Canada). Lanes 1-4 represent 4 case 
cohort DNA samples. Lane BL is a no template control. 
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The 168 bp PCSK9 fragment flanking the PCSK9 rs505151G>A and PCSK9 
rs28362286C>A variants was characterised by direct cycle dye-terminator sequencing. 
Figure 3.6 shows electropherograms of the region encompassing both of PCSK9 the variants, 
which was analysed on the DNASTAR® Lasergene Software (DNASTAR, Inc., Madison, 















3.5.3) Characterisation of the CETP genetic variants 
The 761 bp CETP DNA fragment which encompasses the 12 CETP SNPs was successfully 




Figure 3.6: Electropherogram of sequenced PCSK9 PCR amplified fragments. The PCSK9 rs505151G>A 
and PCSK9 rs28362286C>A variants are highlighted by the red and orange boxes, respectively. A 
represents a sample with the PCSK9 rs505151A/A genotype. B represents a sample with the PCSK9 
rs505151A/G genotype. C represents a sample with the PCSK9 rs505151G/G genotype. D represents a 
sample with the PCSK9 rs28362286C/C genotype. E represents a sample with the PCSK9 rs28362286C/A 






















The 761 bp CETP fragment was characterised for the 12 CETP variants by direct cycle dye-
terminator sequencing. Figure 3.8 shows electropherograms of the regions encompassing the 
CETP rs34065661C>G and rs708272G>A variants, which was analysed on the 
DNASTAR® Lasergene Software (DNASTAR, Inc., Madison, USA) suite at the University 
of Cape Town. Examples of electropherograms for the characterisation of all additional 













Figure 3.7: PCR amplification of the 761 bp CETP fragment electrophoresed at 100 V for 60 
minutes on a 1.5% (w/v) agarose gel. Lane M represents the GeneRuler® 100 bp Plus DNA 
Ladder Molecular Weight Marker (Fermentas, Ontario, Canada). Lanes 1-15 represent 15 case 


















3.5.4) APOE, PCSK9 and CETP genetic variant distribution 
The genotype distribution, HWE analysis, and comparison of allele frequencies by 
stratification by statin use for the APOE, PCSK9 and CETP genetic variants are shown in 
Table 3.7 following successful genotyping and analysis.  The PCSK9 rs28362286C>A and 
CETP rs34680782C>A variants do not follow HWE distribution in the combined cohort 
(p=0.028 and p=0.002, respectively). This is most likely due to the non-random selection of 
our study cohort. We report significant differences in the allele frequencies of the APOE 
rs7412C>T (p<0.001) variant when comparing the Sim+ and Sim- cohorts. The APOE 
rs7412T allele is found more frequently in the Sim- cohort.  
 







Figure 3.8: Electropherogram of sequenced CETP PCR amplified fragments. The CETP 
rs34065661C>G and CETP rs708272G>A variants are highlighted by the red and orange boxes, 
respectively. A represents a sample with the CETP rs34065661C/C genotype. B represents a sample 
with the CETP rs34065661C/G genotype. C represents a sample with the CETP rs34065661G/G 
genotype. D represents a sample with the CETP rs708272A/A genotype. E represents a sample with 





Table 3.7: APOE, PCSK9 and CETP genotype frequencies in the combined T2DM cohort with 
corresponding HWE analysis, and comparison of genotype frequencies in the statin stratified groups. 
Gene SNP ID Genotype Combined 
Cohort               
n (freq.) 
HWE             
P Value 
Sim+ 
Cohort         
n (freq.) 
Sim-  
Cohort        
n (freq.) 
Chi2/FE   
P value 
(global) 
APOE rs429358 T/T 229 (55.05) 0.131 158 (54.48) 46 (53.49) 0.177 
 
 
T/C 167 (40.14)  122 (42.69) 33 (38.37)  
 
 
C/C 20 (4.81)  10 (3.45) 7 (8.14)  
APOE rs7412 C/C 287 (68.99) 0.386 214 (73.79) 45 (52.33) <0.001 
 
 
C/T 120 (28.85)  72 (24.83) 37 (43.02)  
 
 
T/T 9 (2.16)  4 (1.38) 4 (4.65)  
PCSK9 rs505151 A/A 227 (54.83) 0.833 156 (53.98) 51 (59.30) 0.669 
  A/G 158 (38.16)  112 (38.75) 30 (34.88)  
  G/G 29 (7.01)  21 (7.27) 5 (5.81)  
PCSK9 rs28362286 C/C 399 (96.38) 0.028 278 (96.19) 83 (96.51) 0.151 
  C/A 14 (3.38)  11 (3.18) 2 (2.33)  
  A/A 1 (0.24)  0 (0.00) 1 (1.16)  
CETP rs17231520 G/G 352 (89.11) 0.892 247 (88.85) 71 (86.59) 0.655 
  G/A 42 (10.64)  30 (10.79) 11 (13.41)  
  A/A 1 (0.25)  1 (0.36) 0 (0.00)  
CETP rs34065661 C/C 351 (88.86) 0.827 247 (88.85) 71 (86.59) 0.655 
  C/G 43 (10.89)  30 (10.79) 11 (13.41)  
  G/G 1 (0.25)  1 (0.36) 0 (0.00)  
CETP rs711752 G/G 141 (35.70) 0.251 99 (35.61) 29 (35.37) 0.386 
  G/A 199 (50.38)  136 (48.92) 45 (54.88)  
  A/A 55 (13.92)  43 (15.47) 8 (9.76)  
CETP rs708272 G/G 142 (35.95) 0.231 100 (35.97) 29 (35.37) 0.373 
  G/A 199 (50.38)  135 (48.56) 45 (54.88)  
  A/A 54 (13.67)  43 (15.47) 8 (9.76)  
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CETP rs5884 C/C 357 (90.38) 0.301 249 (89.57) 76 (92.68) 0.800 
  C/A 36 (9.11)  27 (9.71) 6 (7.32)  
  A/A 2 (0.51)  2 (0.72) 0 (0.00)  
CETP rs34680782 C/C 384 (97.22) 0.002 271 (97.48) 80 (97.56) 1.000 
  C/A 10 (2.53)  6 (2.16) 2 (2.44)  
  A/A 1 (0.25)  1 (0.28) 0 (0.00)  
CETP rs17231534 C/C 357 (90.38) 0.315 250 (89.93) 76 (92.68) 0.453 
  C/A 38 (9.62)  28 (10.07) 6 (7.32)  
  A/A 0 (0.00)  0 (0.00) 0 (0.00)  
CETP rs3816117 C/C 158 (40.00) 0.823 115 (41.37) 31 (37.80) 0.768 
  C/T 182 (46.08)  123 (44.24) 40 (48.78)  
  T/T 55 (13.92)  40 (14.39) 11 (13.41)  
CETP rs561260717 C/C 394 (99.75) 0.980 278 (100) 82 (100) NA 
  C/T 1 (0.25)  0 (0.00) 0 (0.00)  
  T/T 0 (0.00)  0 (0.00) 0 (0.00)  
CETP rs34119551 T/T 393 (99.49) 0.960 277 (99.64) 81 (99.78) 0.401 
  A/T 2 (0.51)  1 (0.36) 1 (1.22)  
  A/A 0 (0.00)  0 (0.00) 0 (0.00)  
CETP rs5030708 C/C 394 (99.75) 0.980 277 (99.64) 82 (100) 1.000 
  C/T 1 (0.25)  1 (0.36) 0 (0.00)  
  T/T 0 (0.00)  0 (0.00) 0 (0.00)  
CETP rs183782798 G/G 393 (99.49) 0.960 277 (99.64) 81 (99.78) 0.404 
  G/T 2 (0.51)  1 (0.36) 1 (1.22)  
  T/T 0 (0.00)  0 (0.00) 0 (0.00)  
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3.5.5) APOE Isoform distribution 
The distribution of APOE protein isoforms in the combined T2DM cohort could then be 
determined by the haplotype of the APOE rs429358T>C and APOE rs7412C>T genetic 
variants. The results are summarised in Table 3.8. The Ɛ2/Ɛ4 genotype was not seen in our 
cohort. There was a total of 40 APOE rs429358T>C and APOE rs7412C>T double 
heterozygotes in our cohort, for whom the APOE isoform could not be determined using the 
genotyping methods available to us. These individuals have the possibility of being 
heterozygous with any combination of the Ɛ1/ Ɛ2/ Ɛ3/ Ɛ4 alleles. Double heterozygotes were 
excluded from univariate analysis of the APOE genotype but were accounted for when 
investigating the contribution of the APOE rs429358C and APOE rs7412T alleles to altered 
lipid profiles in multivariate analysis. The Ɛ3 isoform is the most common in the indigenous 
black South African population (65 %), with the Ɛ4 allele (22 %) and Ɛ2 (13 %) allele being 
less common. 
 













 APOE Genotype Combined Cohort 
N (frequency) 
APOE   Ɛ2/Ɛ2 9 (0.02) 
APOE   Ɛ2/Ɛ3 79 (0.19) 
APOE   Ɛ2/Ɛ4 0 (0.00) 
APOE   Ɛ3/Ɛ3 141 (0.34) 
APOE   Ɛ3/Ɛ4 127 (0.31) 
APOE   Ɛ4/Ɛ4 19 (0.05) 
Double Ɛ Heterozygotes  40 (0.09) 
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3.5.6) Comparison of the global minor allele frequencies of APOE, PCSK9, and CETP 
genetic variants 
Variant allele frequencies were compared to global population frequencies for additional 
insight into the population specific prevalence of the genetic variants. We report, to the best 
of our knowledge, on the frequencies and distribution of the PCSK9 rs505151A>G, CETP 
rs17231520G>A, CETP rs34065661C>G, CETP rs5884C>A, CETP rs34680782C>A, 
CETP rs17231534C>A, CETP rs3816117C>T, CETP rs561260717C>T, CETP 
rs34119551A>T, and CETP rs5030708C>T SNPs for the first time in a black South African 
population (Table 3.9). 
APOE, PSCK9, and CETP genetic variants’ minor allele frequencies (MAFs) from the South 
African T2DM cohort is compared to data from the 1000 genomes project, GRCh38 
reference genome build. The population groups included are the Luyha from Kenya (LWK), 
the Yoruba from Nigeria (YRI), the Han Chinese from China (CHB) and the Utah residents 
with Northern and Western European ancestry (CEU). Several SNPs including PCSK9 
rs28362286C>A, CETP rs34065661C>G, CETP rs17231520C>A, CETP rs5884C>A, CETP 
rs34680782C>A, CETP rs561260717C>T, CETP rs34119551T>A, and CETP 
rs183782798G>T are present in African populations only. The CETP rs561260717C>T, 
CETP rs34119551T>A, CETP rs183782798G>T, and CETP rs5030708C>T were rare in our 












Table 3.9: Comparison of APOE, PCSK9, and CETP variant allele frequencies from a South African 
T2DM population to variant allele frequencies obtained from the 1000 genomes project. 
Gene Variant Allele South 
African* 
LWK YRI CHB CEU 
APOE rs429358C 0.249 0.379 0.236 0.102 0.177 
APOE  rs7412T 0.166 0.045 0.106 0.107 0.066 
PCSK9 rs505151G 0.261 0.323 0.306 0.075 0.025 
PSCK9 rs28362286A 0.019 0.005 0.023 0.000 0.000 
CETP rs17231520A 0.056 0.111 0.097 0.000 0.000 
CETP rs34065661G 0.057 0.116 0.097 0.000 0.000 
CETP rs711752A 0.391 0.303 0.194 0.437 0.449 
CETP rs708272A 0.389 0.303 0.194 0.437 0.449 
CETP rs5884A 0.051 0.086 0.019 0.000 0.000 
CETP rs34680782A 0.015 0.000 0.023 0.000 0.000 
CETP rs17231534A 0.048 0.131 0.171 0.063 0.040 
CETP rs3816117T 0.370 0.409 0.426 0.451 0.490 
CETP rs561260717T 0.001 0.005 0.000 0.000 0.000 
CETP rs34119551A 0.003 0.025 0.000 0.000 0.000 
CETP rs5030708T 0.001 0.000 0.000 0.000 0.030 
CETP rs183782798T 0.003 0.005 0.005 0.000 0.000 
*Minor allele frequency (MAF) from this study cohort; Bold indicates African specific SNP. 
 
3.5.7) Linkage Disequilibrium (LD) analysis 
The degree of LD between the APOE rs429358T>C and rs7412C>T, the PCSK9 
rs505151G>A and rs28362286C>A, and the multi-allelic CETP SNPs were assessed using r2 
statistics calculated by SHESIS. APOE, PCSK9, and CETP are all present on different 
chromosomes so results represent independent analysis of the variants in each gene. The r2 
coefficients fall between 0 -1and are used to measure the degree of linkage disequilibrium 
between a pair of SNPs. r2 =1 suggest no recombination has occurred between the two SNPs 
and that they are in perfect LD. 
There is no evidence of LD between the APOE rs429358T>C and APOE rs7412C>T SNP 
pair (r2=0.054) or PCSK9 rs505151G>A and PCSK9 rs28362286C>A SNP pair (r2=0.000). 
The CETP rs17231520G>A and CETP rs34065661C>G, and CETP rs711752A>G and 
CETP rs708272G>A SNP pairs are almost in complete LD with an r2 coefficient of 0.98 and 
0.97, respectively (Figure3.9). The CETP rs708272G>A was used as a marker for the CETP 
rs711752A>G, while the CETP rs34065661C>G SNP was used as a marker for CETP 




















3.6) Association of APOE, PSCK9 and CETP genetic variation with altered 
lipid profiles in the black South African T2DM cohort 
We used two methods to investigate the relationship between APOE, PCSK9, and CETP 
genetic variations and aberrant lipid profiles of T2DM patients in our study cohort. The 
primary method was non-parametric univariate investigation using the Mann-Whitney U test 
and Kruskal-Wallis tests. The effect of each genetic variant on lipid profile, on its own, was 
investigated in this analysis, with statin usage was accounted for by stratification. However, 
this method does not take into account the combined effect of multiple genetic variants and 
relevant multiple cofounder variables. We, thus, set out to investigate the potential impacts of 
these variable through multivariate linear regression, using a generalised linear model. In 
  
Figure 3.9: LD analysis of CETP genetic variant pairs. LD plot showing the r2 percentage 
coefficient which indicates the degree of LD between variant pairs. Red blocks indicated SNP pairs 
with high degrees of LD, while white blocks indicate SNP pairs with low degrees of LD.  
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doing so we aimed to identify genetic biomarkers which could potentially predict aberrant 
lipid profile outcomes. 
 
3.6.1) The impact of APOE genetic variation on aberrant lipid profiles 
Analysis of APOE in our T2DM cohort reveal a significant association between the Ɛ4 allele 
and lower median HDL-c levels in the combined cohort, compared to the Ɛ3 allele (p=0.034) 
(Table 3.10). Patients with the Ɛ4/Ɛ4 genotype had on average 22.40 % lower median HDL-c 
levels than those with the more common Ɛ3/Ɛ3 genotype. This association was repeated in the 
Sim- group (p=0.004), but not in the Sim+ group (p=0.391) after stratification by statin use. 
However, a non-significant trend to lower HDL-c in the Ɛ4/Ɛ4 genotype was seen in the Sim+ 
group. Multivariate analysis (Table 3.16) showed that the APOE rs429358C (Ɛ4) allele 
confers 11.9 % risk of lower HDL-c levels when adjusting for gender and statin use 
(OR=0.881, p=1.64e-04). 
Results in Table 3.11 show APOE Ɛ2/Ɛ2 patients having 25.09 % lower median TC and 
17.26 % lower median LDL-c than Ɛ3/Ɛ3 patients in the combined cohort (p<0.0001 in both 
cases). These associations were repeated in the Sim+ group (p=0.027 and p=0.003, 
respectively) but not in the Sim- group (p=0.127 and p=0.485, respectively). Multivariate 
analysis (Table 3.16) showed that the APOE rs7412T (Ɛ2) allele confers a 25.30 % risk of 
lower TC levels (OR=0.747, p=0.028), and a 24.10 % risk of lower LDL-c levels (OR=0.759, 
p=0.012) when adjusting for statin use. 
Thus, there is enough evidence to postulate that the APOE genetic variations do play a 
significant role in dyslipidaemia in T2DM black South Africans. APOE rs429358T>C and 
APOE rs7412C>T are biomarkers of altered HDL-c, and TC and LDL-c in the black South 












Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)           Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
APOE Genotype – Combined cohort    
Ɛ3/Ɛ3 (n=141) 6.6 (2.2 – 28.9) 5.34 (1.64 – 10.99) 1.69 (0.33 – 13.67) 1.25 (0.15 – 2.94) 3.07 (0.48 – 5.59) 
Ɛ3/Ɛ4 (n=127) 6.9 (3.3 – 17.6) 5.25 (2.01 – 13.28) 1.76 (0.40 – 14.53) 1.14 (0.19 – 2.61) 2.82 (0.9 – 6.08) 
Ɛ4/Ɛ4 (n=19) 6.6 (4.0 – 16.2) 4.45 (2.78 – 7.66) 2.36 (0.62 – 5.81) 0.97 (0.43 – 2.42) 2.74 (0.6 – 5.61) 
Global P value 0.705 0.229 0.913 0.034 0.236 
APOE Genotype – Sim+     
Ɛ3/Ɛ3 (n=108) 6.9 (2.2 – 28.9) 5.57 (1.64 – 10.99) 1.86 (0.47 – 13.67) 1.25 (0.15 – 2.94) 3.20 (0.48 – 5.95) 
Ɛ3/Ɛ4 (n=96) 7.1 (3.6 – 17.6) 5.74 (2.01 – 13.28) 1.98 (0.40 – 14.53) 1.23 (0.58 – 2.61) 3.34 (0.90 – 6.08) 
Ɛ4/Ɛ4 (n=10) 8.7 (5.7 – 16.2) 5.55 (2.78 – 7.66) 2.54 (0.62 – 5.81) 1.13 (0.43 – 2.42) 3.21 (0.60 – 5.61) 
Global P Value 0.233 0.610 0.718 0.391 0.656 
APOE Genotype – Sim-     
Ɛ3/Ɛ3 (n=17) 5.65 (2.70 – 8.20) 3.75 (2.07-4.96) 1.13 (0.33 – 2.98) 1.24 (0.67 – 1.60) 2.01 (1.67 – 2.32) 
Ɛ3/Ɛ4 (n=22) 5.40 (3.30 – 11.20) 3.34 (2.35-5.70) 1.34 (0.54 – 4.84) 0.80 (0.19 – 1.36) 1.85 (1.61 – 2.10) 
Ɛ4/Ɛ4 (n=6) 5.50 (4.00 – 11.80) 3.72 (3.20-4.12) 1.33 (0.66 – 4.45) 0.97 (0.83 – 1.45) 1.83 (1.38 – 2.27) 
Global P Value 0.802 0.140 0.603 0.004 0.674 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 





 Table 3.11: Univariate analysis of association between APOE Ɛ3 and APOE Ɛ2 alleles, lipid profile and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                        Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
APOE Genotype – Combined cohort     
 Ɛ3/Ɛ3 (n=141) 6.6 (2.2 – 28.9) 5.34 (1.64 – 10.99) 1.69 (0.33 – 13.67) 1.25 (0.15 – 2.94) 3.07 (0.48 – 5.95) 
Ɛ2/Ɛ3 (n=79) 6.3 (2.9 – 18.6) 4.35 (1.87 – 7.26) 1.48 (0.44 – 6.03) 1.26 (0.11 – 2.26) 2.27 (0.76 – 5.08) 
Ɛ2/Ɛ2 (n=9) 6.1 (3.5 – 14.3) 4.00 (2.65 – 6.96) 1.23 (0.68 – 3.37) 1.39 (0.56 – 1.85) 2.54 (1.15 – 4.09) 
Global P value 0.159 <0.0001 0.159 0.663 <0.0001 
APOE Genotype – Sim+     
 Ɛ3/Ɛ3 (n=108) 6.9 (2.2 – 28.9) 5.57 (1.64 – 10.99) 1.86 (0.47 – 13.67) 1.25 (0.15 – 2.94) 3.20 (0.48 – 5.95) 
Ɛ2/Ɛ3 (n=47) 6.9 (4.00 – 18.6) 5.09 (2.50 – 7.26) 1.62 (0.70 – 6.03) 1.36 (0.76 – 2.26) 2.45 (1.11 – 5.08) 
Ɛ2/Ɛ2 (n=4) 11.25 (6.10 – 14.3) 5.61 (5.30 – 6.96) 2.32 (1.98 – 3.37) 1.74 (0.95 – 1.85) 3.00 (2.54 – 4.09) 
Global P Value 0.379 0.027 0.426 0.555 0.003 
APOE Genotype – Sim-     
 Ɛ3/Ɛ3 (n=17) 5.65 (2.70 – 8.20) 3.75 (2.07 – 4.96) 1.13 (0.33 – 2.98) 1.19 (1.05 – 1.34) 1.91 (0.71 – 3.29) 
Ɛ2/Ɛ3 (n=25) 5.60 (2.90 – 17.30) 3.62 (1.87 – 4.88) 1.32 (0.44 – 3.69) 1.01 (0.87 – 1.16) 1.99 (0.76 – 3.09) 
Ɛ2/Ɛ2 (n=4) 4.15 (3.50 – 6.10) 3.20 (2.65 – 3.65) 0.83 (0.68 – 1.23) 1.07 (0.43 – 1.71) 1.43 (1.15 – 2.78) 
Global P Value 0.439 0.127 0.479 0.225 0.485 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 
A1c. Sim+ = patients on statins; Sim- = patients not on any statins 
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3.6.2) The impact of PCSK9 genetic variation on aberrant lipid profiles 
We reported no significant associations between the PCSK9 rs505151A>G variation and 
lipid profiles through univariate analysis (Appendix V, Table 5.2) and multivariate analysis 
(Table 3.16). This SNP does not play a significant role in our population group and cannot be 
used as a biomarker for dyslipidaemia. 
We report no significant associations between the PCSK9 rs28362286C>A variation, using a 
dominant genetic model, and lipid profiles through univariate analysis (Table 3.12) or 
multivariate analysis (Table 3.16). We do observe a significant association between the 
PCSK9 rs28362286C/A+A/A genotypes, when applying a dominant genetic model, and 
increased HbA1c% (p=0.03). Significance was not repeated when stratifying for statin usage, 
but a trend to increased HbA1c% is seen in both groups. The PCSK9 rs28362286C/A and A/A 
combined genotypes trended towards significantly higher HDL-c in patients on statins 
(p=0.078), and higher TG in patients on no statins (p=0.095). The role of this SNP need to be 



















Variant Median HbA1c (%) Median Total Cholesterol (mmol/L) Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
PCSK9 rs28362286C>A Combined     
C/C (n=399) 6.50 (2.20 –28.9) 4.93 (1.64 – 13.28) 1.61 (0.33 – 14.53) 1.23 (0.11 – 3.42) 2.71 (0.48 – 6.08) 
C/A + A/A (n=14+1) 9.0 (5.00 – 18.40) 5.56 (2.72 – 7.53) 2.06 (1.08 – 3.80) 1.50 (0.80 – 2.32) 2.34 (1.40 – 4.57) 
P Value 0.030 0.949 0.131 0.166 0.295 
PCSK9 rs28362286C>A – Sim+     
C/C (n=277) 6.90 (2.20 –28.9) 5.37 (1.64 – 13.28) 1.79 (0.40 - 14.53) 1.25 (0.15 – 3.42) 3.07 (0.48-6.08) 
C/A + A/A (n=11+0) 9.0 (5.10-14.30) 5.78 (3.23 – 7.53) 2.06 (1.08 – 3.80) 1.51 (0.89 – 2.32) 3.19 (1.40-4.57) 
P Value 0.507 0.752 0.547 0.078 0.587 
PCSK9 rs28362286C>A – Sim-     
C/C (n=83) 5.50 (2.60 – 17.30) 3.67 (1.78 – 7.64) 1.22 (0.33 – 4.84) 1.02 (0.11-2.09) 1.90 (0.71 – 5.17) 
C/A + A/A (n=2+1) 7.80 (5.0 – 11.20) 3.49 (2.72 – 4.81) 2.61 (1.40 – 2.76) 0.80 (0.65-1.12) 1.49 (1.43 – 2.34) 
 P Value 0.223 0.832  0.095 0.365 0.505 




Table 3.13: Univariate analysis of association of the PCSK9 rs28362286C>A with variant Lipid Profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 
A1c. Sim+ = patients on statins; Sim- = patients not on any statins 
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3.6.3) The impact of CETP genetic variation on aberrant lipid profiles 
The CETP rs34065661C/G + G/G genotypes, when applying a dominant genetic model, 
were associated with increased median HDL-c in our combined cohort and Sim+ cohort 
(p=0.017 and p=0.026, respectively), and trended towards significantly lower TG levels 
(Table 3.13). Significance was lost in multivariate analysis (Table 3.16) when adjusting for 
the effects of gender, HbA1c%, and statin use. The CETP rs34065661G allele approached a 
significant increase in risk of high LDL-c levels (OR=1.37, p=0.057), when adjusting for 
statin use.  
Analysis of CETP rs708272G>A in our study cohort showed no significant associations with 
altered lipids (Table 3.14). The CETP rs708272A allele trended towards a significant 
(p=0.073) increase in HDL-c when compared to the rs708272G allele in the combined 
cohort, but significance was not repeated when stratifying by statin use. Multivariate analysis 
(Table 3.17) confirmed these results.  
The CETP rs3816117T allele showed a trend towards significantly lower HDL-c levels in the 
combined cohort (p=0.083) (Table 3.15). However, this trend is not observed once stratified 
by statin use or in multivariate analysis (Table 3.16). The CETP rs34680782A allele was 
significantly associated with 85.2 % increased risk of higher LDL-c in multivariable analysis, 
adjusting for statin use (OR=1.85, p=0.022). There were no significant associations in the 
CETP rs34680782C>A univariate analysis, but a non-significant trend towards higher LDL-c 
was seen in the CETP rs34680782C/A + A/A genotypes when applying a dominant genetic 
model (Appendix V). No other significant associations were found for the other genotyped 













Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                        Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs34065661C>G Combined     
C/C (n=351) 6.60 (2.20 –18.40) 4.90 (1.64 – 11.32) 1.74 (0.33 – 14.53) 1.20 (0.11 – 3.42) 2.71 (0.48 – 6.08) 
C/G + G/G (n=43+1) 7.30 (3.10 – 17.30) 4.93 (2.97– 8.03) 1.41 (0.54 – 4.96) 1.37 (0.22 – 2.64) 2.64 (1.46 – 5.17) 
Global P Value 0.294 0.787 0.068 0.017 0.831 
CETP rs34065661C>G – Sim+      
C/C (n=247) 6.90 (2.20 –17.60) 5.38 (1.64 – 11.32) 1.95 (0.40 - 14.53) 1.24 (0.15 – 3.42) 3.06 (0.48-6.08) 
C/G + G/G (n=30+1) 8.20 (5.10-16.70) 5.43 (3.38 – 8.03) 1.48 (0.59 – 4.96) 1.43 (0.22 – 2.64) 3.02 (1.58-5.05) 
Global P Value 0.222 0.507 0.085 0.026 0.593 
CETP rs34065661C>G – Sim-     
C/C (n=71) 5.50 (2.60 – 12.10) 3.67 (1.78 – 5.70) 1.32 (0.33 – 4.84) 0.99 (0.11-1.87) 1.91 (0.71 – 3.29) 
C/G + G/G (n=11+0) 5.65 (3.10 – 17.30) 3.58 (2.97 – 7.64) 1.21 (0.54 – 2.81) 1.23 (0.27-1.71) 1.91 (1.46 – 5.17) 
 Global P Value 0.341 0.967 0.586 0.462 0.581 




Table 3.14: Univariate analysis of association of the CETP rs34065661C>G variant with Lipid Profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 
A1c. Sim+ = patients on statins; Sim- = patients not on any statins 
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Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                        Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs708272G>A - Combined     
G/G (n=142) 6.60 (3.6 – 18.40) 4.82 (1.87 – 7.76) 1.73 (0.40 – 13.67) 1.17 (0.19 – 2.51) 2.69 (0.60 – 5.54) 
G/A (n=199) 6.80 (2.20 – 17.60) 4.94 (1.78 – 11.32) 1.62 (0.33 – 14.53) 1.24 (0.11 – 3.42) 2.72 (0.48 – 6.08) 
A/A (n=54) 6.45 (2.70 – 16.70) 5.11 (1.64 – 7.72) 1.62 (0.59 – 5.81) 1.24 (0.59 – 2.94) 2.67 (0.68 – 5.46) 
Global P value 0.948 0.465 0.864 0.073 0.849 
CETP rs708272G>A – Sim+     
G/G (n=100) 6.90 (3.60 – 16.70) 5.22 (2.11 – 7.76) 1.87 (0.40 – 13.67) 1.24 (0.19 – 2.51) 3.03 (0.60 – 5.54) 
G/A (n=135) 7.10 (2.20 – 17.60) 5.56 (2.01 – 11.32) 1.79 (0.56 – 6.03) 1.29 (0.15 – 3.42) 3.18 (0.48 – 6.08) 
A/A (n=43) 6.80 (4.40 – 16.70) 5.35 (1.64 – 7.72) 1.82 (0.59 – 5.81) 1.31 (0.59 – 2.94) 2.91 (0.68 – 5.46) 
Global P Value 0.379 0.659 0.738 0.252 0.351 
CETP rs708272G>A – Sim-     
G/G (n=29) 5.40 (3.90 – 12.10) 3.66 (1.87 – 4.90) 1.24 (0.55 – 3.69) 0.93 (0.33 – 1.87) 1.89 (0.71 – 3.09) 
G/A (n=45) 5.55 (2.60 – 17.30) 3.64 (1.78 – 5.70) 1.23 (0.33 – 4.84) 1.12 (0.11 – 1.57) 1.92 (0.97 – 3.29) 
A/A (n=8) 5.40 (2.70 – 11.10) 3.97 (2.60 – 7.64) 1.65 (0.66 – 2.17) 1.03 (0.67 – 1.71) 2.32 (1.29 – 5.17) 
Global P Value 0.986 0.675 0.844 0.694 0.306 




Table 3.15: Univariate analysis of association of the CETP rs708272G>A variant with Lipid Profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin Sim+ = 






Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                        Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs3816117C>T - Combined     
 C/C (n=158) 6.50 (2.20 – 16.70) 5.03 (1.64 – 11.32) 1.49 (0.47 – 14.53) 1.27 (0.11 – 2.94) 2.76 (0.68 – 5.95) 
C/T (n=181) 6.90 (3.30 – 18.40) 4.88 (1.78 – 10.99) 1.78 (0.33 – 7.37) 1.19 (0.11 – 3.24) 2.68 (0.48 – 6.08) 
T/T (n=55) 6.10 (3.60 – 16.70) 4.78 (2.07 – 7.53) 1.64 (0.55 – 13.67) 1.17 (0.58 – 2.51) 2.59 (0.71 – 5.54) 
Global P value 0.162 0.498 0.418 0.083 0.685 
CETP rs3816117C>T – Sim+     
C/C (n=115) 7.00 (2.20 – 16.70) 5.54 (1.64 – 11.32) 1.63 (0.47 – 14.53) 1.33 (0.15 – 2.94) 3.08 (0.68 – 5.95) 
C/T (n=123) 7.10 (4.00 – 17.60) 5.28 (2.01 – 10.99) 1.98 (0.40 – 7.37) 1.24 (0.18 – 3.42) 3.03 (0.48 – 6.08) 
T/T (n=40) 6.60 (3.60 – 16.70) 5.19 (2.11 – 7.53) 1.83 (0.55 – 13.67) 1.25 (0.58 – 2.51) 3.04 (1.21 – 5.54) 
Global P Value 0.596 0.505 0.435 0.145 0.773 
CETP rs3816117C>T – Sim-     
 C/C (n=31) 5.42 (2.60 – 11.20) 3.69 (2.35 – 4.90) 1.39 (0.54 – 4.84) 1.00 (0.11 – 1.71) 1.91 (0.97 – 5.17) 
C/T (n=40 5.56 (3.30 – 17.30) 3.70 (1.78 – 5.70) 1.21 (0.33 – 3.38) 1.03 (0.11 – 1.87) 1.92 (0.79 – 3.29) 
T/T (n=11) 5.00 (3.90 – 11.10) 3.50 (2.07 – 4.64) 1.40 (1.02 – 3.69) 0.93 (0.65 – 1.43) 1.86 (0.71 – 3.03) 
Global P Value 0.456 0.532 0.457 0.839 0.585 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 













Table 3.16: Multivariate analysis of association between APOE, PCSK9 and CETP genetic variations and lipid profiles in the combined South T2DM cohort, 
by multivariable linear regression, using a generalised linear model. 
N=369 due to missing data; *= random shuffling of p value 10000x; Bold indicated statistically significant p values (<0.05). Total cholesterol = TC; Triglycerides = TG; 
High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; BMI = Body mass index; HbA1c = Haemoglobin A1C. OR = odds ratio. CI = 
Confidence Interval. @=adjusted for statin usage; #=adjusted for Age, statin use, BMI, and HbA1c%; ^= adjusted for gender, statin use, and HbA1c%. 
 
 Total Cholesterol@ Triglycerides# LDL-c@ HDL-c^ 













0.839 - 1.159 0.887 
 





0.601 - 0.928 0.028 0.786 
 




0.634 - 0.909 0.012 
 






0.748 - 1.060 0.273 0.910 
 




0.873 - 1.168 0.910 
 






0.818 - 2.085 0.349 1.131 
 




0.737 - 1.588 0.735 
 






0.955 - 1.847 0.158 0.696 
 




1.045 - 1.804 0.057 
 






0.956 - 1.434 0.202 1.122 
 




0.885 - 1.239 0.654 
 














0.936 - 1.612 0.214 
 






1.085 - 3.188 0.059 0.737 
 




1.191 - 2.882 0.022 
 





0.916 - 1.839 0.219 1.514 
 




0.733 - 1.307 0.903 
 





0.885 - 1.320 0.523 1.269 
 




0.880 - 1.230 0.700 
 
0.964 0.889 -1.045 0.451 
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3.6.3.1) Association of CETP haplotype with HDL-c levels 
A haplotype analysis was performed using data from three CETP SNPs, namely, CETP 
rs34065661C>G, CETP rs3816117C>T, and CETP rs708272G>A, which showed 
significant associations and/or trends with altered HDL-c. This was done in order to 
determine if having a combination of previously associated potentially pathogenic CETP 
alleles could have a greater contribution to altered HDL-c. For this analysis individuals were 
spilt into two haplogroups using a dominant genetic model (at least one allele present): those 
with a combination of the HDL-c raising genotypes rs34065661C/G + C/C, rs708272G/A + 
A/A, and rs3816117C/C vs those with a combination of the HDL-c lowering genotypes 
rs34065661G/G, rs708272G/G, and rs3816117C/T + T/T.  
Patients with the rs34065661C/G + C/C, rs708272G/A + A/A, and rs3816117C/C genotypes 
had significantly higher levels of HDL-c (p=0.001) than those with the rs34065661G/G, 
rs708272G/G, and rs3816117C/T + T/T genotypes in the combined cohort (Figure 3.10). 
The association was repeated in patients on statin therapy (p=0.011), but not in patients not 
on statin therapy (p=0.1402). However, there was an observable trend towards lower HDL-c 
in this group. The CETP haplotype groups had no significant associations with other altered 
lipids (p >0.10 in all cases). Thus, we can see that a combination of the CETP 
rs34065661C>G, CETP rs3816117C>T, and CETP rs708272G>A SNPs may be biomarkers 













A B C 
Figure 3.10: Haplotype analysis of CETP HDL-c associated variants.  Box and whisker plot showing the comparison of individuals with a 
combination of the HDL-c raising genotypes rs34065661C/G + C/C, rs708272G/A + A/A and rs3816117C/C vs those with a combination of the 
HDL-c lowering genotypes rs34065661G/G, rs708272G/G, and rs3816117C/T + T/T in: A) the combined T2DM study cohort, B) individuals on 
statins, and C) individuals not on any statin therapy. 
 
Figure 3.10: Haplotype analysis of CETP HDL-c associated variants.  Box and whisker plot showing the comparison of individuals with a combination of 
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Chapter 4: Discussion and Conclusion 
 
In this study we are primarily interested in identifying genetic factors associated with 
abnormal lipid profiles of black South African patients with T2DM. Thus, we carried out 
genetic research to identify population-specific genetic markers that are associated with 
altered lipid metabolism in indigenous black South African patients with T2DM. As the 
lifestyles and diets of the South African population change, it is crucial to understand the role 
of genetic predisposition to dyslipidaemia.  
We aimed to determine the prevalence of known genetic variations and to identify novel 
population-specific variations, which affect lipid metabolism, to better understand the impact 
of genetics on dyslipidaemia in a South African T2DM population. Ultimately, we hope to 
identify a panel of lipid metabolism-relevant genetic variations which can be used to better 
inform clinicians in the diagnosis of dyslipidaemia and aid in the application of appropriate 
management, and preventative strategies. In this Chapter, the results of our study are further 
interrogated in the context of previously published literature. We discuss the clinical and 
demographic features of our study cohort and the qualitative and quantitative differences in 
allele distribution of the studied genes. Most importantly, we discuss the role of the studied 
genetic variants on altered lipid metabolism and determine if they are useful as biomarkers.  
 
4.1) Clinical and demographic characteristics of study participants 
All of the patients included in this study were black South Africans of Bantu origin. This was 
important as there is little data on genetic biomarkers of dyslipidaemia in black South 
Africans. Also, equally important, is the fact that genetic markers are very often population 
specific due to evolutionary and geographical history. Thus, inclusion of other South African 
population groups would complicate analysis, requiring population stratification.  
The clinical and demographical information of the combined cohort (n= 417) is summarised 
in Table 3.1. A number of patients had missing clinical information which was taken into 
account in further analysis. The median age of the combined cohort was 59 years old, with 
ages ranging from 19 to 91 years. This is expected, as the risk of developing T2DM has been 
shown to increase with age, possibly explaining the larger proportion of patients over 40 
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years old. A meta-analysis of 77 studies on the epidemiology of T2DM in China found that 
the prevalence rate of T2DM increased with age132. The prevalence rate was six to sevenfold 
higher in those aged 55-74 years compared to those aged 20-34 years132. The same study 
found an increased prevalence of T2DM in women at 11.6 % (95% CI = 10.0–13.1%), than 
in men at 9.9 % (95 % CI = 8.8–11. 0%)132. In comparison, the reported incidence of diabetes 
in South African is 7.7 % in men and 11.8% in females115. This may explain the higher 
proportion of women (65.04 %) than men (34.96 %) in our cohort. It must be noted that these 
reported incidence rates may be due to differences in lifestyle factors, such as physical 
activity, which are also T2DM risk factors. 
The median BMI of our cohort was 29.5 kg/m2. Of the study cohort 136 (32.61 %) patients 
were classified as overweight (BMI 25- 29.9 kg/m2). Even more worryingly, 183 (43.88 %) 
patients presented with a BMI of 30.0 kg/m2 or greater, which the WHO classifies as obese. 
This proportion of obese patients (43.88 %) is higher than the reported 25 % of the general 
South African population by the WHO, but was similar to the incidence of obesity in the 
Heart of Soweto study (43 %)114,115. The number of obese T2DM patients in this South 
African Cohort is also similar to the proportion reported Centres for Disease Control and 
Prevention (CDC) National Diabetes Statistics Report (45.3 %)133. Thus, T2DM patients tend 
to have higher BMIs, or a high BMI increases your risk of T2DM. This may also be due to 
lifestyle factors such as lack of physical activity and poor diet. Only 82 (21.11 %) of the 
cohort self-reported as smoking regularly. This number may be underestimated as patients 
often omit this information on self-reporting questionnaires. No information was available on 
alcohol usage as the clinical recruiters thought the information given by the patients was 
unreliable, thus it was not recorded in patient files.  
The median HbA1c% of the study cohort was 6.60, with a wide range of between 2.20 and 
28.90. Also, 212 (50.84 %) patients had HbA1c% ≥ 6.5, which is a strong indicator of 
T2DM. Stable HbA1c formation is limited to approximately 100-120 days, the lifespan of 
erythrocytes. Thus, HbA1c% is a reflection of the average blood glucose level of the previous 
2 to 3 months and is a useful parameter for monitoring long-term blood glucose control in 
T2DM patients122. Rapid changes to blood glucose levels can be detected as the preceding 30 
days contribute more to HbA1c% than the earlier 90 – 120 days105. 
All of the patients in this cohort were sent to the clinic with a confirmed T2DM diagnosis, 
with some recruited patients being regular visitors over a long period of time and others on 
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their first visit. Thus, in this study HbA1c% is an indicator of how well a patient is 
controlling their blood glucose levels, which is affected by T2DM treatment adherence and 
response. Patients with very high HbA1c% (e.g. 28.9 %) may not be adhering or responding 
to treatment or may be first time visitors needing further treatment.  However, Insulin and 
Metformin treatment status, as well as adherence data was not made available in this study, 
so this could not be determined. 
 
4.2) Lipid profile analysis of the study cohort 
Four groups of distinct lipid profiles: Group 1 (high TC), group 2 (high TG), group 3 (mixed 
dyslipidaemia) and group 4 (normal lipid levels) were included to ensure that a there was a 
wide range of lipid traits present in the cohort, to tease out any genetic associations. Thus, the 
overall combined lipid profile of the study cohort is a reflection of this non-random selection. 
The lipid profiles of this study cohort were significantly different to the results published 
from the Heart of Soweto study, which examined the lipid profiles of 1832 individuals of 
African descent, among others. For the sake of this comparison, the definition of 
dyslipidaemic traits was taken from the Heart of Soweto study114. The proportion of 
dyslipidaemic TC, TG, and LDL-c patients is higher in our study, while the number of 
patients with HDL-c <1.0 is approximately 2 times lower in our study. However, it must be 
noted that the patients in the Heart of Soweto study were included based on suspected CVD 
diagnosis, while our study consisted of T2DM patients. Only 9 % of the Heart of Soweto 
study patients had T2DM. Thus, there are several co-morbidities or influencing factors that 
differ between the two studies, which could account for the vast difference in dyslipidaemia 
proportions. Also, the cohort in our study was specifically selected based on lipid traits. 
 This comparison provides useful insights into the prevalence of dyslipidaemia in black South 
Africans. While African populations were traditionally found to have favourable lipid 
profiles, there is clear evidence that this is changing and the burden of dyslipidaemia in these 
population groups is growing. This has dire implications for CVD risk profiles, especially in 
patients with co-morbidities such as T2DM. The effect of these factors on lipid profiles will 




4.3) Statin therapy in the study cohort and its implications 
There are a number of issues that come with investigating dyslipidaemia in a T2DM cohort. 
The most apparent is the confounding effect that can be seen with the patients being treated 
with statins. Dyslipidaemia in diabetics is very common. It has been estimated that 60-70 % 
of T2DM patients present with some form of aberrant lipid profile109. In our study cohort 291 
patients (77 %) were on statin (mostly simvastatin) treatment regimes. There is a close 
relationship between glucose and lipid metabolism, as both processes are regulated in the 
liver.  The molecular mechanisms are not fully understood, but the association between 
T2DM and dyslipidaemia is well documented. T2DM are already at greater risk for 
developing more severe CVD (see Chapter 1.5). CVD accounts for 70 % of deaths in T2DM 
patients105. Dyslipidaemia is in itself a major CVD risk factor (See Chapter 1.4), thus T2DM 
patients are regularly prescribed lipid lowering statin therapies as CVD prophylaxis.  
In South Africa, statin therapy is recommended for high risk T2DM patients, regardless of 
their baseline lipid profiles, who are over the age of 40 years or who have had diabetes for 
more than 10 years with one or more additional CVD risk factors (Smoking, hypertension, 
etc.)105. In lower risk T2DM patients, i.e. those younger than 40 years and who have had 
diabetes for less than 10 years with no history of CVD or chronic kidney disease, statin 
therapy is recommended in those with LDL-c levels > 1.8 mmol/l105. In our cohort, 321 
patients of 397 with LDL-c levels available (81 %) have LDL-c > 1.8 mmol/l. However, not 
all of these patients are on statin treatment regimes. The patients, who are at high CVD risk 
due to their T2DM status, may not be on statin therapy regiments at the time of recruitment as 
they may be new comers to the Diabetes clinic. An advantage of a study of this nature is the 
possibility to compare the effects of additional environmental and genetic factors on lipid 
profiles in individuals on statins and on those not on statins.  
The use of lipid lowering therapies was an immediately identifiable confounding factor. 
Statins, or 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors, have a 
well-documented effect on lipid profiles, especially with prolonged use46. The lowering of 
LDL-c by statins is dose dependent and is summarised in a comprehensive review and meta-
analysis by Collins et al. An average reduction of LDL-c of 23 % can be achieved with 5mg 
of simvastatin a day (low intensity regimen)46. As dosage is doubled, an approximate 
reduction of 6 % in average LDL-c can be achieved, resulting in a 37 % reduction of LDL-c 
with 40 mg a day46,134. 
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Thus, one would expect to find lower cholesterol levels in patients who are on statin 
treatment, especially those on long term or high intensity regimens. However, this is not what 
was observed when stratifying the current study cohort by statin use and comparing median 
lipid profiles. A statistically significant increased median TC of 32.47 % (p = 0.0001), TG of 
33.87 % (p = 0.0001), LDL-c of 38.31 % (p = 0.0001), and HDL-c of 21.09 % (p = 0.0001) 
was observed in those on statins than compared to those not on statins. This was confirmed 
by multivariate analysis (Table 3.6). This result is seemingly counterintuitive. A possible 
explanation is that the individuals who had, on average, the least favourable lipid profiles at 
the time of the recruitment were most likely put on statin treatment regimens (Sim+). The 
individuals who were not on statins (Sim-) may not have needed to be, due to more 
favourable lipid profiles or the fact that they were new to the clinic. Thus, the more 
dyslipidaemic patients were on statins, which accounts for the higher median cholesterol 
levels for patients on statin treatment compared to those not on statins. The efficacy of statins 
in reducing the lipid levels for those on treatment would be affected by response to the drug, 
as well as drug adherence. Therapy response can be influenced by a multitude of clinical 
factors, but also by genetic variation in drug metabolism pathways. This is supported by the 
large range of lipid values seen in this group. 
The Sim+ group had higher median HbA1c% levels compared to the Sim- group (6.9 % 
vs.5.5 %, respectively) and were, thus, poorer controllers of blood glucose (p=0.0001). 
Additionally, the Sim+ had a significantly higher median age (59 years and 50.5 years; 
p=0.0002), and higher median BMI approaching significance (30.1 kg/m2 and 29.4 kg/m2; 
p=0.058) compared to the Sim- group. Again, this could be explained by the statin therapy 
recommendation for all T2DM patients over the age of 40105.  
Treatment status has a significant effect on observed lipid profiles and was needed to be 
accounted for in the further analysis of the potential genetic contribution to dyslipidaemia. 
One possibility would be to artificially raise the LDL-c values in the Sim+ group by a 
conservative 23 % based on the reported lowering effects of statins in the literature46. 
However, statin dosage, response to treatment, and adherence data affects response as well. 
Another option would be to convert the continuous lipid profile values into the categorical 
groups of either “Dyslipidaemic” or “Non-dyslipidaemic” based on defined cut-offs, with 
those on statins automatically grouped into the “Dyslipidaemic” regardless of actual lipid 
levels. You would then assess each of the independent variables for risk of developing a 
dyslipidaemic trait by logistic regression. This has the added benefit of resolving the 
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nonnormality issues for the dependent lipid variables. However, this method was not 
performed in this study as using the cut-offs for ideal lipid profiles in T2DM patients as 
defined by the Society for Endocrinology, Metabolism and Diabetes of South Africa 
guidelines would result in the “Non-dyslipidaemic” groups having too small sample sizes in 
comparison with the “Dyslipidaemic” groups.  
Most importantly, in complex diseases, the effect size of single SNPs on phenotypic traits is 
usually small as these disorders are highly polygenic. The potential effect of the SNPs on 
modifying lipid traits within these groups may be undetectable if the effect size is not large 
enough, especially with small sample sizes like in this study. Thus, in the further analysis of 
genetic variations on altered lipid profiles we stratified by statin use to help account for the 
observed effects. Statin therapy status is an indicator of TC, TG, and LDL-c dyslipidaemia. 
 
4.4) The associations between clinical characteristics, demographic 
features, and aberrant lipid profiles 
We used two methods to determine if there was any association between the clinical or 
demographic features of our cohort and altered lipid profiles. We used the non-parametric 
Spearman’s rank test of correlation for univariate analysis and then carried out multiple linear 
regression, using the generalised linear model method described in Chapter 2.16.7 to 
confirm previous analysis. The combination of analysis methods was used to tease out the 
true effects of these variables on the lipid profiles in our cohort, which can be compared to 
the published literature to better inform subsequent genetic analysis. 
The female gender was significantly positively correlated with older age (Rho=0.102, 
p=0.048), which may reflect the greater proportion of elderly and female participants in our 
study. Women had increased HDL-c levels in both univariate (Rho=0.110, p=0.034) and 
multivariate analysis (OR=1.12, p=0.044). This agrees with the published literature. One 
randomized, double blind dietary trial found that women had greater elevations of HDL-c in 
response to dietary supplementation than men do135. This may be due to women channelling 
dietary cholesterol in HDL-c more efficiently than men do, or the fact that they have 
increased lipoprotein lipase activities135. 
Older age was correlated with increased HDL-c levels (Rho=0.136, p=0.009), but this 
association was not repeated in multivariate analysis when adjusting for multiple variables 
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(p=0.328). However, older age was associated with very slight risk of decreased TG 
(OR=0.98, p=0.003). TG levels are inversely correlated with HDL-c levels. Thus, the 
observed correlation of old age with increased HDL-c may be due to there being more 
females of older age in the cohort. There is not enough evidence to say that age plays a major 
role in dyslipidaemia in this cohort. Older age was additionally correlated with increased 
HbA1c% (Rho=0.117, p=0.025) and statin use (Rho=0.206, p=0.001). This is not surprising 
as age is associated with increased incidence of T2DM, and statins are recommended in all 
T2DM over the age of 40 years105,132.  
Smoking status was not significantly correlated with any other clinical variables or altered 
lipid profiles. However, current smokers were found to be less likely to have high TC 
(OR=0.72; p<0.001), high LDL-c (OR=0.68; p<0.001) and more likely to have low HDL-c 
(OR=1.47; p<0.001) in the Heart of Soweto study114. It is possible that the smoking status of 
each patient might not be accurate as it was self-reported. The role of smoking in 
dyslipidaemia in our cohort needs to be further investigated and should still be accounted for 
in future studies due to reported associations in the literature and biological significance to 
CVD and T2DM12. 
Patients with greater BMIs were significantly correlated with increased TG levels in both 
univariate and multivariate analysis (Rho=0.159, p=0.002; OR=1.03, p=0.011). BMI was not 
associated with any other lipids in our study. However, BMI was moderately associated with 
increased TG, TC and LDL-c in the Heart of Soweto study114. Thus, our observation of the 
role of BMI only partly agree with previously published results, but BMI is important in 
dyslipidaemia and should be still accounted for in future studies. 
Poorly controlled T2DM (measured by increased HbA1c%) was significantly correlated with 
increased TG (Rho=0.378, p<0.001; OR=1.11, p=3.26e-05) and very slightly decreased HDL-
c (OR=0.99, p=3.28e-05). It is reported that the most frequent aberrant lipid profiles 
encountered among T2DM patients are moderately increased TG, and LDL-c and decreased 
HDL-c105. Elevated TG and TC are proxies for elevated remnant VLDL and CM particles, 
which are denser and highly atherogenic. LDL-c particles are smaller and denser so there are 
higher concentrations in TC than suggested by the Friedewald equation derived LDL-c 




4.5) APOE, PSCK9 and CETP genetic variation distribution 
The distribution of selected APOE, PSCK9 and CETP genetic variations was investigated in 
the study cohort, following successful genotyping. Genotype frequencies were evaluated for 
deviation from HWE and compared using the between the Sim+ and Sim- groups in order to 
determine if either of the groups had a higher frequency of potentially lipid modulating 
variations.  
Two identified variants, PCSK9 rs28362286C>A (p=0.028) and the CETP rs34680782C>A 
(p=0.002), deviated from HWE. Usually this is an indication of genotyping errors, however, 
these two variants were genotypes for by direct cycle Sanger sequencing, so this is unlikely. 
A more likely explanation is that the assumptions of HWE were not met. The study cohort 
was not completely randomly selected. Samples were included based on the four lipid profile 
groups as explained in Chapter 2.6. This could enrich the frequency of variant SNPs which 
may be associated with altered lipids. The other explanation is that these SNPs are under 
selection forces in this population group. 
Genetic variant minor allele frequencies (MAF) were compared to the global frequencies of 
the Luyha from Kenya (LWK), the Yoruba from Nigeria (YRI), the Han Chinese from China 
(CHB) and the Utah residents with Northern and Western European ancestry (CEU) (Table 
3.9). Seven variants are common in all of the observed population groups. These variants 
may play a common role in dyslipidaemia across populations. Conversely, five variants with 
MAF>0.01 were found in only African populations, with similar frequencies between African 
ethnic groups. The Heart of Soweto study reported significantly different lower (p < 0.01) 
TC, LDL-c and TG levels in individuals of African descent compared to white, mixed 
ancestry and Indian ancestry South Africans114. These differences are possibly due to unique 
lipid altering population specific genetic variants. Thus, we are especially interested in the 
African specific variants as they may explain this variance in lipid profiles between the 
population groups. 
APOE rs7412C>T, had a statistically significant difference in genotype frequency between 
the Sim+ and Sim- groups (p<0.001). A higher proportion of APOE rs7412C/T and APOE 
rs7412T/T individuals were observed in the Sim- group. The APOE rs7412T variant, which is 
a proxy for the APOE Ɛ2 isoform, has been consistently associated with altered lipid 
profiles69. Thus, the APOE rs7412C>T polymorphism may contribute to the observed 
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differences between the lipid profiles of Sim+ and Sim- and will be discussed in detail 
further. 
 
4.6) APOE, PSCK9 and CETP linkage disequilibrium analysis 
LD analysis was performed on APOE, PSCK9 and CETP variants separately as each of these 
genes are on different chromosomes. LD analysis gives us genome level insight into a 
populations evolutionary history, accounting for natural selection and geographical 
subdivision events130. There was no evidence of LD between the APOE rs429358T>C and 
APOE rs7412C>T SNP pair (r2=0.054). This agrees with data from the 1000 genomes project 
which reports no evidence of LD between these SNPs in the YRI, CEU, or CHB population 
groups (r2=0.000 in all)136. The PCSK9 rs505151A>G and PCSK9 rs28362286C>A SNP pair 
had no evidence of LD in our cohort (r2=0.000), or in the YRI population group (r2=0.000)136. 
The PCSK9 rs28362286C>A SNP is only found in African populations. 
The CETP rs17231520G>A and rs34065661C>G, and the CETP rs711752A>G and 
rs708272G>A SNP pairs were almost in complete LD (r2=0.98 and r2=0.97, respectively 
(Figure 3.9). There was no evidence of significant LD between any of the other CETP SNPs. 
Our results are consistent with a study done by Pirim et al., which sequenced the CETP gene 
in Caucasian and African populations. The two CETP SNP pairs were in complete LD in both 
population groups. They found a much higher degree of LD between more CETP SNPs in the 
Caucasian group than in the African group97. It is well established from studies on 
mitochondrial, genomic and sex-chromosome DNA that African populations are the more 
genetically variable due to maintaining larger populations over longer periods time137. This 
allows the effects of genetic drift, recombination and mutation to be fixed in these 
populations and, thus, African populations tend to have smaller LD blocks, while bottleneck 
and founder effects in contemporary European and Asian populations has led to larger LD 
blocks in these groups137.  
The confirmation of complete LD of the two CETP SNP pairs in the South African 
population is useful as it means that analysis of the effect on lipid profiles only needs to be 
done on one SNP in each group. If two alleles are in complete LD, then one of the alleles can 
be used as a genetic marker of the other. Similarly, an allele in complete LD with a defining 
haplotype can be used as a marker of that haplotype. Thus, you can infer the allele frequency 
of the other alleles by genotyping only one marker allele. This has implications for gene 
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mapping of causative alleles. A SNP may be consistently linked to a disease phenotype but 
may have no predicted structural or regulatory effects. The SNP may be in LD with the real 
causative SNP, so it is still useful to genotype for it as a biomarker. This is important in the 
case of a gene with a hotspot of reportedly associated SNPs in a small genomic region such 
as CETP97. Thus, in further analysis CETP rs708272G>A was used as a marker for the CETP 
rs711752A>G, while the CETP rs34065661C>G SNP was used as a marker for CETP 
rs17231520G>A. 
 
4.7) The association between APOE, PSCK9 and CETP genetic variations 
and aberrant lipid profiles 
We used two methods to investigate the relationship between genotyped APOE, PCSK9, and 
CETP genetic variations and aberrant lipid profiles of T2DM patients in our study cohort. 
The primary method was non-parametric univariate investigation using the Mann-Whitney U 
test and Kruskal-Wallis tests, while adjusting for statin usage by stratification. We then 
carried out multiple linear regression, using the generalised linear model method described in 
Chapter 2.16.7 for reasons discussed in this chapter. This was done to confirm previous 
analysis and to potentially reveal significant associations hidden by confounding factors. We 
discuss the role of each variant and its implications further here. 
 
4.7.1) The impact of APOE genetic variation on aberrant lipid profiles 
The APOE rs429358T>C change encodes a destabilising Cys122Arg amino acid change (Ɛ4) 
in the helix of the short hinge region that connects the C and N-terminal domains of APOE. It 
is thought that this changes the interaction of the domains which affects lipid binding 
affinity69. The Ɛ4 isoform binds with better affinity to VLDL, decreasing its clearance and 
reducing the number of VLDL components available for incorporation into HDL-c69. This 
was shown in APOE knockout mice, which had lower HDL-c in those with the Ɛ4 isoform 
compared to Ɛ374. Additionally comprehensive meta-analysis showed a weak inverse 
relationship between HDL-c and the APOE (Ɛ2/Ɛ2, Ɛ2/Ɛ3, Ɛ2/Ɛ4, Ɛ3/Ɛ3, Ɛ3/Ɛ4, Ɛ4/Ɛ4) 




Analysis of APOE isoforms in our T2DM cohort agree with the literature and reveal a 
significant association between the Ɛ4 isoform and lower median HDL-c levels in the 
combined cohort, compared to the Ɛ3 isoform (p=0.034) (Table 3.10). Patients with the Ɛ4/ Ɛ4 
genotype had lower median HDL-c levels than those with the more common Ɛ3/Ɛ3 genotype. 
This association was repeated in the Sim- group (p=0.004), but not in the Sim+ group 
(p=0.391) after stratification by statin use. However, a non-significant trend to lower HDL-c 
in the Ɛ4/ Ɛ4 genotype was seen in the Sim+ group. Multivariate analysis (Table 3.16) 
showed that the APOE rs429358C allele confers risk of lower HDL-c levels when adjusting 
for gender and statin use, which is in agreement with published literature.  
The APOE rs7412C>T SNP encodes the arginine158cysteine amino acid change (Ɛ2) which 
drastically reduces the proteins ability to bind to LDLR69. It is thought that the Ɛ2 isoform 
impairs hydrolysis of TG rich VLDL, which is LPL mediated, leading to lowered LDL-c 
levels in transgenic mice69,76. However, the mechanism is not fully understood. Additionally, 
children with the Ɛ2 allele were found to have lower LDL-c and higher HDL-c levels75. 
Results from our study (Table 3.11) agree with the literature, with Ɛ2/Ɛ2 patients having 
lower median TC and median LDL-c than Ɛ3/Ɛ3 patients in the combined cohort (p<0.0001 in 
both cases). These associations were repeated in the Sim+ group (p=0.027 and p=0.003, 
respectively) but not in the Sim- group (p=0.127 and p=0.485, respectively). Multivariate 
analysis (Table 3.16) showed that the APOE rs7412T allele confers a risk of lower TC levels 
(OR=0.747, p=0.028), and lower LDL-c levels (OR=0.759, p=0.012) when adjusting for 
statin use. 
While we did not see the same linear and inverse relationships between the APOE (Ɛ2/Ɛ2, 
Ɛ2/Ɛ3, Ɛ2/Ɛ4, Ɛ3/Ɛ3, Ɛ3/Ɛ4, Ɛ4/Ɛ4) genotypes and LDL-c and HDL-c, respectively, we did 
repeat the associations when comparing Ɛ2 to Ɛ3 and Ɛ3 to Ɛ4. Significance that was not 
repeated in Sim+ or Sim- groups could be influenced by reducing sample sizes during 
stratification. Additionally, inter-individual response and adherence to statin therapy is not 
accounted for which may play a significant role. Lipid levels in the Sim+ group are 
differentially affected by statin action, possibly masking the effects caused by genetic 
variation. The Sim- group may have additional genetic variations which mitigate and mask 
the effects of APOE variation on LDL-c. With the multivariate analysis, however, there is 
enough evidence to postulate that the common APOE variations do play a significant role in 




4.7.2) The impact of PCSK9 genetic variation on aberrant lipid profiles 
Genetic variation in PCSK9 gene has been an area of great interest in recent studies of 
dyslipidaemia. It plays a vital role in the degradation and recycling of the LDLR and, thus, 
genetic variations, which can either enhance or abolish its function, have been keenly studied 
for their effects on altered LDL-c. Therefore, we decided to investigate the effects of a 
common reportedly gain-of-function variation PCSK9 rs505151A>G, and a rare African 
specific loss-of-function variation PCSK9 rs28362286C>A in our cohort. 
PCSK9 rs505151A>G encodes a glutamic acid to glycine (E670G) change in the cysteine-
rich C- terminal domain of PCSK9. It is thought that this variation may increase the affinity 
for PCSK9 to bind to LDLR, thus enhancing LDLR degradation88 as described in 
Chapter1.4.6. The PCSK9 rs505151G allele has been associated, in a meta-analysis, with 
increased LDL-c levels (OR=1.546, p <0.001) in all studied ethnicities88. We reported no 
such significant associations between the PCSK9 rs505151G>A variation and lipid profiles 
through univariate analysis (Appendix V, Table 5.2) and multivariate analysis (Table 3.16). 
It appears that this SNP does not play a significant role in our population.  
The PCSK9 rs28362286C>A encodes a C679X truncation that disrupts the folding of the C-
terminal domain, thought to be important for the successful secretion of the protein80. PCSK9 
with the C679X truncation is efficiently expressed and processed in human liver cells, 
retaining catalytic activity, but is retained in the ER and is not secreted into the cell 
medium92. The C679X variant was associated with a decrease in LDL-c levels by 27% in 
Zimbabwean women91.   We report no such significant associations between the PCSK9 
rs28362286C>A variation, using a dominant genetic model, and lipid profiles through 
univariate analysis (Table 3.12) or multivariate analysis (Table 3.16). Another study found 
no significant difference in LDL-c levels between 679X carriers and C679 homozygotes in 
black South African women138. It may be possible that enough functional protein is excreted 
in PCSK9 rs28362286C/A heterozygotes and that associations with lower LDL-c can only be 
seen in a recessive genetic model which is difficult to analyse with such a rare mutation. The 
cohort we studied only had one PCSK9 rs28362286A/A homozygote, which was genotyped 
through sequencing, so significant differences in median lipid levels could not be determined. 
This patient should not have any functional PCSK9 secreted into the cell medium, and should 
have lower LDL-c. The 48year old female, who was not on statin therapy, had a lipid profile 
115 
 
as follows: TC (2.72 mmol/L), TG (1.40 mmol/L), HDL-c (0.65 mmol/L), and LDL-c (1.43 
mmol/L). Her lipid profile was low across the board, and she was a poor controller T2DM 
(HbA1c% =7.8). Thus, it is plausible that her PCSK9 rs28362286A/A variation plays a 
protective role against LDL-c dyslipidaemia. 
While the analysis of PCSK9 rs505151A>G and PCSK9 rs28362286C>A did not yield any 
significant results in our study cohort, the role of PCSK9 variation in South Africans still 
need further elucidation. There are many additional variations which could have an impact 
which were not studied in this population due to time constraints. 
 
4.7.3) The impact of CETP genetic variation on aberrant lipid profiles 
The role of CETP in the dyslipidaemia of South Africans populations is relatively under 
investigated. The common CETP rs708272G>A (TaqIB) variant has been reported in a 
population of black South African women, where the TaqIB B2 allele was associated with 
lower LDL-c levels138.  CETP rs708272G>A is a synonymous mutation with no known effect 
on CETP function and no predicted effects on regulation or splicing site alteration. It has 
been hypothesised that reported association is caused by another SNP in strong linkage 
disequilibrium (LD) with CETP rs708272G>A. There is evidence that CETP rs708272G>A 
is in strong LD (r2 = 0.74) with the 5’ upstream CETP rs183130C>T SNP, which was 
strongly associated with increased HDL-c in individuals of African descent97. The CETP 
rs183130C>T variant is predicted to alter a transcription binding site, therefore, it is a good 
candidate for the causative allele in the haplogroup139. However, analysis of CETP 
rs708272G>A in our study cohort showed no significant associations with altered lipids 
(Table 3.14). The CETP rs708272A allele showed a trend towards a significant increase in 
HDL-c (p=0.073) when compared to the rs708272G allele in the combined cohort, but 
significance was not repeated when stratifying by statin use. Multivariate analysis (Table 
3.16) confirmed that there was no significant associations with lipid levels. As CETP 
rs708272G>A is not causative, we would need to investigate the CETP rs183130C>T SNP in 
the future to determine its distribution and role in our population. This would be a further fine 
mapping of the CETP rs708272G>A haplogroup and may provide useful insight going 
further.  
The CETP rs34065661C>G encodes the A15G amino acid change. However, the amino acid 
is cleaved upon secretion of protein, so it has no effect on CETP activity but may affect 
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CETP secretion efficiency140. The CETP rs34065661C/G + G/G genotypes, when applying a 
dominant genetic model, were associated with increased median HDL-c in our combined 
cohort and Sim+ cohort (p=0.017 and p=0.026, respectively) (Table 3.13). This agrees with 
results published by Pirim et al.97. Significance was lost in multivariate analysis (Table 3.16) 
when adjusting for the effects of gender, HbA1c%, and statin use. The CETP rs34065661G 
allele approached a significant increase in risk of high LDL-c levels (OR=1.37, p=0.057), 
when adjusting for statin use. This may be a false positive result caused by small sample size. 
The CETP rs3816117T allele showed a trend towards significantly lower HDL-c levels in the 
combined cohort (p=0.083) (Table 3.15). However, this trend is not observed once stratified 
by statin use or in multivariate analysis (Table 3.16). The CETP rs3816117C>T variant is 
intronic with no reported functional significance. Interestingly, the CETP rs34680782A allele 
was significantly associated with 85.2% increased risk of higher LDL-c in multivariable 
analysis, adjusting for statin use (OR=1.85, p=0.022). There were no significant associations 
in the CETP rs34680782C>A univariate analysis, but a non-significant trend towards higher 
LDL-c was seen in the CETP rs34680782C/A + A/A genotypes when applying a dominant 
genetic model. The SNP is not predicted to be functional and has not been associated with 
LDL-c in the literature, but further investigation is warranted. No other significant 
associations with the other CETP variations and altered lipid profiles was observed 
(Appendix V, Table 3.16). 
One problem with investigating the role of genetics in a complex disorder with multiple 
confounding effects, is that the contribution of single genetic variants may be lost if their 
effect sizes are small. Thus, we decided to investigate the association of a combination of 
three CETP SNPs, namely, CETP rs34065661C>G, CETP rs3816117C>T, and CETP 
rs708272G>A, which showed significant associations and/or trends with altered HDL-c and 
which have been individually associated with altered HDL-c in the literature97. The process 
involved is described in Chapter 3.6.3. Patients with the rs34065661C/G + C/C, 
rs708272G/A + A/A, and rs3816117C/C genotypes had significantly higher levels of HDL-c 
(p=0.001) than those with the rs34065661G/G, rs708272G/G, and rs3816117C/T + T/T 
genotypes in the combined cohort (Figure 3.10). The association was repeated in patients on 
statin therapy (p=0.011), but not in patients not on statin therapy (p=0.1402). We can see that 
a combination of CETP SNPs can have a significant effect on altered HDL-c, highlighting the 
polygenic nature of dyslipidaemia. Therefore, it may be important in the future to genotype as 
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many CETP SNPs as possible in a large cohort to determine the combined effect as CETP 
plays a role in dyslipidaemia in our population. 
 
4.8) Study limitations 
The study cohort was selected from a larger cohort of individuals recruited at the diabetes 
clinic at the Chris Hani Baragwaneth hospital in Johannesburg as part of a main protocol on 
the genetic susceptibility to T2DM carried out by Dr. Donald Tanyanyiwa. A large 
proportion of these patients were on lipid lowering medications (mostly simvastatin) as this is 
a common pharmacological therapy prescribed by clinicians to patients visiting the clinic. 
This was major confounding factor when investigating the statistical association of genetic 
variants with altered lipid levels and had to be accounted for in analysis. 
None of the continuous variables assessed in this study had normal distributions according to 
the Shapiro-Wilk test. Only age approached a normal distribution (p=0.033). This has 
implications for analysis as many tests assume Gaussian distributions for accuracy. Several 
transformations (e.g. log10 transformation) were attempted to improve normality, with no 
success. Outliers were checked for but not removed from analysis as there was already a 
small sample size, and extreme values were of interest to us. Thus, non-parametric tests were 
used to analyse the data further. 
The sample size was small for a genetic association study and, due to resource constraints, 
the number of genetic variants that could be analysed was limited. This meant that previously 
associated genetic variations in other lipid metabolism relevant genes such as LDLR, LPA, 
LCAT, LPL, APOB, ANGPTL3 and ANGPTL4 could not be studied in our cohort. This is 
reflected in the fact that few of our investigated SNPs were associated with altered lipid 
profiles, while no SNPs were reported with altered TG levels. There is great deal of variation 
in lipid profiles which is unaccounted for. Additionally, number of potentially significant 
SNPs in PCSK9 and CETP were not studied in our cohort, so we do not have the full picture 
of the contribution of these genes to dyslipidaemia in our cohort. It also has implications for 
statistical analysis. Power is reduced, HWE deviation may be affected, normality of the 
distribution of variables is affected, and type I error rates increase. 
A number of patients had missing clinical data which meant that they had to be excluded 
from certain statistical analysis. This further reduced the sample sizes available for analysis. 
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There was no information on alcohol usage, so its effect on dyslipidaemia in our cohort could 
not be investigated. The LDL-c values of patients were determined by an indirect method, the 
Friedewald equation, which has intrinsic limitations. In in cases of dysbetalipoproteinemia 
(Type Ill hyperlipoproteinemia), VLDL-c concentrations are underestimated, and LDL-c 
concentrations are overestimated. Additionally, in cases where TG ≥ 4.5mmol/l the equation 
overestimates VLDL-c concentrations and underestimates LDL-c concentrations121.  LDL-c 
cannot be accurately estimated where TG ≥ 4.5mmol/l, thus, these patients had to be 
excluded from analysis of LDL-c. Our study did not have suitable matched controls for 
comparison. The nature of the study cohort, with associated T2DM co-morbidities, made this 
a hard task to accomplish.  
 
4.9) Conclusion and future directions 
Our study set out to characterize the impact of genetic variations in APOE, PCSK9, and 
CETP on aberrant lipid metabolism in an indigenous black South African population with 
T2DM, with the aim of identifying a set of population specific biomarkers which could be 
used to better predict dyslipidaemia in the black South African population.  
In doing so we report on the frequencies and distribution of the PCSK9 rs505151A>G, CETP 
rs17231520G>A, CETP rs34065661C>G, CETP rs5884C>A, CETP rs34680782C>A, 
CETP rs17231534C>A, CETP rs3816117C>T, CETP rs561260717C>T, CETP 
rs34119551A>T, and CETP rs5030708C>T SNPs for the first time in a black South African 
population. We investigated the association between clinical factors and altered lipid profiles 
in a black South African T2DM cohort, and found that gender is associated with HDL-c, age 
is associated with TG, BMI is associated with TG, and HbA1c% is associated with both TG 
and HDL-c. Importantly, we show that statin use is a biomarker of dyslipidaemia for TC, TG, 
and LDL-c. 
Lastly, we identify several genetic biomarkers of dyslipidaemia in the black South African 
T2DM cohort. We show that the APOE rs7412T (Ɛ2) allele is associated with decreased TC 
and LDL-c, the APOE rs429358C (Ɛ4) allele is associated with decreased HDL-c, and that a 
combination of CETP rs34065661C>G, CETP rs3816117C>T, and CETP rs708272G>A 
alleles are associated with altered HDL-c. We also identify two SNPs PCSK9 
rs28362286C>A, and CETP rs34680782C>A which need to be further investigated in our 
population for a conclusive picture of their effect on LDL-c. 
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While our study design had limitations, it assisted us in achieving the aim we set out to 
achieve. However, there are a number of improvements which could be made and future 
work to be done. The number one issue with association studies is sample size. This is a 
study design factor that is greatly influenced by available resources. This can be overcome by 
clever study design and, most importantly, collaboration. The pooling of resources in studies 
with similar end points. 
Ideally, a panel of multiple lipid metabolism relevant variations in genes such as PSCK9, 
CETP, LDLR, LPA, LCAT, LPL, APOB, ANGPTL3 and ANGPTL4, identified as being 
significant in other African populations, would be set up and genotyped for in a larger 
longitudinal study cohort of black South African T2DM patients. Including matched controls. 
The associations could then be investigated and the variance in lipid profiles better explained. 
Next generation sequencing could then be employed to identify novel biomarkers in patients 
with extreme unexplained lipid profiles. 
The end goal would be determining risk of developing dyslipidaemia, early on in life, in a 
method similar to that published by Nuotio et al.141.  The panel of associated genetic 
variations to are used to create a weighted genetic risk score. Childhood lipid levels, which 
they show track to adulthood, could be taken along with established clinical risk factors and 
used in conjunction with the weighted genetic risk score and the risk for developing 
dyslipidaemia established141. We could identify patients who are at high risk for developing 
dyslipidaemia early on and employ the correct prophylaxis management strategies to prevent 
future CVD events and possible preventable fatalities. 
In conclusion, it is evident that there is still a lot of work to be done in order to fully 
characterise the role of genetic variation in dyslipidaemia in the South African population. 
This MSc project is a step in the right direction and achieves its aim in improving the 
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Appendix I: List of Reagents 
 
1) DNA Extraction: 
 
PBS (1 mM KH2PO4, 154 mM NaCl, 5.6 mM Na2HPO4, pH 7.4): 
0.136 g KH2PO4 
9.0 g NaCl 
0.795 g Na2HPO4 
Dissolved in 1 L dH2O. Check pH. Autoclaved. 
 
1 M Tris-HCl (pH 8): 
121.1 g Tris base dissolved in 1 L dH2O.  
Check pH 8 and adjust accordingly. Autoclaved. 
 
Saturated NaCl: 
40 g of NaCl added to 100 ml of dH2O and mixed until completely saturated 
 
Sucrose Triton-X Lysing Buffer: 
10 ml 1 M Tris-HCl (pH 8) 
5 ml 1 M MgCl2 
10 ml Triton X-100 
Made up to 1 L with dH2O. Autoclave and store at 4 °C 
Decant as needed and add 11 g/100 ml Sucrose (D (+) saccharose) before use. 
 
T20E05: 
20 ml 1 M Tris-HCl 
10 ml 0.5 M EDTA  
Made up to 1 L with dH2O. Autoclaved 
 
10 % SDS 




2) Agarose Gel Electrophoresis: 
 
Seakem® LE Agarose (Lonza, Rockland, USA) 
 
Nusieve™ 3:1 agarose gel (Lonza, Rockland, USA) 
 
10 X Tris-Borate EDTA (TBE) buffer: 
108 g Tris Base 
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55 g of boric acid 
7.5 g EDTA 
Made up to 1 L with dH2O. Autoclaved. 
Diluted to 1 X TBE in dH2O.  
 
EZ-VISION™ DNA Dye (VWR Life Science, AMRESCO, Philadelphia, USA) 
 
GelRed® nucleic acid dye (Biotium, Inc., Fremont, CA, USA) 
 
 
3) PCR amplification: 
 
5 X Green GoTaq® Reaction Buffer (Promega, Madison, USA) 
 
10 mM dNTPs (BioLine, London, UK) 
 
25 mM MgCl2 (Promega, Madison, USA) 
 
GoTaq® DNA polymerase (Promega, Madison, USA) 
 





AflIII RE (New England BioLabs, Inc., Ipswich, USA) 
  
NEB3.1 buffer (New England BioLabs, Inc., Ipswich, USA)  
 
HaeII RE (New England BioLabs, Inc., Ipswich, USA)  
 
CutSmart® buffer (New England BioLabs, Inc., Ipswich, USA)  
 
 
5) Post PCR Clean-up: 
 
Fast alkaline phosphatase (FastAP) (Thermo Fisher Scientific, Wyham, USA)  
 
Exonuclease I (ExoI) (Fermentas, Ontario, Canada)  
 
 
6) Direct Cycle Sanger Seqeuncing 
 
ABI Prism® BigDye® Terminator Cycle Sequencing v3.1 Kit (Applied Biosystems, 
Carlsbad, CA, USA): 
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BigDye® Terminator v 3.1 mix containing fluorescently-labelled ddNTPs and Taq 
DNA polymerase  
 
Sequencing buffer  
 
3 M NaOAc: 
246.1 Sodium Acetate in 1 L dH2O. Autoclaved. 
 
70 % (v/v) ice-cold ethanol  
 




 GeneRuler™ 100 bp Plus DNA Ladder and 50bp DNA Ladder:  
132 
 
Appendix II: DNA Quality Control 
 
 












NanoDrop™ 1000 spectrophotometer example: 
 
Table5.1: Extracted DNA concentration and purity determination by NanoDrop™ 
spectrophotometry 
Sample ID Concentration (ng/ul) A260nm/A280nm A260nm/A230nm 
4001 747.26 1.82 1.59 
4002 380.31 1.83 1.93 
4003 13.67 1.73 0.72 
4004 394.55 1.76 1.43 
4005 403.40 1.73 1.19 
4006 689.78 1.78 1.34 













Figure 5.1: DNA integrity by 1% (w/v) agarose gel electrophoresis at 100V 
for 1hour.  Lane M represents the GeneRuler® 100 bp Plus DNA Ladder 
Molecular Weight Marker (Fermentas, Ontario, Canada). Lanes 1-9 represent 
genomic DNA samples extracted from whole blood. A band of intact DNA can 
be seen, as well as smearing indicating various extents of degradation. 
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M      70.0   69.4   68.4   66.9   65.6   63.6   62.6   62.0     BL 
218 bp 
Figure 5.2: Temperature gradient PCR amplification of the 218 bp APOE fragment for Ta 
optimisation electrophoresed at 100 V for 60 minutes on a 1.5 % (w/v) agarose gel. Lane M 
represents the GeneRuler® 100 bp Plus DNA Ladder Molecular Weight Marker (Fermentas, 
Ontario, Canada). Lanes 2-9 represent amplification of control DNA at specified temperatures 




M      64.0    63.1    61.6    59.3    56.6    54.3    52.8    52.0     BL 
Figure 5.3: Temperature gradient PCR amplification of the 168 bp PCSK9 fragment for Ta 
optimisation electrophoresed at 100 V for 60 minutes on a 1.5 % (w/v) agarose gel. Lane M 
represents the GeneRuler® 100 bp Plus DNA Ladder Molecular Weight Marker (Fermentas, 
Ontario, Canada). Lanes 2-9 represent amplification of control DNA at specified temperatures 






























Figure 5.4: Temperature gradient PCR amplification of the 761 bp CETP fragment for Ta 
optimisation electrophoresed at 100 V for 60 minutes on a 1.5 % (w/v) agarose gel. Lane M 
represents the GeneRuler® 100 bp Plus DNA Ladder Molecular Weight Marker (Fermentas, 
Ontario, Canada). Lanes 2-9 represent amplification of control DNA at specified temperatures 
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CETP rs17231520G>A CETP rs711752A>G 
Figure 5.5: Electropherogram 1 of sequenced CETP PCR amplified fragments. The CETP rs17231520G>A and 
CETP rs711752A>G variants are highlighted by the red and orange boxes, respectively. A represents a sample with the 
CETP rs17231520G/G genotype. B represents a sample with the CETP rs17231520G/A genotype. C represents a sample 
with the CETP rs17231520A/A genotype. D represents a sample with the CETP rs711752A/A genotype. E represents a 








CETP rs5884C>A CETP rs34680782C>A 
Figure 5.6: Electropherogram 2 of sequenced CETP PCR amplified fragments. The CETP rs5884C>A and CETP 
rs34680782C>A variants are highlighted by the red and orange boxes, respectively. A represents a sample with the 
CETP rs5884C/C genotype. B represents a sample with the CETP rs5884C/A genotype. C represents a sample with the 
CETP rs5884A/A genotype. D represents a sample with the CETP rs34680782C/C genotype. E represents a sample with 







































CETP rs17231534C>A CETP rs561260717C>T 
Figure 5.7: Electropherogram 3 of sequenced CETP PCR amplified fragments. The CETP rs17231534C>A and 
CETP rs561260717C>T variants are highlighted by the red and orange boxes, respectively. A represents a sample with 
the CETP rs17231534C/C genotype. B represents a sample with the CETP rs17231534C/A genotype. C represents a 







CETP rs3816117C>T CETP rs34119551T>A 
Figure 5.8: Electropherogram 4 of sequenced CETP PCR amplified fragments. The CETP rs3816117C>T and 
CETP rs34119551T>A variants are highlighted by the red and orange boxes, respectively. A represents a sample with 
the CETP rs3816117C/C genotype. B represents a sample with the CETP rs3816117C/T genotype. C represents a 
sample with the CETP rs3816117T/T genotype. D represents a sample with the CETP rs34119551T/T genotype. E 








CETP rs5030708C>T CETP rs183782798G>T 
Figure 5.9: Electropherogram 5 of sequenced CETP PCR amplified fragments. The CETP rs5030708C>T and 
CETP rs183782798G>T variants are highlighted by the red and orange boxes, respectively. A represents a sample with 
the CETP rs5030708C/C genotype. B represents a sample with the CETP rs5030708C/T genotype. C represents a 








Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                        Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
PCSK9 rs505151G>A Combined     
A/A (n=227) 6.60 (2.70 – 28.90) 4.93 (1.78 – 13.28) 1.66 (0.47 – 14.53) 1.25 (0.15 – 2.94) 2.68 (0.48 – 6.08) 
A/G (n=158) 6.70 (2.20 – 17.60) 4.93 (1.64 – 7.66) 1.70 (0.55 – 5.34) 1.26 (0.11 – 2.26) 2.69 (0.60 – 5.61) 
G/G (n=29) 6.00 (4.00 – 16.70) 4.87 (2.87 – 7.44) 1.29 (0.33 – 13.67) 1.39 (0.56 – 1.85) 2.74 (1.24 – 4.71) 
Global P value 0.569 0.185 0.159 0.918 0.826 
PCSK9 rs505151G>A – Sim+     
A/A (n=156) 7.10 (3.60 – 28.90) 5.54 (2.04 – 13.28) 1.98 (0.47 – 14.53) 1.25 (0.15 – 3.42) 3.15 (0.48 – 6.08) 
A/G (n=112) 6.90 (2.20 – 17.60) 5.36 (1.64 – 7.66) 1.86 (0.56 – 5.34) 1.29 (0.19 – 2.94) 2.94 (0.60 – 5.61) 
G/G (n=21) 6.00 (4.00 – 16.70) 5.24 (3.40 – 7.44) 1.41 (0.40 – 13.67) 1.36 (0.79 – 2.42) 2.98 (1.86 – 4.14) 
Global P Value 0.245 0.291 0.255 0.972 0.743 
PCSK9 rs505151G>A – Sim-     
A/A (n=51) 5.40 (2.70 – 17.30) 3.64 (1.78 – 7.64) 1.34 (0.54 – 3.69) 1.01 (0.11 – 2.09) 1.89 (0.76 – 5.17) 
A/G (n=30) 5.70 (2.60 – 11.80) 3.67 (2.07 – 4.96) 1.13 (0.55 – 4.84) 0.96 (0.19 – 1.87) 1.88 (0.71 – 3.29) 
G/G (n=5) 5.25 (4.70 – 7.00) 4.16 (2.87 – 4.90) 1.12 (0.33 – 2.49) 1.17 (0.67 – 1.37) 2.73 (1.24 – 3.09) 
Global P Value 0.911 0.596 0.469 0.775 0.339 
Table 5.2: Univariate analysis of association between PCSK9 rs505151G>A, lipid profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 











Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)         Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs17231520G>A - Combined     
 G/G (n=352) 6.6 (2.20 – 18.40) 4.90 (1.64 – 11.32) 1.73 (0.33 – 14.53) 1.20 (0.11 – 3.42) 2.71 (0.48 – 6.08) 
G/A+ A/A (n=42+1) 7.35 (3.10 – 17.30) 4.94 (2.97 – 8.03) 1.41 (0.54 – 4.96) 1.36 (0.22 – 2.64) 2.65 (1.46 – 5.17) 
Global P value 0.249 0.687 0.078 0.023 0.709 
CETP rs17231520G>A – Sim+     
 G/G (n=247) 6.9 (2.2 – 17.6) 5.38 (1.64 – 11.32) 1.95 (0.40 – 14.53) 1.24 (0.15 – 3.42) 3.06 (0.48-6.08) 
G/A+ A/A (n=30+1) 8.2 (5.1 – 16.7) 5.43 (3.38 – 5.43) 1.48 (0.59 – 4.96) 1.43 (0.22 – 2.64) 3.02 (1.58-5.05) 
Global P value 0.222 0.509 0.085 0.026 0.593 
CETP rs17231520G>A – Sim-     
 G/G (n=71) 5.5 (2.60 – 12.10) 3.67 (1.78 – 5.70) 1.32 (0.33 – 4.84) 0.99 (0.11-1.87) 1.91 (0.71 – 3.29) 
G/A+ A/A (n=11+0) 5.65 (3.10 – 17.30) 3.58 (2.97 – 7.64) 1.21 (0.54 – 2.81) 1.23 (0.27-1.71) 1.91 (1.46 – 5.17) 
Global P value 0.341 0.967 0.586 0.462 0.581 
Table 5.3: Univariate analysis of association between CETP rs17231520G>A, lipid profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 








Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                        Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs711752G>A – Combined     
 G/G (n=141) 6.55 (3.6 – 18.40) 4.81 (1.87 – 7.76) 1.74 (0.40 – 13.67) 1.17 (0.19 – 2.51) 2.69 (0.60 – 5.54) 
G/A (n=199) 6.80 (2.20 – 17.60) 4.95 (1.78 – 11.32) 1.62 (0.33 – 14.53) 1.24 (0.11 – 3.42) 2.74 (0.48 – 6.08) 
A/A (n=54) 6.45 (2.70 – 16.70) 5.03 (1.64 – 7.72) 1.58 (0.59 – 5.81) 1.26 (0.59 – 2.94) 2.66 (0.68 – 5.46) 
Global P value 0.929 0.448 0.823 0.066 0.729 
CETP rs711752G>A - On Statins     
G/G (n=99) 6.90 (3.60 – 16.70) 5.24 (2.11 – 7.76) 1.88 (0.40 – 13.67) 1.24 (0.19 – 2.51) 3.02 (0.60 – 5.54) 
G/A (n=136) 7.10 (2.20 – 17.60) 5.55 (2.01 – 11.32) 1.78 (0.56 – 14.53) 1.29 (0.15 – 3.42) 3.19 (0.48 – 6.08) 
A/A (n=43) 6.80 (4.40 – 16.70) 5.35 (1.64 – 7.72) 1.82 (0.59 – 5.81) 1.31 (0.59 – 2.94) 2.91 (0.68 – 5.46) 
Global P Value 0.845 0.677 0.708 0.271 0.339 
CETP rs711752G>A – Not on Statins     
G/G (n=29) 5.40 (3.90 – 12.10) 3.66 (1.87 – 4.90) 1.24 (0.55 – 3.69) 0.93 (0.33 – 1.87) 1.89 (0.71 – 3.09) 
G/A (n=45) 5.55 (2.60 – 17.30) 3.64 (1.78 – 5.70) 1.23 (0.33 – 4.84) 1.12 (0.11 – 1.57) 1.92 (0.97 – 3.29) 
A/A (n=8) 5.40 (2.70 – 11.10) 3.97 (2.60 – 7.64) 1.65 (0.66 – 2.17) 1.03 (0.67 – 1.71) 2.32 (1.29 – 5.17) 
Global P Value 0.986 0.675 0.844 0.694 0.306 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 













Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                                  Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs5884C>A - Combined     
C/C (n=357) 6.70 (2.20 –18.40) 4.90 (1.64 – 11.32) 1.65 (0.33 – 14.53) 1.23 (0.11 – 3.42) 2.67 (0.48 – 6.08) 
C/A + A/A (n=36+2) 6.50 (2.90 – 15.20) 5.03 (3.03 – 8.03) 1.62 (0.47 – 6.03) 1.27 (0.11 – 2.64) 3.00 (1.27 – 5.61) 
Global P Value 0.267 0.375 0.546 0.288 0.399 
CETP rs5884C>A – Sim+     
C/C (n=249) 7.10 (2.20 –17.60) 5.41 (1.64 – 11.32) 1.96 (0.40 - 14.53) 1.27 (0.15 – 3.42) 3.06 (0.48- 6.08) 
C/A + A/A (n=27+2) 6.60 (4.40 - 15.20) 5.38 (3.03 – 8.03) 1.49 (0.47 – 6.03) 1.36 (0.66 – 2.64) 3.16 (1.55- 5.61) 
Global P Value 0.199 0.709 0.081 0.347 0.497 
CETP rs5884C>A – Sim-     
C/C (n=76) 5.50 (2.60 – 17.30) 3.67 (1.78 – 7.64) 1.24 (0.33 – 4.84) 0.99 (0.11 – 1.71) 1.93 (0.71 – 5.17) 
C/A + A/A (n=6+0) 4.65 (2.90 – 8.20) 3.59 (3.23 – 4.70) 1.76 (0.77 – 3.60) 1.21 (0.11 – 1.87) 1.77 (1.27 – 2.09) 
Global P Value 0.236 0.776 0.359 0.398 0.227 
Table 5.5: Univariate analysis of association between CETP rs5884C>A, lipid profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage  
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 










Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                                  Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs34680782C>A - Combined     
C/C (n=384) 6.70 (2.20 –18.40) 4.90 (1.64 – 11.32) 1.64 (0.33 – 14.53) 1.23 (0.11 – 3.42) 2.69 (0.48 – 6.08) 
C/A + A/A (n=11+1) 6.00 (4.50 – 15.90) 5.85 (2.96 – 6.68) 1.56 (0.59 – 4.52) 0.92 (0.58 – 2.51) 3.53 (1.32 – 4.51) 
P Value 0.791 0.304 0.857 0.173 0.117 
CETP rs34680782C>A – On Statins     
C/C (n=271) 7.00 (2.20 –17.60) 5.36 (1.64 – 11.32) 1.84 (0.40 - 14.53) 1.27 (0.15 – 3.42) 3.05 (0.48- 6.08) 
C/A + A/A (n=6+1) 6.50 (4.90 - 15.90) 6.13 (4.01 – 6.68) 1.88 (0.78 – 3.56) 1.31 (0.83 – 2.51) 3.68 (2.82- 4.15) 
P Value 0.931 0.183 0.819 0.869 0.145 
CETP rs34680782C>A – Not On Statins     
C/C (n=80) 5.50 (2.60 – 17.30) 3.67 (1.78 – 7.64) 1.26 (0.33 – 4.84) 1.02 (0.11 – 1.71) 1.91 (0.71 – 5.17) 
C/A + A/A (n=2+0) 5.60 (5.40 – 5.80) 3.36 (2.96 – 3.75) 1.39 (0.22 – 1.56) 1.21 (0.11 – 1.87) 1.94 (1.32 – 2.56) 
P Value NA (n= C/A too 
small) 
NA (n= C/A too small) NA (n= C/A too small) NA (n= C/A too small) NA (n= C/A too small) 
Table 5.6: Univariate analysis of association between CETP rs34680782C>A, lipid profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 









Variant Median HbA1c (%) Median Total Cholesterol (mmol/L)                                  Median Triglycerides (mmol/L) Median HDL-C (mmol/L) Median LDL-C (mmol/L) 
CETP rs17231534C>A - Combined     
C/C (n=357) 6.60 (2.20 –18.40) 4.42 (1.64 – 10.99) 1.67 (0.33 – 13.67) 1.23 (0.11 – 3.42) 2.70 (0.48 – 6.08) 
C/A (n=38) 7.00 (4.00 – 16.70) 4.78 (3.03 – 11.32) 1.48 (0.68 – 14.53) 1.29 (0.41 – 2.80) 2.51 (0.90 – 5.25) 
Global P Value 0.966 0.512 0.460 0.237 0.324 
CETP rs17231534C>A – Sim+     
C/C (n=250) 6.90 (2.20 –17.60) 5.42 (1.64 – 10.99) 1.86 (0.40 - 13.67) 1.26 (0.15 – 3.42) 3.15 (0.48- 6.08) 
C/A (n=28) 7.20 (4.00 – 16.70) 5.14 (3.03 – 11.32) 1.71 (0.74 – 14.53) 1.40 (0.41 – 2.80) 2.75 (0.90 – 5.25) 
Global P Value 0.655 0.308 0.799 0.181 0.086 
CETP rs17231534C>A – Sim-     
C/C (n=76) 5.50 (2.60 – 17.30) 3.65 (1.78 – 7.64) 1.26 (0.33 – 4.84) 1.02 (0.11 – 1.87) 1.90 (0.71 – 5.17) 
C/A (n=6) 5.80 (5.00 – 6.10) 3.92 (3.11 – 4.90) 1.27 (0.68 – 2.49) 0.93 (0.56 – 1.39) 2.11 (0.82 – 3.09) 
Global P Value 0.793 0.332 0.993 0.482 0.154 
Table 5.7: Univariate analysis of association between CETP rs17231534C>A, lipid profile, and HbA1c% in the combined T2DM cohort, and after stratifying by statin usage 
status. 
 
Values represent median (range); Bold indicates significance p<0.05; High-density lipoprotein cholesterol = HDL-c; Low-density lipoprotein cholesterol = LDL-c; HbA1c = Haemoglobin 






Appendix VI: Consent Forms and Information Packet: 
 
Study title: GENETICS AND DIABETIC DYSLIPIDAEMIA IN THE BLACK SOUTH 
AFRICANS 
Greeting: Good day, my name is Donald Tanyanyiwa. I work in Chemical Pathology here at 
Chris Hani Baragwanath Academic Hospital  
Introduction:  
We are doing some work to help us understand causes of increased fat /lipids in some African people 
with diabetes. It is known that some people with diabetes develop abnormal levels of fats/lipids.  
People are born with fat carrying protein, which may be different because of changes 
(mutations/polymorphism) in the seed (genes) that produce them and that causes them to do their job 
differently; others do it faster than others. The change may occur in one seed or many seeds. This 
causes some people to have increased amounts of different types of fat because their fat carrying 
proteins will not be working properly or may be reduced.  Fats/Lipids are required by the body, but 
when in excess it becomes harmful. The body normally manages to keep the fat within the required 
levels, but during illness or the presence of inherited disease, the body may not be able to clear the fat. 
High amounts of these fats have been associated with disruption of the normal heart and blood 
transport system.  A lot of research to identify the different causes of increased amount has been done 
but very little if any has been done to identify the common causes of fat accumulation in African 
people with diabetes. The study will examine to see if mutations/polymorphism in the genes of some 
(four proteins) associated with lipid metabolism are responsible for the abnormal fat/lipid (cholesterol 
and triglyceride) content in people with diabetes. The study will require only a small amount of blood 
(1.5 teaspoons) of the blood already sent to the laboratory for diagnostics purposes. There will be no 
immediate benefits to you but depending on the results benefits may be realised later. Patients who do 
not participate or withdraw from the study will continue to receive the same recommended standard 
intervention as the participants. It is hoped that the findings and advice given to the patients will go a 
long way in improving the quality of life. Venesection is a very safe method of obtaining blood for the 
repeat lipogram if required and the only risk that can be encountered is prolonged bleeding in those 
with some coagulopathy, a condition that will be excluded by the medical history on previous 
venesection.  
 
Invitation to participate:  We saw from your results that you are one of those diabetic people with 
increased amounts of these fats. Usually a small amount of blood (one and half (1½) teaspoons) is 
sent to test fat content in blood. We are asking your permission to keep that blood and find out the 
reason why the fat is increased 
   
What is involved in the study – We will not need any blood from you and we will not examine you. 
However we will require your permission to go and look at your hospital/clinic file to get your age, 
and how you are being treated. If you are taking tablets we will record their names.  You will not be 
expected to make any special visit to Chris Hani Baragwanath Academic Hospital for this study.   
 
Risks: There is no risk at all in this study because the fat carrying protein is already in the blood 
you sent to the laboratory and that is the one we will be using. 
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Benefits - The benefits of this study will only be realized if the cause of increased fat is identified 
and because it is the first such study, I will present it for as a PhD thesis.   
 
Participation is voluntary – It is your right to accept or refuses to take part in this study and 
whatever decision you make nothing will change regarding your treatment. It is also your right to tell 






































Analysis and storage of Biologic Samples: Plasma and DNA  
 I hereby consent to the removal, storage waiting processing, and analysis of the above material from 
my own body for the purpose of diagnosis and research into disorders of lipid and lipoprotein 
metabolism associated with diabetes. After due explanation I understand that  
1) Conventional procedures and techniques are employed and that the health risk is minimal. 
2) The material and results of the investigations remain strictly confidential according to medical 
practice and such ethical guidelines that govern research at the universities and country at large. To 
preserve anonymity the samples are coded by numbers and my written consent is required for release 
of identifiable information to another party 
3)  Precise diagnosis may not always be possible because the defect(s) may not yet be known or there 
is inadequate  information to derive the defect owing to modulatory roles that other genes or the 
environment may play.   
4) The stored material may be used anonymously in future to derive information or for research 
purposes. Such future use may be of no direct benefit to the subject. 
5) Permission to participate in the study may be withdrawn at any time and any stored biological 
material will also be destroyed. The withdrawal will not affect the subject’s future medical care. 
 
6) I confirm that the purpose of this study was explained in the language that I preferred and I fully 
understood it. I have not received any financial benefit and I do not expect to receive any in future and 
undertake not to make any future financial claims following the outcome and publication of the 
finding. 
 
Singed at -------------------------------------------day -----------------month---------2013 
 
Print Name ---------------------------------------- Signature---------------------------------- 
 
Witness (Subject’s Choice) 
 




Witness (Health Personnel) 
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